Crystals and structure of Synagis Fab

ABSTRACT

The present invention provides machine readable media embedded with the three-dimensional atomic structure coordinates of Synagis Fab, and subsets thereof, and methods of using them.

1. CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit under 35 U.S.C. § 119 of copending provisional application No. 60/288,005, filed May 1, 2001, the content of which is hereby incorporated by reference in its entirety.

2. INTRODUCTION

The present invention concerns crystalline forms of polypeptides that correspond to Synagis (palivizumab) or a fragment thereof such as Synagis Fab, methods of obtaining such crystals and the high-resolution X-ray diffraction structures and atomic structure coordinates obtained therefrom. The crystals of the invention and the atomic structural information obtained therefrom are useful for solving the crystal and solution structures of related and unrelated proteins, and for screening for, identifying and/or designing compounds that bind and/or modulate a biological activity of respiratory syncytial virus.

3. BACKGROUND OF THE INVENTION

Respiratory Syncytial Virus (“RSV”) is the most important respiratory pathogen in infancy and early childhood. Studies estimate that RSV causes up to 90% of brochiolitis and approximately 90% of all pneumonia in infancy. These conditions result in over 90,000 hospitalizations and 4500 deaths annually in the United States alone (Hall, 1998, Textbook of Pediatric Infectious Diseases, 2084-2111). RSV infection in early childhood might be an important risk factor for subsequent development of recurrent wheezing and asthma (Eigen, 1999, J. Pediatr. 135:S1-S50; Stein et al., 1999, Lancet 354:541-545).

Current methods for treatment and prevention of RSV infection are limited. For instance, vaccination against RSV has not been successful to date. Vaccination of infants with an inactivated RSV actually increased the severity of RSV infection and pulmonary pathology when vaccinated infants were later challenged with RSV (Groothius, 1994, Antiviral Res 23:1-10; Hall et al., 1995, Principles and Practice of Infectious Disease, 1501-1519; Wyde, 1998, Antiviral Res. 39:63-79).

Direct administration of antibodies against RSV has had some prophylactic effect. A human immunoglobulin against RSV (“RSVIG”) was approved in 1996 for the prevention of serious lower respiratory tract disease caused by RSV in premature infants and infants with bronchopulmonary dysplasia (PREVENT study group, 1999, Pediatrics 99:93-99). Recently, Synagis (or palivizumab), a humanized monoclonal antibody against the surface fusion glycoprotein (“F protein”) of RSV, was approved for similar indications (Meissner et al., 1999, Pediatrics 18:223-31; Johnson et al., 1997, J. Infect. Dis. 176:1215-1224; Impact-RSV Study Group, 1998, Pediatrics 102:531-537). In studies on test animals, Synagis was twice as potent as RSVIG in inhibiting the RSV-induced potentiation of inflammation when administered before or in the early phase of RSV infection (Piedimonte et al., 2000, Pediatric Research 47:351-356).

Although Synagis provides safe and effective prevention of RSV infection, improved therapeutics, such as small molecule therapeutics, are needed to treat and/or prevent RSV infection. Small molecule therapeutics are easier and less expensive to manufacture and also easier to administer orally. In addition, a small molecule therapeutic such as an antigen that mimics the epitope recognized by Synagis could be administered to generate an immune response against RSV. A composition comprising an antigen that mimics RSV would provide a safer method of preventing RSV infection. An effective antigen mimic of RSV could be administered, to persons with a functioning immune system, as an immunoprophylactic to raise an immune response against the virus with minimal or no danger of infection caused by the immunoprophylactic itself.

The three-dimensional structure coordinates of crystalline Synagis would enable the design or selection of such an antigen mimic. Synagis is effective in preventing RSV infection in vivo, and a mimic of an antigen bound specifically by Synagis could raise an immune response that is as effective or even more effective than Synagis in preventing infection. The structure coordinates of the antigen binding region of crystalline Synagis and/or the structure coordinates of a co-crystal complex of Synagis and an antigen would elucidate the atomic requirements of binding between Synagis and the antigen. This atomic resolution information could then be used to design and/or select a mimic of the antigen to be used as an immunoprophylactic against RSV.

Furthermore, the atomic structure coordinates of crystalline Synagis would enable the design of an antibody with improved virus binding and/or neutralizing properties. The atomic structure coordinates of crystalline Synagis would identify those residues of Synagis that are involved in antigen-antibody binding. These residues could then be selectively altered to generate mutant Synagis molecules that could be screened for binding and/or virus neutralizing effects. These improved Synagis molecules would provide more and perhaps improved options for prevention of RSV infection.

Until the present invention, the ability to obtain the atomic structure coordinates of Synagis has not been realized.

4. SUMMARY OF THE INVENTION

In one aspect, the invention provides compositions comprising crystalline forms of polypeptides corresponding to Synagis (palivizumab), a humanized monoclonal antibody with specificity for the F protein of respiratory syncytial virus (“RSV”), or a fragment thereof such as an Fab fragment of Synagis (“Synagis Fab”). The amino acid sequences of the crystalline polypeptides may correspond to the sequence of wild-type Synagis Fab, or mutants thereof. The crystals of the invention include native crystals, in which the crystalline Synagis Fab is substantially pure; heavy-atom atom derivative crystals, in which the crystallizine Synagis Fab is in association with one or more heavy-metal atoms; and co-crystals, in which the crystalline Synagis Fab is in association with one or more binding compounds, including but not limited to, antigens, eptiopes, epitope analogs, inhibitors, etc. to form a crystalline co-complex. Preferably, such binding compounds bind the antigen binding site of Synagis Fab. The co-crystals may be native co-crystals, in which the co-complex is substantially pure, or they may be heavy-atom derivative co-crystals, in which the co-complex is in association with one or more heavy-metal atoms.

The Synagis Fab crystals (FIG. 1) of the invention are characterized by space group symmetry P2₁2₁2₁ and an orthorhombic unit cell (i.e., a unit cell wherein a≠b≠c; and α=β=γ=90°) with dimensions of a=77.36±0.2 Å, b=103.92±0.2 Å and c=68.87±0.2 Å and are preferably of diffraction quality. A typical diffraction pattern is illustrated in FIG. 2. In more preferred embodiments, the crystals of the invention are of sufficient quality to permit the determination of the three-dimensional X-ray diffraction structure of the crystalline polypeptide to high resolution, preferably to a resolution of greater than about 3 Å, typically greater than about 2.5 Å, and more usually to a resolution of about 2 Å, 1.9 Å, 1.8 Å or even greater. The three-dimensional structural information may be used in a variety of methods to design and screen for compounds that bind Synagis Fab, as described in more detail below.

In another aspect, the invention provides methods of making the crystals of the invention. Generally, native crystals of the invention are grown by dissolving substantially pure Synagis Fab polypeptide in an aqueous buffer that includes a precipitant at a concentration just below that necessary to precipitate the polypeptide. Water is then removed by controlled evaporation to produce precipitating conditions, which are maintained until crystal growth ceases.

Co-crystals of the invention are prepared by soaking a native crystal prepared according to the above method in a liquor comprising the binding compound of the desired co-complex. Alternatively, the co-crystals may be prepared by co-crystallizing the polypeptide in the presence of the compound according to the method discussed above or by forming a co-complex comprising the polypeptide and the binding compound and crystallizing the co-complex.

Heavy-atom derivative crystals of the invention may be prepared by soaking native crystals or co-crystals prepared according to the above method in a liquor comprising a salt of a heavy atom or an organometallic compound. Alternatively, heavy-atom derivative crystals may be prepared by crystallizing a polypeptide comprising selenomethionine and/or selenocysteine residues according to the methods described previously for preparing native crystals.

In another aspect, the invention provides machine and/or computer-readable media embedded with the three-dimensional structural information obtained from the crystals of the invention, or portions or subsets thereof. Such three-dimensional structural information will typically include the atomic structure coordinates of the crystalline Synagis Fab polypeptides, either alone or in a co-complex with a binding compound, or the atomic structure coordinates of a portion thereof such as, for example, the atomic structure coordinates of residues comprising an antigen binding site, but may include other structural information, such as vector representations of the atomic structures coordinates, etc. The types of machine- or computer-readable media into which the structural information is embedded typically include magnetic tape, floppy discs, hard disc storage media, optical discs, CD-ROM, electrical storage media such as RAM or ROM, and hybrids of any of these storage media. Such media further include paper on which is recorded the structural information that can be read by a scanning device and converted into a three-dimensional structure with an OCR and also include stereo diagrams of three-dimensional structures from which coordinates can be derived. The machine readable media of the invention may further comprise additional information that is useful for representing the three-dimensional structure, including, but not limited to, thermal parameters, chain identifiers, and connectivity information.

The atomic structure coordinates and machine readable media of the invention have a variety of uses. For example, the coordinates are useful for solving the three-dimensional X-ray diffraction and/or solution structures of other proteins, including mutated Synagis Fab, co-complexes comprising Synagis Fab, and unrelated proteins, to high resolution. Structural information may also be used in a variety of molecular modeling and computer-based screening applications to, for example, intelligently design mutants of the crystallized Synagis that have altered biological activity and to computationally design and identify compounds that bind the antibody or a portion or fragment of the antibody, such as the antigen binding site. Such compounds may be used as lead compounds in pharmaceutical efforts to identify compounds that mimic the epitope of the RSV F protein recognized by Synagis as a therapeutic approach toward the development of, e.g., an anti-idiotypic vaccine for the treatment of respiratory infections caused by RSV.

Accordingly, the invention further includes methods of designing or identifying compounds that bind Synagis Fab as an approach to developing new therapeutic agents. In one method, the three-dimensional structure of Synagis Fab can be used to design molecules which bind the antigen binding site of Synagis Fab. For instance, a binding molecule can be synthesized computationally from a series of chemical groups or fragments that bind Synagis Fab. Alternatively, the three-dimensional structure of can be used to screen a plurality of molecules to identify those that bind Synagis Fab at binding sites including, for example, the antigen binding site of Synagis Fab. The potential inhibitory or binding effect of molecules can be analyzed by actual synthesis and testing or by the use of modeling techniques. The compounds can be optimized by further modeling and/or testing.

4.1 Abbreviations

The amino acid notations used herein for the twenty genetically encoded L-amino acids are conventional and are as follows:

One-Letter Three-Letter Amino Acid Symbol Symbol Alanine A Ala Arginine R Arg Asparagine N Asn Aspartic acid D Asp Cysteine C Cys Glutamine Q Gln Glutamic acid E Glu Glycine G Gly Histidine H His Isoleucine I Ile Leucine L Leu Lysine K Lys Methionine M Met Phenylalanine F Phe Proline P Pro Serine S Ser Threonine T Thr Tryptophan W Trp Tyrosine Y Tyr Valine V Val

As used herein, unless specifically delineated otherwise, the three-letter amino acid abbreviations designate amino acids in either the D- or L-configuration. Specific enantiomers are preceded with a “D-” or “L-”, depending upon the enantiomer. The capital one-letter abbreviations refer to amino acids in the L-configuration. Lower-case one-letter abbreviations designate amino acids in the D-configuration. For example, “R” and “L-Arg” designate L-arginine, and “r” and “D-Arg” designate D-arginine.

Unless noted otherwise, when polypeptide sequences are presented as a series of one-letter and/or three-letter abbreviations, the sequences are presented in the N→C direction, in accordance with common practice.

4.2 Definitions

As used herein, the following terms shall have the following meanings:

“Genetically Encoded Amino Acid” refers to L-isomers of the twenty amino acids that are defined by genetic codons. The genetically encoded amino acids are the L-isomers of glycine, alanine, valine, leucine, isoleucine, serine, methionine, threonine, phenylalanine, tyrosine, tryptophan, cysteine, proline, histidine, aspartic acid, asparagine, glutamic acid, glutamine, arginine and lysine.

“Genetically Non-Encoded Amino Acid” refers to amino acids that are not defined by genetic codons. Genetically non-encoded amino acids include derivatives or analogs of the genetically-encoded amino acids that are capable of being enzymatically incorporated into nascent polypeptides using conventional expression systems, such as selenomethionine (SeMet) and selenocysteine (SeCys); isomers of the genetically-encoded amino acids that are not capable of being enzymatically incorporated into nascent polypeptides using conventional expression systems, such as D-isomers of the genetically-encoded amino acids; L- and D-isomers of naturally occurring or synthetic α-amino acids that are not defined by genetic codons, such as α-aminoisobutyric acid (Aib); and other amino acids that are not encoded by genetic codons such as β-amino acids, γ-amino acids, etc. In addition to the D-isomers of the genetically-encoded amino acids, common genetically non-encoded amino acids include, but are not limited to norleucine (Nle), penicillamine (Pen), N-methylvaline (MeVal), homocysteine (hCys), homoserine (hSer), 2,3-diaminobutyric acid (Dab) and ornithine (Orn). Additional exemplary genetically non-encoded amino acids are found, for example, in Practical Handbook of Biochemistry and Molecular Biology, 1989, Fasman, Ed., CRC Press, Inc., Boca Raton, Fla., pp. 3-76 and the various references cited therein.

“Hydrophilic Amino Acid” refers to an amino acid having a side chain exhibiting a hydrophobicity of less than zero according to the normalized consensus hydrophobicity scale of Eisenberg et al., 1984, J. Mol. Biol. 179:125-142. Genetically encoded hydrophilic amino acids include, but are not limited to, L-Thr (T), L-Ser (S), L-His (H), L-Glu (E), L-Asn (N), L-Gln (Q), L-Asp (D), L-Lys (K) and L-Arg (R). Genetically non-encoded hydrophilic amino acids include the D-isomers of the above-listed genetically-encoded amino acids, ornithine (Orn), 2,3-diaminobutyric acid (Dab) and homoserine (hSer).

“Acidic Amino Acid” refers to a hydrophilic amino acid having a side chain pK value of less than 7 under physiological conditions. Acidic amino acids typically have negatively charged side chains at physiological pH due to loss of a hydrogen ion. Genetically encoded acidic amino acids include, but are not limited to, L-Glu (E) and L-Asp (D). Genetically non-encoded acidic amino acids include, but are not limited to, D-Glu (e) and D-Asp (d).

“Basic Amino Acid” refers to a hydrophilic amino acid having a side chain pK value of greater than about 7 under physiological conditions. Basic amino acids typically have positively charged side chains at physiological pH due to association with hydronium ion. Genetically encoded basic amino acids include, but are not limited to, L-His (H), L-Arg (R) and L-Lys (K). Although L-His might have a pK value slightly less than 7.0 when included in a polypeptide, L-His residues are generally classified as basic amino acids. Genetically non-encoded basic amino acids include, but are not limited to, the D-isomers of the above-listed genetically-encoded amino acids, ornithine (Orn) and 2,3-diaminobutyric acid (Dab).

“Polar Amino Acid” refers to a hydrophilic amino acid having a side chain that is uncharged at physiological pH, but which comprises at least one covalent bond in which the pair of electrons shared in common by two atoms is held more closely by one of the atoms and is thus capable of participating in a hydrogen bond. Genetically encoded polar amino acids include, but are not limited to, L-Asn (N), L-Gln (Q), LSer (S) and L-Thr (T). Genetically non-encoded polar amino acids include, but are not limited to, the D-isomers of the above-listed genetically-encoded amino acids and homoserine (hSer).

“Hydrophobic Amino Acid” refers to an amino acid having a side chain exhibiting a hydrophobicity of greater than zero according to the normalized consensus hydrophobicity scale of Eisenberg et al., 1984, J. Mol. Biol. 179:125-142. Genetically encoded hydrophobic amino acids include, but are not limited to, L-Pro (P), L-Ile (I), L-Phe (F), L-Val (V), L-Leu (L), L-Trp (W), L-Met (M), L-Ala (A), L-Gly (G) and L-Tyr (Y). Genetically non-encoded hydrophobic amino acids include, but are note limited to, the D-isomers of the above-listed genetically-encoded amino acids, norleucine (Nle) and N-methyl valine (MeVal).

“Aromatic Amino Acid” refers to a hydrophobic amino acid having a side chain comprising at least one aromatic or heteroaromatic ring. The aromatic or heteroaromatic ring may contain one or more substituents such as —OH, —SH, —CN, —F, —Cl, —Br, —I, —NO₂, —NO, —NH₂, —NHR, —NRR, —C(O)R, —C(O)OH, —C(O)OR, —C(O)NH₂, —C(O)NHR, —C(O)NRR and the like where each R is independently (C₁-C₆) alkyl, (C₂-C₆) alkenyl, or (C₂-C₆) alkynyl. Genetically encoded aromatic amino acids include, but are not limited to, L-Phe (F), L-Tyr (Y), L-Trp (W) and L-His (H). Genetically non-encoded aromatic amino acids include, but are not limited to, the D-isomers of the above-listed genetically-encoded amino acids.

“Apolar Amino Acid” refers to a hydrophobic amino acid having a side chain that is uncharged at physiological pH and which has bonds in which the pair of electrons shared in common by two atoms is generally held equally by each of the two atoms (i.e., the side chain is not polar). Genetically encoded apolar amino acids include, but are not limited to, L-Leu (L), L-Val (V), L-Ile (I), L-Met (M), L-Gly (G) and L-Ala (A). Genetically non-encoded apolar amino acids include, but are not limited to, the D-isomers of the above-listed genetically-encoded amino acids, norleucine (Nle) and N-methyl valine (MeVal).

“Aliphatic Amino Acid” refers to a hydrophobic amino acid having an aliphatic hydrocarbon side chain. Genetically encoded aliphatic amino acids include, but are not limited to, L-Ala (A), L-Val (V), L-Leu (L) and L-Ile (1). Genetically non-encoded aliphatic amino acids include, but are not limited to, the D-isomers of the above-listed genetically-encoded amino acids, norleucine (Nle) and N-methyl valine (MeVal).

“Helix-Breaking Amino Acid” refers to those amino acids that have a propensity to disrupt the structure of α-helices when contained at internal positions within the helix.

Amino acid residues exhibiting helix-breaking properties are well-known in the art (see, e.g., Chou & Fasman, 1978, Ann. Rev. Biochem. 47:251-276) and include, but are not limited to L-Pro (P), D-Pro (p), L-Gly (G) and potentially all D-amino acids (when contained in an L-polypeptide; conversely, L-amino acids disrupt helical structure when contained in a D-polypeptide).

“Cysteine-like Amino Acid” refers to an amino acid having a side chain capable of participating in a disulfide linkage. Thus, cysteine-like amino acids generally have a side chain containing at least one thiol (—SH) group. Cysteine-like amino acids are unusual in that they can form disulfide bridges with other cysteine-like amino acids. The ability of L-Cys (C) -residues and other cysteine-like amino acids to exist in a polypeptide in either the reduced free —SH or oxidized disulfide-bridged form affects whether they contribute net hydrophobic or hydrophilic character to a polypeptide. Thus, while L-Cys (C) exhibits a hydrophobicity of 0.29 according to the consensus scale of Eisenberg (Eisenberg, 1984, supra), it is to be understood that for purposes of the present invention L-Cys (C) is categorized as a polar hydrophilic amino acid, notwithstanding the general classifications defined above. Other cysteine-like amino acids are similarly categorized as polar hydrophilic amino acids. Typical cysteine-like residues include, but are not limited to, penicillamine (Pen), homocysteine (hCys), etc.

As will be appreciated by those of skill in the art, the above-defined classes or categories are not mutually exclusive. Thus, amino acids having side chains exhibiting two or more physico-chemical properties can be included in multiple categories. For example, amino acid side chains having aromatic groups that are have a side chain pKa that is ionizable above or below pH 7.0, such as His (H), may exhibit both aromatic hydrophobic properties and basic or acidic hydrophilic properties, and could therefore be included in both the aromatic and basic or acidic categories. Typically, amino acids will be categorized in the class or classes that most closely define their net physico-chemical properties. The appropriate categorization of any amino acid will be apparent to those of skill in the art.

The classifications of the genetically encoded and common non-encoded amino acids according to the categories defined above are summarized in Table 1, below. It is to be understood that Table 1 is for illustrative purposes only and does not purport to be an exhaustive list of the amino acid residues belonging to each class. Other amino acid residues not specifically mentioned herein can be readily categorized based on their observed physical and chemical properties in light of the definitions provided herein.

TABLE 1 CLASSIFICATIONS OF COMMONLY ENCOUNTERED AMINO ACIDS Genetically Genetically Classification Encoded Non-Encoded Hydrophobic Aromatic F, Y, W f, y, w Apolar L, V, I, M, G, A, P l, v, i, m, a, p, Nle, MeVal Aliphatic A, V, L, I a, v, l, i, Nle, MeVal Hydrophilic Acidic D, E d, e Basic H, K, R h, k, r, Orn, Dab Polar C, Q, N, S, T c, q, n, s, t, hSer Helix-Breaking P, G p

“Synagis” or “palivizumab” refers to the humanized monoclonal antibody that is sold under the tradename SYNAGIS (MedImmune), or that is known by the name palivizumab. Synagis comprises an immunoglobulin complex of a Synagis heavy chain and a Synagis light chain that specifically binds the F protein of respiratory syncytial virus (“RSV”), as defined herein.

“Synagis heavy chain” refers to a polypeptide having an amino acid sequence that corresponds identically to the amino acid sequence of SEQ ID NO:1 (FIG. 3A).

“Synagis light chain” refers to a polypeptide having an amino acid sequence that corresponds identically to the amino acid sequence of SEQ ID NO:7 (FIG. 3B).

“Smagis Fab” refers to the antigen binding fragment of Synagis which can be obtained by digesting Synagis with papain. Synagis Fab includes the antigen binding region of Synagis and comprises a complex of Synagis light chain (SEQ ID NO:7) and N-terminal fragment (residues 1 to 220) of Synagis heavy chain (SEQ ID NO:2) linked by a disulfide bridge between Cys 216 of SEQ ID NO:2 and Cys 214 of Synagis light chain (SEQ ID NO:7). Unless stated otherwise, “Synagis Fab” includes either wild-type Syangis Fab and mutant Synagis Fab as defined herein.

“Synagis Fc” refers to a fragment of Synagis which can be obtained by digesting Synagis with papain. Synagis Fc does not include the antigen binding region of Synagis and comprises a complex of two C-terminal fragments of Synagis heavy chain (SEQ ID NO:3) linked by at least two disulfide bridges, one between the Cys 222 residues of the two chains and the other between the Cys 225 residues of the two chains.

“Synagis Fv” refers to a complex comprising the N-terminal variable segment residues 1 to 105 of Synagis heavy chain (SEQ ID NO:1) and the N-terminal sequence residues 1 to 109 of Synagis light chain (SEQ. ID NO:7). Synagis Fv includes the complementarity determining regions (“CDRs”) of Synagis heavy chain, H1 (SEQ ID NO:4), H2 (SEQ ID NO:5) and H3 (SEQ ID NO:6), and the CDRs of Synagis light chain, L1 (SEQ ID NO:8), L2 (SEQ ID NO:9) and L3 (SEQ ID NO:10).

“Association” refers to a condition of proximity between a chemical entity or compound, or portions or fragments thereof, and a polypeptide such as Synagis Fab, or portions or fragments thereof. The association may be non-covalent, i.e., where the juxtaposition is energetically favored by, e.g., hydrogen-bonding, van der Waals, electrostatic or hydrophobic interactions, or it may be covalent.

“Co-Complex” refers to a complex between Synagis, Synagis Fab, Synagis Fv or another binding fragment of Synagis and another compound, for example, an antigen, an epitope, a hapten or an analog, a mimic or a fragment thereof or an inhibitor of Synagis.

“Antibody” or “Immunoglobulin” refers to a glycoprotein produced by B leukocyte cells in response to stimulation with an immunogen, or a synthetic or recombinant version or analog of such a glycoprotein. Antibodies comprise heavy chains and light chains linked together by disulfide bonds. IgG type antibodies typically comprise two antigen binding sites.

“Complementarity Determining Region” or “CDR” refers to the hypervariable regions of an antibody that form the three-dimensional cavity or surface where an antigen or an epitope binds to the antibody. Typically, heavy chains and light chains contribute three CDRs to the antigen binding region of an antibody.

“Antigen” refers to a substance that specifically binds with antibody CDRs.

“Epitope” refers to the smallest structural area on an antigen molecule that binds an antibody.

“Antigen binding site” or “antibody binding site” refers to the location on an antibody molecule where the antigen or eptiope binds. The antigen binding site is located at the molecular surface define by the N-terminal CDRs and/or in a cleft bordered by the N-terminal CDRs of the heavy and light chains of the Fab region of an antibody molecule.

“Crystallized Synagis” refers to Synagis which is in crystalline form.

“Crystallized Synagis Fab” refers to a Synagis Fab complex which is in the crystalline form.

“Wild-type” refers to a Synagis molecule, that comprises Synagis heavy chain corresponding identically to SEQ ID NO:1 and/or Synagis light chain corresponding identically to SEQ ID NO:7, or fragments thereof. Although Synagis is a humanized antibody not derived from a natural source, for convenience the phrase “wild-type” is used to refer to a molecule which corresponds identically to Synagis, or a fragment thereof, and the phrase “mutant” is used as defined below.

“Mutant” refers to a polypeptide or complex of polypeptides characterized by an amino acid sequence that differs from the wild-type Synagis heavy chain and/or light chain sequence by the substitution of at least one amino acid residue of the wild-type Synagis sequence with a different amino acid residue and/or by the addition and/or deletion of one or more amino acid residues to or from the wild-type Synagis sequence. The additions and/or deletions can be from an internal region of the wild-type Synagis sequence and/or at either or both of the N- or C-termini. A mutant may have, but need not have, Synagis activity. Preferably, a mutant displays biological activity that is substantially similar to that of Synagis.

“Conservative Mutant” refers to a mutant in which at least one amino acid residue from the wild-type Synagis heavy chain and/or light chain sequence is substituted with a different amino acid residue that has similar physical and chemical properties, i.e., an amino acid residue that is a member of the same class or category, as defined above. For example, a conservative mutant may be a polypeptide that differs in amino acid sequence from the wild-type Synagis sequence by the substitution of a specific aromatic Phe (F) residue with an aromatic Tyr (Y) or Trp (W) residue.

“Non-Conservative Mutant” refers to a mutant in which at least one amino acid residue from the wild-type Synagis heavy chain and/or light chain sequence is substituted with a different amino acid residue that has dissimilar physical and/or chemical properties, i.e., an amino acid residue that is a member of a different class or category, as defined above. For example, a non-conservative mutant may be a polypeptide that differs in amino acid sequence from the wild-type Synagis sequence by the substitution of an acidic Glu (E) residue with a basic Arg (R), Lys (K) or Orn residue.

“Deletion Mutant” refers to a mutant having an amino acid sequence that differs from the wild-type Synagis heavy chain and/or light chain sequence by the deletion of one or more amino acid residues from the wild-type sequence. The residues may be deleted from internal regions of the wild-type Synagis sequence and/or from one or both termini.

“Truncated Mutant” refers to a deletion mutant in which the deleted residues are from the N- and/or C-terminus of the wild-type Synagis sequence.

“Extended Mutant” refers to a mutant in which additional residues are added to the N- and/or C-terminus of the wild-type Synagis sequence.

“Methionine mutant” refers to (1) a mutant in which at least one methionine residue of the wild-type Synagis heavy chain and/or light chain sequence is replaced with another residue, preferably with an aliphatic residue, most preferably with a Leu (L) or Ile (I) residue; or (2) a mutant in which a non-methionine residue, preferably an aliphatic residue, most preferably a Leu (L) or Ile (I) residue, of the wild-type Synagis sequence is replaced with a methionine residue.

“Selenomethionine mutant” refers to (1) a mutant which includes at least one selenomethionine (SeMet) residue, typically by substitution of one or more Met residues of the wild-type Synagis heavy chain and/or light chain sequence with a SeMet residue, or by addition of one or more SeMet residues at one or more termini, or (2) a methionine mutant in which at least one Met residue is substituted with a SeMet residue. Preferred SeMet mutants are those in which each Met residue is substituted with a SeMet residue.

“Cysteine mutant” refers to (1) a mutant in which at least one cysteine residue of the wild-type Synagis heavy chain and/or light chain sequence is replaced with another residue, preferably with a Ser (S) residue; or (2) a mutant in which a non-cysteine residue, preferably a Ser (S) residue, of the wild-type Synagis sequence is replaced with a cysteine residue.

“Selenocysteine mutant” refers to (1) a mutant which includes at least one selenocysteine (SeCys) residue, typically by substitution of one or more Cys residues of the wild-type Synagis heavy chain and/or light chain sequence with a SeCys residue, or by addition of one or more SeCys residues at one or more termini, or (2) a cysteine mutant in which at least one Cys residue is substituted with a SeCys residue. Preferred SeCys mutants are those in which each Cys residue or selected Cys residues of Synagis not typically involved in disulfide bonding under physiological conditions is substituted with a SeCys residue. One such Cys residue in the Synagis Fab fragment that may be substituted with selenocysteine is Cys 25 in the light chain (SEQ. ID NO: 7).

“Homologue” refers to a polypeptide having at least 70%, 80%, 90%, 95% or 99% amino acid sequence identity or having a BLAST score of 1×10⁻⁶ over at least 100 amino acids (Altschul et al., 1997, Nucleic Acids Res. 25:3389-402) with wild-type Synagis, Synagis heavy chain and/or Synagis light chain, or any functional domain of Synagis, Synagis heavy chain and/or Synagis light chain, as defined herein.

“Crystal” refers to a composition comprising a polypeptide and/or polypeptides in crystalline form. The term “crystal” includes native crystals, heavy-atom derivative crystals and co-crystals, as defined herein.

“Native Crystal” refers to a crystal wherein the polypeptide and/or polypeptides are substantially pure. As used herein, native crystals do not include crystals of polypeptides comprising amino acids that are modified with heavy atoms, such as crystals of selenomethionine mutants, selenocysteine mutants, etc.

“Heavy-atom Derivative Crystal” refers to a crystal wherein the polypeptide and/or polypeptides are in association with one or more heavy-metal atoms. As used herein, heavy-atom derivative crystals include native crystals into which a heavy metal atom is soaked, as well as crystals of selenomethionine mutants and selenocysteine mutants.

“Co-Crystal” refers to a composition comprising a co-complex, as defined above, in crystalline form. Co-crystals include native co-crystals and heavy-atom derivative co-crystals.

“Diffraction Quality Crystal” refers to a crystal that is well-ordered and of a sufficient size, i.e., at least 10 μm, preferably at least 50 μm, and most preferably at least 100 μm in its smallest dimension such that it produces measurable diffraction to at least 3 Å resolution, preferably to at least 2 Å resolution, and most preferably to at least 1.5 Å resolution or lower. Diffraction quality crystals include native crystals, heavy-atom derivative crystals, and co-crystals.

“Unit Cell” refers to the smallest and simplest volume element (i.e., parallelpiped-shaped block) of a crystal that is completely representative of the unit or pattern of the crystal, such that the entire crystal can be generated by translation of the unit cell. The dimensions of the unit cell are defined by six numbers: dimensions a, b and c and angles α, β and γ (Blundel et al., 1976, Protein Crystallography, Academic Press.). A crystal is an efficiently packed array of many unit cells.

“Triclinic Unit Cell” refers to a unit cell in which a≠b≠c and α≠β≠γ.

“Monoclinic Unit Cell” refers to a unit cell in which a≠b≠c; α=γ=90°; and β≠90°, defined to be ≧90°.

“Orthorhombic Unit Cell” refers to a unit cell in which a≠b≠c; and α=β=γ=90°.

“Tetragonal Unit Cell” refers to a unit cell in which a=b≠c; and α=β=γ=90°.

“Trigonal/Rhombohedral Unit Cell” refers to a unit cell in which a=b=c; and α=β=γ≠90°.

“Trigonal/Hexagonal Unit Cell” refers to a unit cell in which a=b=c; α=β=90°; and γ=120°.

“Cubic Unit Cell” refers to a unit cell in which a=b=c; and α=β=γ=90°.

“Crystal Lattice” refers to the array of points defined by the vertices of packed unit cells.

“Space Group” refers to the set of symmetry operations of a unit cell. In a space group designation (e.g., C2) the capital letter indicates the lattice type and the other symbols represent symmetry operations that can be carried out on the unit cell without changing its appearance.

“Asymmetric Unit” refers to the largest aggregate of molecules in the unit cell that possesses no symmetry elements that are part of the space group symmetry, but that can be juxtaposed on other identical entities by symmetry operations.

“Crystallographically-Related Dimer” refers to a dimer of two molecules wherein the symmetry axes or planes that relate the two molecules comprising the dimer coincide with the symmetry axes or planes of the crystal lattice.

“Non-Crystallographically-Related Dimer” refers to a dimer of two molecules wherein the symmetry axes or planes that relate the two molecules comprising the dimer do not coincide with the symmetry axes or planes of the crystal lattice.

“Isomorphous Replacement” refers to the method of using heavy-atom derivative crystals to obtain the phase information necessary to elucidate the three-dimensional structure of a crystallized polypeptide (Blundel et al., 1976, Protein Crystallography, Academic Press.).

“Multi-Wavelength Anomalous Dispersion or MAD” refers to a crystallographic technique in which X-ray diffraction data are collected at several different wavelengths from a single heavy-atom derivative crystal, wherein the heavy atom has absorption edges near the energy of incoming X-ray radiation. The resonance between X-rays and electron orbitals leads to differences in X-ray scattering from absorption of the X-rays (known as anomalous scattering) and permits the locations of the heavy atoms to be identified, which in turn provides phase information for a crystal of a polypeptide. A detailed discussion of MAD analysis can be found in Hendrickson, 1985, Trans. Am. Crystallogr. Assoc., 21:11; Hendrickson et al, 1990, EMBO J. 9:1665; and Hendrickson, 1991, Science 4:91.

“Single Wavelength Anomalous Dispersion or SAD” refers to a crystallographic technique in which X-ray diffraction data are collected at a single wavelength from a single native or heavy-atom derivative crystal, and phase information is extracted using anomalous scattering information from atoms such as sulfur or chlorine in the native crystal or from the heavy atoms in the heavy-atom derivative crystal. The wavelength of X-rays used to collect data for this phasing technique need not be close to the absorption edge of the anomalous scatterer. A detailed discussion of SAD analysis can be found in Brodersen et al., 2000, Acta Cryst., D56:431-441.

“Single Isomorphous Replacement With Anomalous Scattering or SIRAS” refers to a crystallographic technique that combines isomorphous replacement and anomalous scattering techniques to provide phase information for a crystal of a polypeptide. X-ray diffraction data are collected at a single wavelength, usually from a single heavy-atom derivative crystal. Phase information obtained only from the location of the heavy atoms in a single heavy-atom derivative crystal leads to an ambiguity in the phase angle, which is resolved using anomalous scattering from the heavy atoms. Phase information is therefore extracted from both the location of the heavy atoms and from anomalous scattering of the heavy atoms. A detailed discussion of SIRAS analysis can be found in North, 1965, Acta Cryst. 18:212-216; Matthews, 1966, Acta Cryst. 20:82-86.

“Molecular Replacement” refers to the method of calculating initial phases for a new crystal of a polypeptide whose structure coordinates are unknown by orienting and positioning a polypeptide whose structure coordinates are known within the unit cell of the new crystal so as to best account for the observed diffraction pattern of the new crystal. Phases are then calculated from the oriented and positioned polypeptide and combined with observed amplitudes to provide an approximate Fourier synthesis of the structure of the polypeptides comprising the new crystal. This, in turn, is subject to any of several methods of refinement to provide a final, accurate set of structure coordinates for the new crystal (Lattman, 1985, Methods in Enzymology 115:55-77; Rossmann, 1972, “The Molecular Replacement Method,” Int. Sci. Rev. Ser. No. 13, Gordon & Breach, New York; Brünger et al, 1991, Acta Crystallogr A. 47:195-204).

“Having Substantially the Same Three-dimensional Structure” refers to a polypeptide that is characterized by a set of atomic structure coordinates that have a root mean square deviation (r.m.s.d.) of less than or equal to about 2 Å when superimposed onto the atomic structure coordinates of Table 2, or a subset thereof such as individual CDRs, individual secondary structure elements or grouped secondary structure elements such as β-sheets, when at least about 50% to 100% of the Cα atoms of the coordinates are included in the superposition.

“Cα:” As used herein, “Cα” refers to the alpha carbon of an amino acid residue.

5. BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 provides a photograph of an orthorhombic crystal of Synagis Fab;

FIG. 2 provides a diffraction pattern (1° oscillation) of Synagis Fab prepared as described in the Examples;

FIG. 3A provides the amino acid sequences of Synagis heavy chain (SEQ ID NO:1), Synagis heavy chain Fab fragment (SEQ ID NO:2), Synagis heavy chain Fc fragment (SEQ ID NO:3), Synagis heavy chain variable region H1 (SEQ ID NO:4), heavy chain variable region H2 (SEQ ID NO:5) and Synagis heavy chain variable region H3 (SEQ ID NO:6).

FIG. 3B provides the amino acid sequences of Synagis light chain (SEQ ID NO:7), Synagis light chain variable region L1 (SEQ ID NO:8), Synagis light chain variable region L2 (SEQ ID NO:9) and Synagis light chain variable region L3 (SEQ ID NO:10).

FIG. 4 provides a ribbon diagram of the three-dimensional X-ray diffraction structure of Synagis Fab;

FIG. 5 provides a photograph of a tetragonal crystal form of Synagis Fab;

FIG. 6 provides a schematic representation of a generalized IgG type antibody showing the relative positions of the light chain VL and CL domains and the heavy chain VH, CH1, CH2 and CH3 domains;

FIG. 7A provides a ribbon diagram of the three-dimensional structure of Synagis VH and VL domains;

FIG. 7B provides a ribbon diagram of the three-dimensional structure of Synagis Fab CL and CH1 domains;

FIG. 8 provides a stereo view of a superposition of Synagis light chain CDRs L1, L2 & L3 with representative canonical structures;

FIG. 9 provides a stereo view of a superposition of Synagis heavy chain CDRs H1 & H2 with representative canonical structures; and

FIG. 10 provides a Ramachandran plot of the model Synagis Fab crystal structure.

5.1. BRIEF DESCRIPTION OF THE TABLES

Table 1 Classifications of Commonly Encountered Amino Acids;

Table 2 Coordinates of Synagis Fab;

Table 3 Description and Comparison of Synagis Light Chain CDR Canonical Structure;

Table 4 Description and Comparison of Synagis Heavy Chain CDR Canonical Structure;

Table 5 Data Collection Summary;

Table 6 Refinement Parameters.

6. DETAILED DESCRIPTION OF THE INVENTION 6.1 Crystalline Synagis Fab

The crystals of the invention may be obtained include native crystals and heavy-atom derivative crystals. Native crystals generally comprise substantially pure polypeptides corresponding to Synagis Fab in crystalline form.

It is to be understood that the crystalline Synagis Fab of the invention that can be obtained is not limited to wild-type Synagis Fab. Indeed, the crystals may comprise mutants of wild-type Synagis Fab. Mutants of wild-type Synagis Fab are obtained by replacing at least one amino acid residue in the sequence of the wild-type Synagis Fab with a different amino acid residue, or by adding or deleting one or more amino acid residues within the wild-type sequence and/or at the N- and/or C-terminus of the wild-type Synagis Fab. Such mutants should crystallize under crystallization conditions that are substantially similar to those used to crystallize the wild-type Synagis Fab.

The types of mutants contemplated by this invention include conservative mutants, non-conservative mutants, deletion mutants, truncated mutants, extended mutants, methionine mutants, selenomethionine mutants, cysteine mutants and selenocysteine mutants. A mutant or a fragment may have, but need not have, Synagis activity. Preferably, a mutant or a fragment displays biological activity that is substantially similar to that of the wild-type Synagis. Methionine, selenomethione, cysteine, and selenocysteine mutants are particularly useful for producing heavy-atom derivative crystals, as described in detail, below.

It will be recognized by one of skill in the art that the types of mutants contemplated herein are not mutually exclusive; that is, for example, a polypeptide having a conservative mutation in one amino acid may in addition have a truncation of residues at the N-terminus, and several Leu or Ile→Met mutations.

Sequence alignments of polypeptides in a protein family or of homologous polypeptide domains can be used to identify potential amino acid residues in the polypeptide sequence that are candidates for mutation. Identifying mutations that do not significantly interfere with the three-dimensional structure of Synagis and/or that do not deleteriously affect, and that may even enhance, the activity of Synagis will depend, in part, on the region where the mutation occurs. In the CDR regions of the molecule, such as those shown in FIG. 4, non-conservative substitutions as well as conservative substitutions may be tolerated without significantly disrupting the three-dimensional structure and/or biological activity of the molecule. In framework regions, or regions containing significant secondary structure, such as those regions shown in FIG. 4, conservative amino acid substitutions are preferred.

Conservative amino acid substitutions are well-known in the art, and include substitutions made on the basis of a similarity in polarity, charge, solubility, size, hydrophobicity and/or the hydrophilicity of the amino acid residues involved. Typical conservative substitutions are those in which the amino acid is substituted with a different amino acid that is a member of the same class or category, as those classes are defined herein. Thus, typical conservative substitutions include aromatic to aromatic, apolar to apolar, aliphatic to aliphatic, acidic to acidic, basic to basic, polar to polar, etc. Other conservative amino acid substitutions are well known in the art. It will be recognized by those of skill in the art that generally, a total of about 20% or fewer, typically about 10% or fewer, most usually about 5% or fewer, of the amino acids in the wild-type polypeptide sequence can be conservatively substituted with other amino acids without deleteriously affecting the biological activity and/or three-dimensional structure of the molecule, provided that such substitutions do not involve residues that are critical for structure or activity, as discussed above. There has been no complete examination of the effect of conservative mutations of the closely conserved amino acids in immunoglobulin framework regions.

In some embodiments, it may be desirable to make mutations in the active site of a protein or in the antigen binding site of an antibody, e.g., to reduce or completely eliminate antibody activity. While in most instances the amino acids of Synagis will be substituted with genetically-encoded amino acids, in certain circumstances mutants may include genetically non-encoded amino acids. For example, non-encoded derivatives of certain encoded amino acids, such as SeMet and/or SeCys, may be incorporated into the polypeptide chain using biological expression systems (such SeMet and SeCys mutants are described in more detail, infra).

Alternatively, in instances where the mutant will be prepared in whole or in part by chemical synthesis, virtually any non-encoded amino acids may be used, ranging from D-isomers of the genetically encoded amino acids to non-encoded naturally-occurring natural and synthetic amino acids.

Conservative amino acid substitutions for many of the commonly known non-genetically encoded amino acids are well known in the art. Conservative substitutions for other non-encoded amino acids can be determined based on their physical properties as compared to the properties of the genetically encoded amino acids.

In some instances, it may be particularly advantageous or convenient to substitute, delete from and/or add amino acid residues to Synagis in order to provide convenient cloning sites in cDNA encoding the polypeptide, to aid in purification of the polypeptide, etc. Such substitutions, deletions and/or additions that do not substantially alter the three dimensional structure of the native Synagis will be apparent to those having skills in the art. These substitutions, deletions and/or additions include, but are not limited to, His tags, intein-containing self-cleaving tags, maltose binding protein fusions, glutathione S-transferase protein fusions, antibody fusions, green fluorescent protein fusions, signal peptide fusions, biotin accepting peptide fusions, and the like.

Mutations may also be introduced into a polypeptide sequence where there are residues, e.g., cysteine residues, that interfere with crystallization. Such cysteine residues can be substituted with an appropriate amino acid that does not readily form covalent bonds with other amino acid residues under crystallization conditions; e.g., by substituting the cysteine with Ala, Ser or Gly. Any cysteine residue that does not form disulfide bonds either between a heavy chain and a light chain or between two heavy chains of Synagis is a good candidate for replacement. Preferably, Cys residues that are known to participate in disulfide bridges are not substituted or are conservatively substituted with other cysteine-like amino acids so that the residue can participate in a disulfide bridge. In addition, other cysteine residues located in a non-helical or non-β-stranded segment, based on secondary structure assignments, are good candidates for replacement. One such Cys residue in the Synagis Fab crystal structure is at light chain position 25 (SEQ. ID NO: 7).

It should be noted that the mutants contemplated herein need not exhibit Synagis activity. Indeed, amino acid substitutions, additions or deletions that interfere with the activity of Synagis are specifically contemplated by the invention. Such crystalline polypeptides, or the atomic structure coordinates obtained therefrom, can be used to provide phase information to aid the determination of the three-dimensional X-ray structures of other related or non-related crystalline polypeptides.

The heavy-atom derivative crystals from which the atomic structure coordinates of the invention can be obtained generally comprise a crystalline Synagis Fab complex in association with one or more heavy metal atoms. The complex may correspond to a wild-type or a mutant Synagis Fab, which may optionally be in co-complex with one or more molecules, as previously described. The complex may also correspond to another Synagis fragment or to a mutated form thereof. There are two types of heavy-atom derivatives of polypeptides: heavy-atom derivatives resulting from exposure of the protein to a heavy metal in solution, wherein crystals are grown in medium comprising the heavy metal, or in crystalline form, wherein the heavy metal diffuses into the crystal, and heavy-atom derivatives wherein the polypeptide comprises heavy-atom containing amino acids, e.g., selenomethionine and/or selenocysteine mutants.

In practice, heavy-atom derivatives of the first type can be formed by soaking a native crystal in a solution comprising heavy metal atom salts, or organometallic compounds, e.g., lead chloride, gold thiomalate, ethylmercurithiosalicylic acid-sodium salt (thimerosal), uranyl acetate, platinum tetrachloride, osmium tetraoxide, zinc sulfate, and cobalt hexamine, which can diffuse through the crystal and bind to the crystalline polypeptide.

Heavy-atom derivatives of this type can also be formed by adding to a crystallization solution comprising the polypeptide to be crystallized an amount of a heavy metal atom salt, which may associate with the protein and be incorporated into the crystal. The location(s) of the bound heavy metal atom(s) can be determined by X-ray diffraction analysis of the crystal. This information, in turn, is used to generate the phase information needed to construct the three-dimensional structure of the protein.

Heavy-atom derivative crystals may also be prepared from polypeptides that include one or more SeMet and/or SeCys residues (SeMet and/or SeCys mutants). Such selenocysteine or selenomethionine mutants may be made from wild-type or mutant Synagis Fab by expression of Synagis Fab-encoding cDNAs in auxotrophic E. coli strains. Hendrickson et al., 1990, EMBO J. 9(5):1665-1672. The selenocysteine or selenomethionine mutants may also be made from intact Synagis, other fragments of Synagis, or mutated forms thereof. In this method, a cDNA encoding a wild-type or mutant Synagis polypeptide may be expressed in a host organism on a growth medium depleted of either natural cysteine or methionine (or both) but enriched in selenocysteine or selenomethionine (or both). Alternatively, selenocysteine or selenomethionine mutants may be made using nonauxotrophic E. coli strains, e.g., by inhibiting methionine biosynthesis in these strains with high concentrations of Ile, Lys, Thr, Phe, Leu or Val and then providing selenomethionine in the medium (Doublié, 1997, Methods in Enzymology 276:523-530). Furthermore, selenocysteine can be selectively incorporated into polypeptides by exploiting the prokaryotic and eukaryotic mechanisms for selenocysteine incorporation into certain classes of proteins in vivo, as described in U.S. Pat. No. 5,700,660 to Leonard et al. (filed Jun. 7, 1995). One of skill in the art will recognize that selenocysteine is preferably not incorporated in place of cysteine residues that form disulfide bridges, as these may be important for maintaining the three-dimensional structure of the protein and are preferably not to be eliminated. One of skill in the art will further recognize that, in order to obtain accurate phase information, approximately one selenium atom should be incorporated for every 140 amino acid residues of the polypeptide chain. The number of selenium atoms incorporated into the polypeptide chain can be conveniently controlled by designing a Met or Cys mutant having an appropriate number of Met and/or Cys residues, as described more fully below.

In some instances, a polypeptide to be crystallized may not contain cysteine or methionine residues. Therefore, if selenomethionine and/or selenocysteine mutants are to be used to obtain heavy-atom derivative crystals, methionine and/or cysteine residues must be introduced into the polypeptide chain. Likewise, Cys residues may be introduced into the polypeptide chain if the use of a cysteine-binding heavy metal, such as mercury, is contemplated for production of a heavy-atom derivative crystal.

Such mutations are preferably introduced into the polypeptide sequence at sites that will not disturb the overall protein fold. For example, a residue that is conserved among many members of the protein family or that is thought to be involved in maintaining its activity or structural integrity, as determined by, e.g., sequence alignments, should not be mutated to a Met or Cys. In addition, conservative mutations, such as Ser to Cys, or Leu or Ile to Met, are preferably introduced. One additional consideration is that, in order for a heavy-atom derivative crystal to provide phase information for structure determination, the location of the heavy atom(s) in the crystal unit cell must be determinable and provide phase information. Therefore, a mutation is preferably not introduced into a portion of the protein that is likely to be mobile, e.g., at, or within about 1-5 residues of, the N- and C-termini.

Conversely, if there are too many methionine and/or cysteine residues in a polypeptide sequence, over-incorporation of the selenium-containing side chains can lead to the inability of the polypeptide to fold and/or crystallize, as well as to complications in solving the crystal structure. In this case, methionine and/or cysteine mutants are prepared by substituting one or more of these Met and/or Cys residues with another residue. The considerations for these substitutions are the same as those discussed above for mutations that introduce methionine and/or cysteine residues into the polypeptide. Specifically, the Met and/or Cys residues are preferably conservatively substituted with Leu/Ile and Ser, respectively.

As DNA encoding cysteine and methionine mutants can be used in the methods described above for obtaining SeCys and SeMet heavy-atom derivative crystals, the preferred Cys or Met mutant will have one Cys or Met residue for every 140 amino acids.

6.2 Production of Polypeptides

The native and mutated Synagis polypeptides described herein may be chemically synthesized in whole or part using techniques that are well-known in the art (see, e.g., Creighton, 1983, Proteins: Structures and Molecular Principles, W. H. Freeman & Co., NY.). Alternatively, methods that are well known to those skilled in the art can be used to construct expression vectors containing a native or mutated Synagis polypeptide coding sequence and appropriate transcriptional/translational control signals. These methods include in vitro recombinant DNA techniques, synthetic techniques and in vivo recombination/genetic recombination. See, for example, the techniques described in Maniatis et al., 1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, NY and Ausubel et al., 1989, Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley Interscience, NY.

A variety of host-expression vector systems may be utilized to express Synagis coding sequences. These include but are not limited to microorganisms such as bacteria transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing the Synagis coding sequences; yeast transformed with recombinant yeast expression vectors containing the Synagis coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing the Synagis coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing the Synagis coding sequences; or animal cell systems. The expression elements of these systems vary in their strength and specificities.

Specifically designed vectors allow the shuttling of DNA between hosts such as bacteria-yeast or bacteria-animal cells. An appropriately constructed expression vector may contain: an origin of replication for autonomous replication in host cells, selectable markers, a limited number of useful restriction enzyme sites, a potential for high copy number, and active promoters. A promoter is defined as a DNA sequence that directs RNA polymerase to bind to DNA and initiate RNA synthesis. A strong promoter is one that causes mRNAs to be initiated at high frequency.

Depending on the host/vector system utilized, any of a number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used in the expression vector. For example, when cloning in bacterial systems, inducible promoters such as the T7 promoter, pL of bacteriophage λ, plac, ptrp, ptac (ptrp-lac hybrid promoter) and the like may be used; when cloning in insect cell systems, promoters such as the baculovirus polyhedrin promoter may be used; when cloning in plant cell systems, promoters derived from the genome of plant cells (e.g., heat shock promoters; the promoter for the small subunit of RUBISCO; the promoter for the chlorophyll a/b binding protein) or from plant viruses (e.g., the 35S RNA promoter of CaMV; the coat protein promoter of TMV) may be used; when cloning in mammalian cell systems, promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter) may be used; when generating cell lines that contain multiple copies of the tyrosine kinase domain DNA, SV40-, BPV- and EBV-based vectors may be used with an appropriate selectable marker.

The expression vector may be introduced into host cells via any one of a number of techniques including but not limited to transformation, transfection, infection, protoplast fusion, and electroporation. The expression vector-containing cells are clonally propagated and individually analyzed to determine whether they produce Synagis. Identification of Synagis expressing host cell clones may be done by several means, including but not limited to immunological reactivity with anti-Synagis antibodies, and the presence of host cell-associated Synagis activity.

Expression of Synagis cDNA may also be performed using in vitro produced synthetic mRNA. Synthetic mRNA can be efficiently translated in various cell-free systems, including but not limited to wheat germ extracts and reticulocyte extracts, as well as efficiently translated in cell based systems, including but not limited to microinjection into frog oocytes.

To determine the Synagis cDNA sequence(s) that yields optimal levels of Synagis activity and/or Synagis protein, modified Synagis cDNA molecules are constructed. Host cells are transformed with the cDNA molecules and the levels of Synagis RNA and/or protein are measured.

Levels of Synagis protein in host cells are quantitated by a variety of methods such as immunoaffinity and/or ligand affinity techniques, Synagis-specific affinity beads or Synagis-specific antibodies are used to isolate ³⁵S-methionine labeled or unlabeled Synagis protein. Labeled or unlabeled Synagis protein is analyzed by SDS-PAGE. Unlabeled Synagis is detected by Western blotting, ELISA or RIA employing Synagis-specific antibodies.

Following expression of a Synagis polypeptide in a recombinant host cell, the Synagis polypeptide may be recovered to provide Synagis Fab in active form. Several Synagis purification procedures are available and suitable for use. Recombinant Synagis may be purified from cell lysates or from conditioned culture media, by various combinations of, or individual application of, fractionation, or chromatography steps that are known in the art.

In addition, a recombinant Synagis polypeptide can be separated from other cellular proteins by use of an immuno-affinity column made with monoclonal or polyclonal antibodies specific for full length nascent Synagis or polypeptide fragments thereof.

Alternatively, a Synagis polypeptide may be recovered from a host cell in an unfolded, inactive form, e.g., from inclusion bodies of bacteria. Proteins recovered in this form may be solublized using a denaturant, e.g., guanidinium hydrochloride, and then refolded into an active form using methods known to those skilled in the art, such as dialysis (Rudolph & Lee, FASEB J., 10:49-56).

6.3 Crystallization of Polypeptides and Characterization of Crystal

The native crystalline Synagis Fab from which the atomic structure coordinates of the invention are obtained can be obtained by conventional means and are well-known in the art of protein crystallography, including batch, liquid bridge, dialysis, and vapor diffusion methods (see, e.g., McPherson, 1982, Preparation and Analysis of Protein Crystals, John Wiley, New York; McPherson, 1990, Eur. J. Biochem. 189:1-23.; Weber, 1991, Adv. Protein Chem. 41:1-36.).

Generally, native crystals are grown by dissolving substantially pure Synagis Fab in an aqueous buffer containing a precipitant at a concentration just below that necessary to precipitate the protein. Examples of precipitants include, but are not limited to, polyethylene glycol, ammonium sulfate, 2-methyl-2,4-pentanediol, sodium citrate, sodium chloride, glycerol, isopropanol, lithium sulfate, sodium acetate, sodium formate, potassium sodium tartrate, ethanol, hexanediol, ethylene glycol, dioxane, t-butanol and combinations thereof. Water is removed by controlled evaporation to produce precipitating conditions, which are maintained until crystal growth ceases.

In a preferred embodiment, native crystals are grown by vapor diffusion in hanging drops (McPherson, 1982, Preparation and Analysis of Protein Crystals, John Wiley, New York; McPherson, 1990, Eur. J. Biochem. 189:1-23.). In this method, the polypeptide/precipitant solution is allowed to equilibrate in a closed container with a larger aqueous reservoir having a precipitant concentration optimal for producing crystals. Generally, less than about 25 μL of substantially pure polypeptide solution is mixed with an equal volume of reservoir solution, giving a precipitant concentration about half that required for crystallization. This solution is suspended as a droplet underneath a coverslip, which is sealed onto the top of the reservoir. The sealed container is allowed to stand, usually for about 2-6 weeks, until crystals grow.

For native crystals from which the atomic structure coordinates of the invention are obtained, it has been found that hanging drops or sitting drops containing about 2 μL of Synagis Fab (15 mg/mL in 1 mM Tris, pH 7.6) and 2 μL reservoir solution (15% w/v PEG 4000, 10% 2-propanol, 0.2 M ammonium sulfate and 100 mM Tris, pH 8.5) suspended over 500 μL reservoir solution for about 10 to 14 days at 22° C. provide diffraction quality crystals.

Of course, those having skill in the art will recognize that the above-described crystallization conditions can be varied. Such variations may be used alone or in combination, and include polypeptide solutions containing Synagis Fab concentrations between 3 mg/mL and 10 mg/mL, Tris concentrations between 50 mM and 100 mM, 2-propanol concentrations between 7% and 20%, pH ranges between 6.4 and 11, PEG concentrations of 7% to 10%, PEG molecular weights of 3350 to 8000; and equilibrated with reservoir solutions containing PEG 4000 concentrations between 14% and 20% (w/v), polyethylene glycol molecular weights between 3350 and 8000, 2-propanol concentrations between 7% and 20% (v/v). Other buffer solutions may be used such as sodium cacodylate, HEPES, CAPS, CAPSO, bicine and glycine buffer, so long as the desired pH range is maintained.

Synagis Fab has also been crystallized using ammonium sulfate as the precipitant. These crystals (FIG. 5) are grown from a solution of 15 mg/ml Synagis Fab with equal volume of 1.8 to 2.1 M ammounium sulfate, pH 9.0, equilibrated against 1.8 to 2.1 M ammonium sulfate. The crystals are tetragonal, space group R32 with a=b=92.63 Å, c=179.02 Å, α=β=γ=90°. These Synagis Fab crystals diffract to 3.5 Å or better.

Heavy-atom derivative crystals can be obtained by soaking native crystals in mother liquor containing salts of heavy metal atoms. It has been found that soaking a native crystal in a solution identical to the crystallization solution and additionally containing 1 mM to about 100 mM of a molecule containing the desired heavy atom (Hg, Ur, Pt, Sm, Cd, W, Os, Ir, Pb, ect.) for about 1 hour to several months. One to two day soakings of the crystal in the heavy atom containing solution should be sufficient to provide derivative crystals suitable for use as isomorphous replacements in determining the X-ray crystal structure of the Synagis Fab polypeptide.

Heavy-atom derivative crystals can also be obtained from SeMet and/or SeCys mutants, as described above for native crystals.

Mutant proteins may crystallize under slightly different crystallization conditions than wild-type protein, or under very different crystallization conditions, depending on the nature of the mutation, and its location in the protein. For example, a non-conservative mutation may result in alteration of the hydrophilicity of the mutant, which may in turn make the mutant protein either more soluble or less soluble than the wild-type protein. Typically, if a protein becomes more hydrophilic as a result of a mutation, it will be more soluble than the wild-type protein in an aqueous solution and a higher precipitant concentration will be needed to cause it to crystallize. Conversely, if a protein becomes less hydrophilic as a result of a mutation, it will be less soluble in an aqueous solution and a lower precipitant concentration will be needed to cause it to crystallize. If the mutation happens to be in a region of the protein involved in crystal lattice contacts, crystallization conditions may be affected in more unpredictable ways.

Co-crystals can be obtained by soaking a native crystal in mother liquor containing compound that binds Synagis Fab such as an antigen or an analog thereof, or by co-crystallizing Synagis Fab in the presence of one or more binding compounds.

6.4 Characterization of Crystals

The dimensions of a unit cell of a crystal are defined by six numbers, the lengths of three unique edges, a, b, and c, and three unique angles, α, β, and γ. The type of unit cell that comprises a crystal is dependent on the values of these variables, as discussed above in Section 3.2.

When a crystal is placed in an X-ray beam, the incident X-rays interact with the electron cloud of the molecules that make up the crystal, resulting in X-ray scatter. The combination of X-ray scatter with the lattice of the crystal gives rise to nonuniformity of the scatter; areas of high intensity are called diffracted X-rays. The angle at which diffracted beams emerge from the crystal can be computed by treating diffraction as if it were reflection from sets of equivalent, parallel planes of atoms in a crystal (Bragg's Law). The most obvious sets of planes in a crystal lattice are those that are parallel to the faces of the unit cell. These and other sets of planes can be drawn through the lattice points. Each set of planes is identified by three indices, hkl. The h index gives the number of parts into which the a edge of the unit cell is cut, the k index gives the number of parts into which the b edge of the unit cell is cut, and the l index gives the number of parts into which the c edge of the unit cell is cut by the set of hkl planes. Thus, for example, the 235 planes cut the a edge of each unit cell into halves, the b edge of each unit cell into thirds, and the c edge of each unit cell into fifths. Planes that are parallel to the bc face of the unit cell are the 100 planes; planes that are parallel to the ac face of the unit cell are the 010 planes; and planes that are parallel to the ab face of the unit cell are the 001 planes.

When a detector is placed in the path of the diffracted X-rays, in effect cutting into the sphere of diffraction, a series of spots, or reflections, are recorded to produce a “still” diffraction pattern. Each reflection is the result of X-rays reflecting off one set of parallel planes, and is characterized by an intensity, which is related to the distribution of molecules in the unit cell, and hkl indices, which correspond to the parallel planes from which the beam producing that spot was reflected. If the crystal is rotated about an axis perpendicular to the X-ray beam, a large number of reflections is recorded on the detector, resulting in a diffraction pattern as shown in FIG. 2.

The unit cell dimensions and space group of a crystal can be determined from its diffraction pattern. First, the spacing of reflections is inversely proportional to the lengths of the edges of the unit cell. Therefore, if a diffraction pattern is recorded when the X-ray beam is perpendicular to a face of the unit cell, two of the unit cell dimensions may be deduced from the spacing of the reflections in the x and y directions of the detector, the crystal-to-detector distance, and the wavelength of the X-rays. Those of skill in the art will appreciate that, in order to obtain all three unit cell dimensions, the crystal must be rotated such that the X-ray beam is perpendicular to another face of the unit cell. Second, the angles of a unit cell can be determined by the angles between lines of spots on the diffraction pattern. Third, the absence of certain reflections and the repetitive nature of the diffraction pattern, which may be evident by visual inspection, indicate the internal symmetry, or space group, of the crystal. Therefore, a crystal may be characterized by its unit cell and space group, as well as by its diffraction pattern. Because the lengths of the unit cell axes in a protein crystal are large and the concomitant reciprocal cell lengths are very short, the unit cell dimensions and space group of a protein crystal can be determined from one reciprocal space photograph if the crystal is rotated through approximately one degree. A digital representative of such a photograph is shown in FIG. 2 for the orthorhombic Synagis Fab crystal.

Once the dimensions of the unit cell are determined, the likely number of polypeptides in the asymmetric unit can be deduced from the size of the polypeptide, the density of the average protein, and the typical solvent content of a protein crystal, which is usually in the range of 30-70% of the unit cell volume (Matthews, 1968. J. Mol. Biol. 33:491-497).

The Synagis Fab crystals of the present invention are generally characterized by a diffraction pattern, as shown in FIG. 2. The crystals are further characterized by unit cell dimensions and space group symmetry information obtained from the diffraction patterns, as described above. The crystals, which may be native crystals, heavy-atom derivative crystals or co-crystals, have an a orthorhombic unit cell (i.e., unit cells wherein a≠b≠c; and α=β=γ=90°) and space group symmetry P2₁2₁2₁.

In one form of crystalline Synagis Fab, the unit cell has dimensions of a=77.36+/−0.2 Å, b=103.92+/−0.2 Å, c=68.87+/−0.2 Å. There is one Synagis Fab complex in the asymmetric unit.

6.5 Collection of Data and Determination of Structure Solutions

The diffraction pattern is related to the three-dimensional shape of the molecule by a Fourier transform. The process of determining the solution is in essence a re-focusing of the diffracted X-rays to produce a three-dimensional image of the molecule in the crystal. Since re-focusing of X-rays cannot be done with a lens at this time, it is done via mathematical operations.

The sphere of diffraction has symmetry that depends on the internal symmetry of the crystal, which means that certain orientations of the crystal will produce the same set of reflections. Thus, a crystal with high symmetry has a more repetitive diffraction pattern, and there are fewer unique reflections that need to be recorded in order to have a complete representation of the diffraction. The goal of data collection, a dataset, is a set of consistently measured, indexed intensities for as many reflections as possible. A complete dataset is collected if at least 80%, preferably at least 90%, most preferably at least 95% of unique reflections are recorded. In one embodiment, a complete dataset is collected using one crystal. In another embodiment, a complete dataset is collected using more than one crystal of the same type.

Sources of X-rays include, but are not limited to, a rotating anode X-ray generator such as a Rigaku RU-200 or a beamline at a synchrotron light source, such as the Advanced Photon Source at Argonne National Laboratory. Suitable detectors for recording diffraction patterns include, but are not limited to, X-ray sensitive film, multiwire area detectors, image plates coated with phosphorus, and CCD cameras. Typically, the detector and the X-ray beam remain stationary, so that, in order to record diffraction from different parts of the crystal's sphere of diffraction, the crystal itself is moved via an automated system of moveable circles called a goniostat.

One of the biggest problems in data collection, particularly from macromolecular crystals having a high solvent content, is the rapid degradation of the crystal in the X-ray beam. In order to slow the degradation, data is often collected from a crystal at liquid nitrogen temperatures. In order for a crystal to survive the initial exposure to liquid nitrogen, the formation of ice within the crystal must be prevented by the use of a cryoprotectant. Suitable cryoprotectants include, but are not limited to, low molecular weight polyethylene glycols, ethylene glycol, sucrose, glycerol, xylitol, and combinations thereof. Crystals may be soaked in a solution comprising the one or more cryoprotectants prior to exposure to liquid nitrogen, or the one or more cryoprotectants may be added to the crystallization solution. Data collection at liquid nitrogen temperatures may allow the collection of an entire dataset from one crystal.

Once a dataset is collected, the information is used to determine the three-dimensional structure of the molecule in the crystal. However, this cannot be done from a single measurement of reflection intensities because certain information, known as phase information, is lost between the three-dimensional shape of the molecule and its Fourier transform, the diffraction pattern. This phase information must be acquired by methods described below in order to perform a Fourier transform on the diffraction pattern to obtain the three-dimensional structure of the molecule in the crystal. It is the determination of phase information that in effect refocuses X-rays to produce the image of the molecule.

One method of obtaining phase information is by isomorphous replacement, in which heavy-atom derivative crystals are used. In this method, the positions of heavy atoms bound to the molecules in the heavy-atom derivative crystal are determined, and this information is then used to obtain the phase information necessary to elucidate the three-dimensional structure of a native crystal. (Blundel et al., 1976, Protein Crystallography, Academic Press).

Another method of obtaining phase information is by molecular replacement, which is a method of calculating initial phases for a new crystal of a polypeptide whose structure coordinates are unknown by orienting and positioning a polypeptide whose structure coordinates are known, and believed to be similar to the polypeptide of unknown structure, within the unit cell of the new crystal so as to best account for the observed diffraction pattern of the new crystal. Phases are then calculated from the oriented and positioned polypeptide and combined with observed amplitudes to provide an approximate Fourier synthesis of the structure of the molecules comprising the new crystal. (Lattman, 1985, Methods in Enzymology 115:55-77; Rossmann, 1972, “The Molecular Replacement Method,” Int. Sci. Rev. Ser. No. 13, Gordon & Breach, New York; Brünger et al., 1991, Acta Crystallogr A. 47:195-204).

A third method of phase determination is multi-wavelength anomalous diffraction or MAD. In this method, X-ray diffraction data are collected at several different wavelengths from a single crystal containing at least one heavy atom with absorption edges near the energy of incoming X-ray radiation. The resonance between X-rays and electron orbitals leads to differences in X-ray scattering that permits the locations of the heavy atoms to be identified, which in turn provides phase information for a crystal of a polypeptide. A detailed discussion of MAD analysis can be found in Hendrickson, 1985, Trans. Am. Crystallogr. Assoc., 21:11; Hendrickson et al., 1990, EMBO J. 9:1665; and Hendrickson, 1991, Science 4:91.

A fourth method of determining phase information is single wavelength anomalous dispersion or SAD. In this technique, X-ray diffraction data are collected at a single wavelength from a single native or heavy-atom derivative crystal, and phase information is extracted using anomalous scattering information from atoms such as sulfur or chlorine in the native crystal or from the heavy atoms in the heavy-atom derivative crystal. The wavelength of X-rays used to collect data for this phasing technique need not be close to the absorption edge of the anomalous scatterer. A detailed discussion of SAD analysis can be found in Brodersen et al., 2000, Acta Cryst., D56:431-441.

A fifth method of determining phase information is single isomorphous replacement with anomalous scattering or SIRAS. This technique combines isomorphous replacement and anomalous scattering techniques to provide phase information for a crystal of a polypeptide. X-ray diffraction data are collected at a single wavelength, usually from a single heavy-atom derivative crystal. Phase information obtained only from the location of the heavy atoms in a single heavy-atom derivative crystal leads to an ambiguity in the phase angle, which is resolved using anomalous scattering from the heavy atoms. Phase information is therefore extracted from both the location of the heavy atoms and from anomalous scattering of the heavy atoms. A detailed discussion of SIRAS analysis can be found in North, 1965, Acta Cryst. 18:212-216; Matthews, 1966, Acta Cryst. 20:82-86.

Once phase information is obtained, it is combined with the diffraction data to produce an electron density map, an image of the electron clouds that surround the atoms of the molecule(s) in the unit cell. The higher the resolution of the data, the more distinguishable are the features of the electron density map, e.g., amino acid side chains and the positions of carbonyl oxygen atoms in the peptide backbones, because atoms that are closer together are resolvable. A model of the macromolecule is then built into the electron density map with the aid of a computer, using as a guide all available information, such as the polypeptide sequence and the established rules of molecular structure and stereochemistry. Interpreting the electron density map is a process of finding the chemically realistic conformation that fits the map precisely.

After a model is generated, a structure is refined. Refinement is the process of minimizing the function ${R - {factor}} = \frac{\underset{({h,k,l})}{\Sigma}{{{F_{obs}\left( {h,k,l} \right)}{ - }{F_{calc}\left( {h,k,l} \right)}}}}{\underset{({h,k,l})}{\Sigma}{{F_{obs}\left( {h,k,l} \right)}}}$ which is an average of the differences between observed structure factors (square-root of intensity) and calculated structure factors which are a function of the position, temperature factor and occupancy of each non-hydrogen atom in the model. This usually involves alternate cycles of real space refinement, i.e., calculation of electron density maps and model building, and reciprocal space refinement, i.e., computational attempts to improve the agreement between the original intensity data and intensity data generated from each successive model. Refinement ends when the R-factor converges on a minimum wherein the model fits the electron density map and is stereochemically and conformationally reasonable. During refinement, ordered solvent molecules are added to the structure.

6.6.1 Structures of Synagis Fab

The present invention provides, for the first time, the high-resolution three-dimensional structures and atomic structure coordinates of crystalline Synagis Fab as determined by X-ray crystallography. The specific methods used to obtain the structure coordinates are provided in the examples, infra. The atomic structure coordinates of crystalline Synagis Fab, obtained from the P2₁2₁2₁ form of the crystal to 1.8 Å resolution, are listed in Table 2.

Those having skill in the art will recognize that atomic structure coordinates as determined by X-ray crystallography are not without error. Thus, it is to be understood that any set of structure coordinates obtained for crystals of Synagis Fab, whether native crystals, heavy-atom derivative crystals or co-crystals, that have a root mean square deviation (“r.m.s.d.”) of less than or equal to about 2 Å when superimposed, using backbone atoms (N, Cα, C and O), on the structure coordinates listed in Table 2 are considered to be identical with the structure coordinates listed in the Table when at least about 50% to 100% of the backbone atoms of Synagis Fab are included in the superposition.

All IgG-type antibodies have a common structure of two identical light chains of about 25 kilodaltons and two identical heavy chains of about 50 kilodaltons. Each light chain is attached to a heavy chain by disulfide bridges and the two heavy chains are likewise attached by disulfide bridges (FIG. 6). Both the light and heavy chains contain a series of repeating, homologous units, each about 110 amino acids residues in length and a characteristic molecular weight of 12 kDa. Each of these homologous units or domains fold independently into a common structural motif call an immunoglobulin fold (FIG. 7A; FIG. 7B). The amino acid sequences of the amino terminal domains of the heavy and light chains are called variable regions (V_(H) and V_(L)) due to sequence diversity between antibodies at the variable domain CDRs. The remaining domains, C_(L) of the light chain and C_(H1), C_(H2) and C_(H3) of the heavy chain differ less among antibodies and are thus classified as constant regions.

In IgG-type antibodies light chains fall into one of two so-called isotypes, κ and λ. Each member of a light-chain isotype shares amino acid sequence identity of the carboxy terminus with all other members of that isotype. As for IgG light chains, IgG heavy chain polypeptides contain a series of segments, each approximately 110 amino acid residues in length. The segments are likewise homologous to each other and all fold into characteristic 12 kilodalton domains. As in the light chains, the amino terminal variable domain (V_(H)) displays the greatest sequence variation among heavy chains, and the most variable residues are concentrated into three stretches of amino acids called CDR1, CDR2 and CDR3.

The association between light and heavy chains involves both covalent and non-covalent interactions. Covalent interactions are in the form of disulfide bonds between the carboxy terminus of the light chain and the C_(H1) domain of the heavy chain. Non-covalent interactions arise primarily from hydrophobic interactions between V_(L) and V_(H) domains and between the C_(L) and C_(H1) domains.

Immunoglobulin V and C domains consists of sequence discontinuous antiparallel β-strands forming two β-pleated sheets linked by an intrachain disulfide bond. In the V domains, nine such β-strands form the β-sheets (FIG. 7A) while in the C domains seven strands form the β-sheets (FIG. 7B). The β strands of the V domains, comprising the ‘framework’ regions support the hypervariable loops or complementary determining regions that form the antigen binding site. As the β-strands are tightly packed in the formation of the β-sheets through hydrogen bonding to main-chain atoms and by side chain interactions, non-conservative mutants of the framework amino acids may be deleterious to the proper formation of these so-called “immunoglobulin folds” (Poljak et al., 1973, Proc. Natl. Acad. Sci. USA 70:3305-3310). Additionally, the quaternary structure of immunoglobulins requires the association of the domains of the heavy and light immunoglobulin chains. As such, amino acids involved in the associations of the β-strands forming the β-pleated sheets and of the β-pleated sheets of individual domains in the formation of immunoglobulin quaternary structure are assumed to be strongly conserved, or replaceable by closely conserved amino acids. The solvent exposed amino acids on the exterior of the V_(L)-V_(H) complex and C_(L)-C_(H1) complex, are assumed to be subject to less restriction in the substitution of amino acids.

The antigen binding fragment Fab, composed of the four domains V_(H), V_(L), C_(H1) and C_(L), has been the subject of numerous X-ray crystallographic structure determinations (reviewed in Padlan, 1994, Mol. Immunol. 31:169-217). Each immunoglobulin domain is paired with a second (i.e. V_(H)-V_(L), C_(H1)-C_(L)) with the components of each of these pairs related by a pseudo two-fold rotation axis (FIG. 4). Moreover, each antibody domain is joined to a subsequent domain (i.e. V_(H)-C_(H1), V_(L)-C_(L)) by a short segment of polypeptide sometimes refered to as the “switch”. This sequence of extended polypeptide permits intersegmental flexiblity of the Fab and, as such, allows for differing relative orientations of the V_(H), V_(L) (i.e. the Fv fragment) and the C_(H1) and C_(L) domains. The relative disposition of the variable and constant domains (the so-called elbow angle) of an Fab is defined as the angle between the pseudo two-fold rotation axes of the Fv and C_(H1)-C_(L) domains. Thus, an elbow angle of 180° specifies that the pseudo two-fold axes of the Fv and C_(H1)-C_(L) domains are colinear and angles greater or less than 180° specifly an Fab which is asymmetric.

The structure of the Fv fragment consists of the two immunoglobulin variable domains (V_(H) and V_(L)) which, as stated previously, are related by a pseudo two-fold rotation axis. Six hypervariable segments, or complementarity-determining-regions (CDRs), three each from the V_(H) (H1, H2 and H3; FIG. 4) and V_(L) (L1, L2 and L3; FIG. 4) domains, are formed from loops which connect beta strands in the immunoglobulin variable domains. The conformation of the CDR loops are generally determined by the length of the loop, the distance between the invariant (framework) residues which anchor the loop and the primary sequence of amino acids. By comparing the sequences and lengths of CDR loops of known structure, Chothia et al., 1989, Nature 342:877-833 discovered that each CDR loop, with the exception of the third hypervariable loop of the heavy chain (CDR H3), generally comformed to one of a few structural posibilities (i.e. canonical models). Thus, while there may be an extremely large repertoire of primary sequences of hypervariable loops, there appears to be some limit to the number of tertiary structures into which the backbone polypeptide chain at each loop can fold. This limits the overall structural design but still provides for structural diversity at the level of the amino acid side chain. As yet, no canonical models have been suggested for CDR H3. Since the specificity of antigen binding is determined almost exclusively by the topology of the CDRs, the structure of the CDRs and the interaction of the CDR with antigen has been the primary focus in the study of antibody structure.

The hypervariable loops, or CDRs, L1, L2, L3, H1 and H2 from immunoglobulins have been noted to usually have one of a small number of main chain conformations or canonical structures. The conformation of a particular canonical structure is determined by the length of the loop and residues present at key sites that interact with the loop. The conformation of CDR H3, however, does not appear to be limited based on the length of the loop as are the other CDRs.

The canonical classification of the CDRs for the Synagis Fab crystal structure were assigned by comparing loop lengths, sequences and root-mean-square deviations to example canonical loops. Tables 3 and 4 detail the canonical conformations for the free Synagis Fab crystal structure and selected representative CDRs for each canonical loop. The average main chain atom deviations for each of the defined canonical structures are significantly less than 1.0 Å and unambiguously assign the 5 CDRs to canonical classes. It is interesting to note that CDR L1 is a member of the type 1 canonical structure which is absent in the human V_(L) repertoire. Superpositioning of the Synagis CDRs with representative canonical loops as shown in FIGS. 8 & 9.

6.7 Structure Coordinates

The atomic structure coordinates can be used in molecular modeling and design, as described more fully below. The present invention encompasses the structure coordinates and other information, e.g., amino acid sequence, connectivity tables, vector-based representations, temperature factors, etc., used to generate the three-dimensional structure of the polypeptide for use in the software programs described below and other software programs.

The invention encompasses machine readable media embedded with the three-dimensional structure of the model described herein, or with portions thereof. As used herein, “machine readable medium” refers to any medium that can be read and accessed directly by a computer or scanner. Such media include, but are not limited to: magnetic storage media, such as floppy discs, hard disc storage medium and magnetic tape; optical storage media such as optical discs or CD-ROM; electrical storage media such as RAM or ROM; and hybrids of these categories such as magnetic/optical storage media. Such media further include paper on which is recorded a representation of the atomic structure coordinates, e.g., Cartesian coordinates, that can be read by a scanning device and converted into a three-dimensional structure with an OCR.

A variety of data storage structures are available to a skilled artisan for creating a computer readable medium having recorded thereon the atomic structure coordinates of the invention or portions thereof and/or X-ray diffraction data. The choice of the data storage structure will generally be based on the means chosen to access the stored information. In addition, a variety of data processor programs and formats can be used to store the sequence and X-ray data information on a computer readable medium. Such formats include, but are not limited to, Protein Data Bank (“PDB”) format (Research Collaboratory for Structural Bioinformatics; http://www.rcsb.org/pdb/docs/format/pdbguide2.2/guide2.2_frame.html); Cambridge Crystallographic Data Centre format (http://www.ccdc.cam.ac.uk/support/csd_doc/volume3/z323.html); Structure-data (“SD”) file format (MDL Information Systems, Inc.; Dalby et al., 1992, J. Chem. Inf. Comp. Sci. 32:244-255), and line-notation, e.g., as used in SMILES (Weininger, 1988, J. Chem. Inf. Comp. Sci. 28:31-36). Methods of converting between various formats read by different computer software will be readily apparent to those of skill in the art, e.g., BABEL (v. 1.06, Walters & Stahl, ©1992, 1993, 1994; http://www.brunel.ac.uk/departments/chem/babel.htm.) All format representations of the polypeptide coordinates described herein, or portions thereof, are contemplated by the present invention. By providing computer readable medium having stored thereon the atomic coordinates of the invention, one of skill in the art can routinely access the atomic coordinates of the invention, or portions thereof, and related information for use in modeling and design programs, described in detail below.

While Cartesian coordinates are important and convenient representations of the three-dimensional structure of a polypeptide, those of skill in the art will readily recognize that other representations of the structure are also useful. Therefore, the three-dimensional structure of a polypeptide, as discussed herein, includes not only the Cartesian coordinate representation, but also all alternative representations of the three-dimensional distribution of atoms. For example, atomic coordinates may be represented as a Z-matrix, wherein a first atom of the protein is chosen, a second atom is placed at a defined distance from the first atom, a third atom is placed at a defined distance from the second atom so that it makes a defined angle with the first atom. Each subsequent atom is placed at a defined distance from a previously placed atom with a specified angle with respect to the third atom, and at a specified torsion angle with respect to a fourth atom. Atomic coordinates may also be represented as a Patterson function, wherein all interatomic vectors are drawn and are then placed with their tails at the origin. This representation is particularly useful for locating heavy atoms in a unit cell. In addition, atomic coordinates may be represented as a series of vectors having magnitude and direction and drawn from a chosen origin to each atom in the polypeptide structure. Furthermore, the positions of atoms in a three-dimensional structure may be represented as fractions of the unit cell (fractional coordinates), or in spherical polar coordinates.

Additional information, such as thermal parameters, which measure the motion of each atom in the structure, chain identifiers, which identify the particular chain of a multi-chain protein in which an atom is located, and connectivity information, which indicates to which atoms a particular atom is bonded, is also useful for representing a three-dimensional molecular structure.

6.8 Uses of the Atomic Structure Coordinates

Structure information, typically in the form of the atomic structure coordinates, can be used in a variety of computational or computer-based methods to, for example, design, screen for and/or identify compounds that bind crystallized Synagis Fab or a portion or fragment thereof, or to intelligently design mutants that have altered biological properties.

In one embodiment, the crystals and structure coordinates obtained therefrom are useful for identifying and/or designing compounds that bind Synagis Fab as an approach towards developing new therapeutic agents. For example, a high resolution X-ray structure will often show the locations of ordered solvent molecules around the protein, and in particular at or near putative binding sites on the protein. This information can then be used to design molecules that bind these sites, the compounds synthesized and tested for binding in biological assays. Travis, 1993, Science 262:1374.

In another embodiment, the structure is probed with a plurality of molecules to determine their ability to bind to the Synagis Fab at various sites. Such compounds can be used as targets or leads in medicinal chemistry efforts to identify, for example, inhibitors of potential therapeutic importance.

In still another embodiment, compounds that can isomerize to short-lived reaction intermediates in the chemical reaction of a Synagis Fab-binding compound with Synagis Fab can be developed. Thus, the time-dependent analysis of structural changes in Synagis Fab during its interaction with other molecules is enabled. The reaction intermediates of Synagis Fab can also be deduced from the reaction product in co-complex with Synagis Fab. Such information is useful to design improved analogues of known Synagis Fab inhibitors or to design novel classes of inhibitors based on the reaction intermediates of Synagis Fab and Synagis Fab-inhibitor co-complexes. This provides a novel route for designing Synagis Fab inhibitors with both high specificity and stability.

In yet another embodiment, the structure can be used to computationally screen small molecule data bases for chemical entities or compounds that can bind in whole, or in part, to Synagis Fab. In this screening, the quality of fit of such entities or compounds to the binding site may be judged either by shape complementarity or by estimated interaction energy. Meng et al., 1992, J. Comp. Chem. 13:505-524.

The design of compounds that bind to or inhibit Synagis Fab according to this invention generally involves consideration of two factors. First, the compound must be capable of physically and structurally associating with Synagis Fab. This association can be covalent or non-covalent. For example, covalent interactions may be important for designing irreversible or suicide inhibitors of a protein. Non-covalent molecular interactions important in the association of Synagis Fab with its substrate include hydrogen bonding, ionic interactions and van der Waals and hydrophobic interactions. Second, the compound must be able to assume a conformation that allows it to associate with Synagis Fab. Although certain portions of the compound will not directly participate in this association with Synagis Fab, those portions may still influence the overall conformation of the molecule. This, in turn, may have a significant impact on potency. Such conformational requirements include the overall three-dimensional structure and orientation of the chemical group or compound in relation to all or a portion of the binding site, or the spacing between functional groups of a compound comprising several chemical groups that directly interact with Synagis Fab.

The potential inhibitory or binding effect of a chemical compound on Synagis Fab may be analyzed prior to its actual synthesis and testing by the use of computer modeling techniques. If the theoretical structure of the given compound suggests insufficient interaction and association between it and Synagis Fab, synthesis and testing of the compound is unnecessary. However, if computer modeling indicates a strong interaction, the molecule may then be synthesized and tested for its ability to bind to Synagis Fab and inhibit its activity. In this manner, synthesis of ineffective compounds may be avoided.

An inhibitory or other binding compound of Synagis Fab may be computationally evaluated and designed by means of a series of steps in which chemical groups or fragments are screened and selected for their ability to associate with the individual binding pockets or other areas of Synagis Fab. One skilled in the art may use one of several methods to screen chemical groups or fragments for their ability to associate with Synagis Fab. This process may begin by visual inspection of, for example, the active site on the computer screen based on the Synagis Fab coordinates. Selected fragments or chemical groups may then be positioned in a variety of orientations, or docked, within an individual binding pocket of Synagis Fab as defined supra. Docking may be accomplished using software such as QUANTA and SYBYL, followed by energy minimization and molecular dynamics with standard molecular mechanics forcefields, such as CHARMM and AMBER.

Specialized computer programs may also assist in the process of selecting fragments or chemical groups. These include:

1. GRID (Goodford, 1985, J. Med. Chem. 28:849-857). GRID is available from Oxford University, Oxford, UK;

2. MCSS (Miranker & Karplus, 1991, Proteins: Structure, Function and Genetics 11:29-34). MCSS is available from Molecular Simulations, Burlington, Mass.;

3. AUTODOCK (Goodsell & Olsen, 1990, Proteins: Structure, Function, and Genetics 8:195-202). AUTODOCK is available from Scripps Research Institute, La Jolla, Calif.; and

4. DOCK (Kuntz et al., 1982, J. Mol. Biol. 161:269-288). DOCK is available from University of California, San Francisco, Calif.

Once suitable chemical groups or fragments have been selected, they can be assembled into a single compound or inhibitor. Assembly may proceed by visual inspection of the relationship of the fragments to each other in the three-dimensional image displayed on a computer screen in relation to the structure coordinates of Synagis Fab. This would be followed by manual model building using software such as QUANTA or SYBYL.

Useful programs to aid one of skill in the art in connecting the individual chemical groups or fragments include:

1. CAVEAT (Bartlett et al., 1989, ‘CAVEAT: A Program to Facilitate the Structure-Derived Design of Biologically Active Molecules’. In Molecular Recognition in Chemical and Biological Problems’, Special Pub., Royal Chem. Soc. 78:182-196). CAVEAT is available from the University of California, Berkeley, Calif.;

2. 3D Database systems such as MACCS-3D (MDL Information Systems, San Leandro, Calif.). This area is reviewed in Martin, 1992, J. Med. Chem. 35:2145-2154); and

3. HOOK (available from Molecular Simulations, Burlington, Mass.).

Instead of proceeding to build a Synagis Fab inhibitor in a step-wise fashion one fragment or chemical group at a time, as described above, Synagis Fab binding compounds may be designed as a whole or ‘de novo’ using either an empty active site or optionally including some portion(s) of a known inhibitor(s). These methods include:

1. LUDI (Bohm, 1992, J. Comp. Aid. Molec. Design 6:61-78). LUDI is available from Molecular Simulations, Inc., San Diego, Calif.;

2. LEGEND (Nishibata & Itai, 1991, Tetrahedron 47:8985). LEGEND is available from Molecular Simulations, Burlington, Mass.; and

3. LeapFrog (available from Tripos, Inc., St. Louis, Mo.).

Other molecular modeling techniques may also be employed in accordance with this invention. See, e.g., Cohen et al, 1990, J. Med. Chem. 33:883-894. See also, Navia & Murcko, 1992, Current Opinions in Structural Biology 2:202-210.

Once a compound has been designed or selected by the above methods, the efficiency with which that compound may bind to Synagis Fab may be tested and optimized by computational evaluation. For example, a compound that has been designed or selected to function as a Synagis Fab-inhibitor must also preferably occupy a volume not overlapping the volume occupied by the active site residues when the native substrate is bound. An effective Synagis Fab inhibitor must preferably demonstrate a relatively small difference in energy between its bound and free states (i.e., it must have a small deformation energy of binding). Thus, the most efficient Synagis Fab inhibitors should preferably be designed with a deformation energy of binding of not greater than about 10 kcal/mol, preferably, not greater than 7 kcal/mol. Synagis Fab inhibitors may interact with the protein in more than one conformation that is similar in overall binding energy. In those cases, the deformation energy of binding is taken to be the difference between the energy of the free compound and the average energy of the conformations observed when the inhibitor binds to the enzyme.

A compound selected or designed for binding to Synagis Fab may be further computationally optimized so that in its bound state it would preferably lack repulsive electrostatic interaction with the target protein. Such non-complementary electrostatic interactions include repulsive charge-charge, dipole-dipole and charge-dipole interactions. Specifically, the sum of all electrostatic interactions between the inhibitor and the protein when the inhibitor is bound to it preferably make a neutral or favorable contribution to the enthalpy of binding.

Specific computer software is available in the art to evaluate compound deformation energy and electrostatic interaction. Examples of programs designed for such uses include: Gaussian 92, revision C (Frisch, Gaussian, Inc., Pittsburgh, Pa. ©1992); AMBER, version 4.0 (Kollman, University of California at San Francisco, ©1994); QUANTA/CHARMM (Molecular Simulations, Inc., Burlington, Mass., ©1994); and Insight II/Discover (Biosym Technologies Inc., San Diego, Calif., ©1994). These programs may be implemented, for instance, using a computer workstation, as are well-known in the art. Other hardware systems and software packages will be known to those skilled in the art.

Once a Synagis Fab-binding compound has been optimally selected or designed, as described above, substitutions may then be made in some of its atoms or chemical groups in order to improve or modify its binding properties. Generally, initial substitutions are conservative, i.e., the replacement group will have approximately the same size, shape, hydrophobicity and charge as the original group. One of skill in the art will understand that substitutions known in the art to alter conformation should be avoided. Such altered chemical compounds may then be analyzed for efficiency of binding to Synagis Fab by the same computer methods described in detail above.

Because Synagis Fab may crystallize in more than one crystal form, the structure coordinates of Synagis Fab, or portions thereof, are particularly useful to solve the structure of those other crystal forms of Synagis or other Synagis fragments. They may also be used to solve the structure of Synagis mutants, Synagis co-complexes, fragments thereof, or of the crystalline form of any other protein that shares significant amino acid sequence homology with a structural domain of Synagis Fab.

One method that may be employed for this purpose is molecular replacement. In this method, the unknown crystal structure, whether it is another crystal form of Synagis Fab, a Synagis Fab mutant, or a Synagis Fab co-complex, or the crystal of some other protein with significant amino acid sequence homology to any functional domain of Synagis Fab, may be determined using phase information from the Synagis Fab structure coordinates. The phase information may also be used to determine the crystal structure of full-length Synagis, fragments of Synagis other than Synagis Fab, and mutants or co-complexes thereof, and other proteins with significant homology to Synagis or fragments thereof. This method will provide an accurate three-dimensional structure for the unknown protein in the new crystal more quickly and efficiently than attempting to determine such information ab initio. In addition, in accordance with this invention, Synagis Fab mutants may be crystallized in co-complex with known Synagis Fab inhibitors. The crystal structures of a series of such complexes may then be solved by molecular replacement and compared with that of wild-type Synagis Fab. Potential sites for modification within the various binding sites of the protein may thus be identified. This information provides an additional tool for determining the most efficient binding interactions, for example, increased hydrophobic interactions, between Synagis Fab and a chemical group or compound.

If an unknown crystal form has the same space group as and similar cell dimensions to the known Synagis Fab crystal form, then the phases derived from the known crystal form can be directly applied to the unknown crystal form, and in turn, an electron density map for the unknown crystal form can be calculated. Difference electron density maps can then be used to examine the differences between the unknown crystal form and the known crystal form. A difference electron density map is a subtraction of one electron density map, e.g., that derived from the known crystal form, from another electron density map, e.g., that derived from the unknown crystal form. Therefore, all similar features of the two electron density maps are eliminated in the subtraction and only the differences between the two structures remain. For example, if the unknown crystal form is of a Synagis Fab co-complex, then a difference electron density map between this map and the map derived from the native, uncomplexed crystal will ideally show only the electron density of the ligand. Similarly, if amino acid side chains have different conformations in the two crystal forms, then those differences will be highlighted by peaks (positive electron density) and valleys (negative electron density) in the difference electron density map, making the differences between the two crystal forms easy to detect. However, if the space groups and/or cell dimensions of the two crystal forms are different, then this approach will not work and molecular replacement must be used in order to derive phases for the unknown crystal form.

All of the complexes referred to above may be studied using well-known X-ray diffraction techniques and may be refined versus 50 Å to 1.5 Å or greater resolution X-ray data to an R value of about 0.20 or less using computer software, such as X-PLOR (Yale University, (c) 1992, distributed by Molecular Simulations, Inc.). See, e.g., Blundel et al., 1976, Protein Crystallography, Academic Press.; Methods in Enzymology, vol. 114 & 115, Wyckoff et al., eds., Academic Press, 1985. This information may thus be used to optimize known classes of Synagis Fab inhibitors, and more importantly, to design and synthesize novel classes of Synagis Fab inhibitors.

The structure coordinates of Synagis Fab mutants will also facilitate the identification of related proteins or enzymes analogous to Synagis Fab in function, structure or both, thereby further leading to novel therapeutic modes for treating or preventing Synagis Fab mediated diseases.

Subsets of the atomic structure coordinates can be used in any of the above methods. Particularly useful subsets of the coordinates include, but are not limited to, coordinates of single domains, coordinates of residues lining an antigen binding site, coordinates of residues of a CDR, coordinates of residues that participate in important protein-protein contacts at an interface, and Ca coordinates. For example, the coordinates of a fragment of an antibody that contains the antigen binding site may be used to design inhibitors that bind to that site, even though the antibody is fully described by a larger set of atomic coordinates. Therefore, a set of atomic coordinates that define the entire polypeptide chain, although useful for many applications, do not necessarily need to be used for the methods described herein.

7. EXAMPLE Preparation of Crystals of Synagis Fab

The subsections below describe the production of a polypeptide containing the Synagis Fab, and the preparation and characterization of diffraction quality crystals, heavy-atom derivative crystals.

7.1 Production and Purification of Synagis Fab

Synagis IgG was prepared as described in U.S. Pat. No. 5,824,307, which is hereby incorporated by reference in its entirety.

The Synagis Fab fragment was produced by papain digestion of Synagis IgG. In brief, 20 mg of IgG was digested in a solution of PBS buffer, 1 mM EDTA, 1 mM b-mercaptoethanol and 0.2 mg papain. Digestion was carried out for 45 minutes at 37° C. The resultant digested antibody was concentrated to 250 ul in 50 mM Tris buffer, ph 8.5. This solution was applied to a Q-2 anion exchange column (BioRad) with a flow rate of 1 ml/min. The Fab fragment eluted in the void volume. The Fab preparation was further purified by size exclusion chromatography using a Pharmacia S-200 SEC column and PBS buffer flowing at a rate of 0.5 ml/min. Pure Fab eluted as a sharp peak at the appropriate molecular weight. Finally, the Fab preparation was concentrated and buffer-exchanged with Centricon P-20 centrifugal concentrators (Spectrum).

The final concentration of Synagis Fab measured at 280 nm was 15 mg/mL in approximately 1 mM Tris, pH 7.6.

7.1.1 Preparation of Synagis Fab Native Crystals

Crystals were grown at room temperature by the hanging drop vapor diffusion method using Linbro multi-well plates. Drops containing 2 μL of the protein solution and 2 μL of precipitant buffer were equilibrated against 500 μL precipitant buffer. The precipitant buffer was 15% PEG 4000, 10% 2-propanol, 0.2 M ammonium sulfate, 0.1 M Tris, pH 8.5. Crystals shaped as long rectangular prisms appeared after 4 days and grew to a maximum size of 0.8×0.1×0.1 mm in 10 to 14 days.

7.2 Analysis and Characterization of Synagis Fab Crystals

7.2.1 Diffraction Data Collection

X-ray diffraction data were collected using graphite-monochromated Cu Kα x-rays from a Siemens rotating anode source. Intensities were measured in 1° oscillation steps using a MAR 345 imaging plate and processed with the Denzo/Scalepack suite of programs. A single crystal was used to collect the diffraction data. The crystal was cryo-protected in a solution of the crystallization buffer with the addition of glycerol. The crystal was mounted in a nylon loop and flash frozen to 100 K. Data indicate that the crystals are orthorhombic, space group P2¹2₁2₁ and cell parameters a=77.361, b=103.925, c=68.866. Data extend to 1.8 Å, the limit available by detector geometry at the crystal to detector distance of 12 cm. Statistics for the data collection and data reduction are listed in Table 5.

7.2.2 Structure Determination

Estimation of solvent content suggest one Fab molecule per asymmetric unit in the crystal. A preliminary model for the Synagis Fab structure was determined by molecular replacement techniques. The procedure was carried out using the program XPLOR (Brunger) running on a Silicon Graphics Indigo2 workstation. The procedure followed that used for the molecular replacement solution of Fab 26-10 (Brunger). For the test model, the anti-tumor Fab (CTM01, IgG1 κ, Protein Data Bank code 1AD9) was chosen. Best rotation and translation solutions were found with the model modified by a −20° change in the elbow angle. A single solution emerged from the application of rotation function, PC-refinement and translation function. Using the molecular replacement solution an initial crystallographic R-value, based on rigid body refinement of the four 1AD9 model domains (V_(L), C_(L), V_(H) and C_(H1)), was calculated to be 0.42.

Using the model from the molecular replacement approach and the rigid body refinement, a single cycle of simulated annealing refinement (SA) followed by a cycle of grouped B-factor refinement resulted in a crystallographic residual of 0.29. Inspection of initial 2Fo-Fc and Fo-Fc electron density maps clearly indicated the differences in amino acid sequence between and model and Synagis Fab. Refinement was continued with alternate cycles of manual model building using the visualization program TURBO and simulated annealing refinement using XPLOR, and by the 5th cycle of refinement, the complete Synagis Fab sequence was fit to electron density. Refinement continued for an additional 15 cycles with improvements to stereochemistry of the polypeptide and the addition of solvent water molecules. Refinement was terminated when no peaks in an Fo-Fc difference Fourier were greater than 2.5σ. Electron density for the light chain is well resolved from residues 4 through the C-terminus residue 213. The entire heavy chain has been modeled from the N-terminus residue 1 through C-terminus residue 220. No breaks in the electron density for the modeled polypeptides are found.

TABLE 5 Data Collection Summary Native X-ray source Cu Rotating Anode Resolution limit (Å) 1.86 Å R_(sym) ^(b)(%) 6.0 Total observations 425,773 Unique reflections 39,800 Completeness (%) 92 Signal % > 2σ) 83 ^(b)R_(sym) = 100 × Σ_(h)Σ_(i)|I_(i)(h) − <I(h)>|/Σ_(h)Σ_(i)I_(i)(h). 7.2.3 Structure Analyses

A Ramachandran (Φ, Ψ) plot of the final model shows only one residue in a region usually considered to be disallowed (light chain Thr 51, CDR L2, FIG. 10). This residue, at residue i+1 of a γ turn, has been noted to occur with this conformation in class 3 γ turns (Milner-White & Poet, 1987). Moreover, the conformation of this residue is in agreement with the classification of CDR L2 as a class 1 canonical loop. The errors in atomic coordinates estimated by the method of Luzzatti (1952) are 0.21 Å.

The following table summarizes the X-ray crystallography refinement parameters of the structure of crystalline Synagis Fab of the invention.

TABLE 6 Refinement Parameters Synagis Fab: 429 residues, 357 water molecules (3664 atoms) R- R.m.s.d. d-spacings Reflections value^(a) bonds angles B-values^(b) (Å) (N) (%) (Å) (°) (Å²) Synagis 1.86 33,300 19.4 0.01 1.84 25.6 Fab: (21.4)^(c) ^(a)R-value = 100 × Σ_(h) ∥F_(obs)(h)| − |F_(calc))h)∥/Σ_(h)|F_(obs)(h)| for reflections with F_(obs) > 2σ. ^(b)For bonded protein atoms. ^(c)Value in parentheses is the free R-value (Brünger, 1992, “Free R value: a novel statistical quantity for assessing the accuracy of crystal structures,” Nature 355:472-475.) determined from 5% of the data.

Table 2, following this page, provides the atomic structure coordinates of Synagis Fab. The amino acid residue numbers coincide with those used in FIGS. 3A and 3B.

The following abbreviations are used in Table 2:

“Atom Type” refers to the element whose coordinates are provided. The first letter in the column defines the element.

“A.A.” refers to amino acid.

“X, Y and Z” provide the Cartesian coordinates of the element.

“B” is a thermal factor that measures movement of the atom around its atomic center.

“OCC” refers to occupancy, and represents the percentage of time the atom type occupies the particular coordinate. OCC values range from 0 to 1, with 1 being 100%.

Structures coordinates for Synagis Fab according to Table 2 may be modified by mathematical manipulation. Such manipulations include, but are not limited to, crystallographic permutations of the raw structure coordinates, fractionalization of the raw structure coordinates, integer additions or subtractions to sets of the raw structure coordinates, inversion of the raw structure coordinates and any combination of the above.

The present invention is not to be limited in scope by the exemplified embodiments, which are intended as illustrations of single aspects of the invention. Indeed, various modifications of the invention in addition to those described herein will become apparent to those having skill in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall with in the scope of the appended claims.

TABLE 3 Synagis VL CDR canonical structure L1-canonical structure type 1-10 residues Torsion Angles Synagis J539 (PDB code 2FBJ) Residue Amino Acid Φ Ψ Amino Acid Φ Ψ 24 Lys −114 123 Ser −123 143 25 Cys −107 151 Ala −107 147 26 Gln −73 −26 Ser −71 −16 28 Leu −105 147 Ser −157 169 29 Ser −61 145 Ser −59 133 30 Val −123 140 Val −113 151 31 Gly −71 −61 Ser −75 −37 32 Tyr −142 164 Ser −157 160 33 Met −128 148 Leu −141 140 34 His −117 149 His −136 156 r.m.s. difference Ca postitions = 0.297A; r.m.s. difference main-chain atoms = 0.685A L2-canonical structure type 1 Torsion Angles Synagis HyHel-5 (PDB code 1BQL) Residue Amino Acid Φ Ψ Amino Acid Φ Ψ 50 Asp 48 43 Asp 41 57 51 Thr 67 −46 Thr 54 −64 52 Ser −133 5 Ser −107 −6 53 Lys −85 119 Lys −85 124 54 Leu −68 126 Leu −72 139 55 Ala −71 166 Ala −78 161 56 Ser −69 135 Ser −53 100 r.m.s. difference Ca postitions = 0.098A; r.m.s. difference main-chain atoms = 0.261A L3-canonical structure type 1 Torsion Angles Synagis TE33 (PDB code 1TET) Residue Amino Acid Φ Ψ Amino Acid Φ Ψ 89 Phe −132 129 Phe −142 141 90 Gln −107 106 Gln −117 135 91 Gly −120 10 Gly −129 32 92 Ser −80 −21 Ser −97 −35 93 Gly −152 167 His −124 125 94 Tyr −87 142 Phe −81 124 95 Pro −88 150 Pro −81 140 96 Phe −67 131 Phe −61 128 97 Thr −147 153 Thr −124 151 r.m.s. difference Ca postitions = 0.240A; r.m.s. difference main-chain atoms = 0.622A

TABLE 4 Synagis V_(H) CDR canonical structure residues and torsion angles H1-canonical structure type 1 Synagis 50.1 (PDB code 2GGI) Residue Amino Acid Φ Ψ Amino Acid Φ Ψ 26 Gly 92 0 Gly 114 −14 27 Phe −169 168 Phe −165 132   27A Ser −124 135 Ser −80 145   27B Leu −73 1 Leu −77 6 28 Ser −93 −18 Ser −90 −13 29 Thr −65 132 Thr −65 127 30 Ser −43 134 Tyr −60 124 31 Gly 85 −10 Gly 94 6 32 Met −76 143 Met −82 154 33 Ser −150 151 Gly 179 159 34 Val −129 124 Val −132 135 35 Gly −116 165 Ser −100 154 r.m.s. difference Ca postitions = 0.218A; r.m.s. difference main-chain atoms = 0.390A H2-canonical structure type 1 Synagis HC19 (PDB code 1GIG) Residue Amino Acid Φ Ψ Amino Acid Φ Ψ 50 Asp −152 167 Val −143 149 51 Ile −138 134 Ile −126 117 52 Trp −90 165 Trp −79 165 53 Trp −55 −29 Ala −50 −42 54 Asp −91 12 Gly −75 −5 55 Asp 77 8 Gly 98 −5 56 Lys −70 132 Asn −69 144 57 Lys −112 140 Thr −125 155 58 Asp −130 143 Asn −138 143 59 Tyr −135 149 Tyr −123 154 60 Asn −67 125 Asn −66 125 61 Pro −55 125 Ser −56 −35 62 Ser −58 −31 Ala −58 −40 63 Leu −111 −12 Leu −90 −32 64 Lys −34 −47 Met −3 −59 65 Ser −53 −34 Ser −66 −44 r.m.s. difference Ca postitions = 0.106A; r.m.s. difference main−chain atoms = 0.243A

TABLE 2 Atom A.A. Type X Y Z Occ B ATOM CB MET L 4 69.801 42.361 −3.359 1.00 52.70 ATOM CG MET L 4 70.492 41.405 −4.309 1.00 51.32 ATOM SD MET L 4 72.128 42.056 −4.674 1.00 57.06 ATOM CE MET L 4 72.891 41.926 −3.102 1.00 53.48 ATOM C MET L 4 67.468 42.053 −4.233 1.00 49.95 ATOM O MET L 4 66.690 41.125 −4.478 1.00 51.62 ATOM N MET L 4 68.326 40.617 −2.404 1.00 53.46 ATOM CA MET L 4 68.367 41.989 −2.995 1.00 51.42 ATOM N THR L 5 67.583 43.119 −5.019 1.00 44.36 ATOM CA THR L 5 66.756 43.254 −6.205 1.00 40.62 ATOM CB THR L 5 66.015 44.603 −6.189 1.00 40.31 ATOM OG1 THR L 5 65.256 44.692 −4.977 1.00 42.05 ATOM CG2 THR L 5 65.074 44.729 −7.390 1.00 38.21 ATOM C THR L 5 67.506 43.078 −7.527 1.00 37.94 ATOM O THR L 5 68.429 43.831 −7.841 1.00 35.88 ATOM N GLN L 6 67.085 42.085 −8.305 1.00 33.98 ATOM CA GLN L 6 67.696 41.816 −9.598 1.00 31.54 ATOM CB GLN L 6 68.193 40.367 −9.660 1.00 29.52 ATOM CG GLN L 6 69.005 40.022 −10.899 1.00 23.42 ATOM CD GLN L 6 69.621 38.625 −10.838 1.00 23.94 ATOM OE1 GLN L 6 70.059 38.085 −11.855 1.00 25.77 ATOM NE2 GLN L 6 69.684 38.048 −9.643 1.00 17.08 ATOM C GLN L 6 66.673 42.086 −10.701 1.00 29.67 ATOM O GLN L 6 65.479 41.868 −10.530 1.00 29.35 ATOM N SER L 7 67.141 42.560 −11.838 1.00 29.10 ATOM CA SER L 7 66.244 42.855 −12.927 1.00 29.63 ATOM CB SER L 7 65.667 44.273 −12.772 1.00 33.97 ATOM OG SER L 7 66.678 45.280 −12.827 1.00 38.37 ATOM C SER L 7 67.021 42.748 −14.217 1.00 28.45 ATOM O SER L 7 68.242 42.910 −14.216 1.00 27.60 ATOM N PRO L 8 66.348 42.341 −15.308 1.00 28.70 ATOM CD PRO L 8 66.881 42.417 −16.681 1.00 28.01 ATOM CA PRO L 8 64.922 41.991 −15.316 1.00 28.37 ATOM CB PRO L 8 64.554 42.151 −16.783 1.00 29.19 ATOM CG PRO L 8 65.817 41.747 −17.482 1.00 29.51 ATOM C PRO L 8 64.743 40.547 −14.832 1.00 29.08 ATOM O PRO L 8 65.667 39.752 −14.932 1.00 30.35 ATOM N SER L 9 63.575 40.212 −14.294 1.00 28.83 ATOM CA SER L 9 63.333 38.857 −13.797 1.00 30.10 ATOM CB SER L 9 61.986 38.773 −13.061 1.00 31.53 ATOM OG SER L 9 60.912 38.862 −13.978 1.00 37.73 ATOM C SER L 9 63.356 37.849 −14.945 1.00 29.29 ATOM O SER L 9 63.765 36.689 −14.781 1.00 27.22 ATOM N THR L 10 62.883 38.296 −16.098 1.00 28.81 ATOM CA THR L 10 62.839 37.468 −17.292 1.00 31.44 ATOM CB THR L 10 61.426 36.830 −17.508 1.00 30.75 ATOM OG1 THR L 10 60.415 37.843 −17.438 1.00 34.36 ATOM CG2 THR L 10 61.128 35.787 −16.441 1.00 30.35 ATOM C THR L 10 63.225 38.341 −18.487 1.00 31.24 ATOM O THR L 10 63.135 39.568 −18.433 1.00 31.34 ATOM N LEU L 11 63.737 37.712 −19.528 1.00 32.55 ATOM CA LEU L 11 64.132 38.432 −20.717 1.00 33.50 ATOM CB LEU L 11 65.473 39.126 −20.500 1.00 35.64 ATOM CG LEU L 11 65.986 39.917 −21.709 1.00 39.37 ATOM CD1 LEU L 11 65.040 41.089 −22.003 1.00 39.67 ATOM CD2 LEU L 11 67.387 40.421 −21.437 1.00 39.27 ATOM C LEU L 11 64.261 37.471 −21.881 1.00 33.70 ATOM O LEU L 11 64.755 36.361 −21.723 1.00 32.16 ATOM N SER L 12 63.751 37.881 −23.031 1.00 33.08 ATOM CA SER L 12 63.857 37.090 −24.245 1.00 34.60 ATOM CB SER L 12 62.479 36.805 −24.827 1.00 34.91 ATOM OG SER L 12 61.601 36.360 −23.810 1.00 42.30 ATOM C SER L 12 64.610 38.050 −25.140 1.00 33.62 ATOM O SER L 12 64.251 39.232 −25.224 1.00 35.15 ATOM N ALA L 13 65.691 37.583 −25.742 1.00 30.90 ATOM CA ALA L 13 66.482 38.439 −26.599 1.00 30.58 ATOM CE ALA L 13 67.607 39.084 −25.801 1.00 30.23 ATOM C ALA L 13 67.039 37.583 −27.707 1.00 31.78 ATOM O ALA L 13 67.214 36.380 −27.544 1.00 31.55 ATOM N SER L 14 67.289 38.204 −28.851 1.00 33.80 ATOM CA SER L 14 67.816 37.494 −30.011 1.00 33.44 ATOM CB SER L 14 67.526 38.294 −31.277 1.00 33.43 ATOM OG SER L 14 66.232 38.878 −31.214 1.00 37.66 ATOM C SER L 14 69.308 37.280 −29.897 1.00 31.30 ATOM O SER L 14 69.984 37.924 −29.101 1.00 33.92 ATOM N VAL L 15 69.820 36.367 −30.698 1.00 31.26 ATOM CA VAL L 15 71.239 36.100 −30.720 1.00 29.90 ATOM CB VAL L 15 71.525 34.913 −31.632 1.00 26.09 ATOM CG1 VAL L 15 72.997 34.762 −31.859 1.00 27.20 ATOM CG2 VAL L 15 70.977 33.662 −31.014 1.00 25.79 ATOM C VAL L 15 71.940 37.371 −31.239 1.00 33.94 ATOM O VAL L 15 71.432 38.085 −32.122 1.00 33.32 ATOM N GLY L 16 73.086 37.682 −30.644 1.00 36.81 ATOM CA GLY L 16 73.840 38.853 −31.045 1.00 35.94 ATOM C GLY L 16 73.498 40.058 −30.212 1.00 35.51 ATOM O GLY L 16 74.262 41.014 −30.194 1.00 39.24 ATOM N ASP L 17 72.366 40.016 −29.520 1.00 34.04 ATOM CA ASP L 17 71.946 41.121 −28.672 1.00 34.26 ATOM CE ASP L 17 70.547 40.856 −28.113 1.00 34.85 ATOM CG ASP L 17 69.447 41.156 −29.110 1.00 37.86 ATOM OD1 ASP L 17 68.303 41.380 −28.658 1.00 37.46 ATOM OD2 ASP L 17 69.717 41.172 −30.332 1.00 38.37 ATOM C ASP L 17 72.896 41.368 −27.500 1.00 34.67 ATOM O ASP L 17 73.665 40.484 −27.112 1.00 33.04 ATOM N ARG L 18 72.857 42.581 −26.956 1.00 33.25 ATOM CA ARG L 18 73.666 42.913 −25.803 1.00 32.51 ATOM CE ARG L 18 74.286 44.304 −25.932 1.00 37.82 ATOM CG ARG L 18 75.007 44.766 −24.667 1.00 42.38 ATOM CD ARG L 18 75.722 46.081 −24.870 1.00 45.92 ATOM NE ARG L 18 77.152 45.955 −24.600 1.00 52.00 ATOM CZ ARG L 18 78.042 45.463 −25.459 1.00 55.43 ATOM NH1 ARG L 18 77.660 45.038 −26.661 1.00 56.79 ATOM NH2 ARG L 18 79.324 45.401 −25.119 1.00 57.64 ATOM C ARG L 18 72.662 42.882 −24.671 1.00 32.18 ATOM O ARG L 18 71.569 43.443 −24.793 1.00 32.94 ATOM N VAL L 19 73.018 42.215 −23.579 1.00 30.42 ATOM CA VAL L 19 72.118 42.081 −22.449 1.00 29.59 ATOM CB VAL L 19 71.638 40.584 −22.304 1.00 30.77 ATOM CG1 VAL L 19 70.816 40.395 −21.036 1.00 28.91 ATOM CG2 VAL L 19 70.803 40.173 −23.538 1.00 29.02 ATOM C VAL L 19 72.795 42.561 −21.173 1.00 28.10 ATOM O VAL L 19 73.964 42.275 −20.941 1.00 27.17 ATOM N THR L 20 72.035 43.285 −20.359 1.00 28.30 ATOM CA THR L 20 72.508 43.827 −19.100 1.00 31.45 ATOM CE THR L 20 72.585 45.362 −19.149 1.00 33.55 ATOM OG1 THR L 20 73.469 45.771 −20.204 1.00 33.44 ATOM CG2 THR L 20 73.075 45.916 −17.801 1.00 32.77 ATOM C THR L 20 71.540 43.456 −17.982 1.00 33.30 ATOM O THR L 20 70.343 43.747 −18.061 1.00 32.85 ATOM N ILE L 21 72.082 42.840 −16.935 1.00 34.18 ATOM CA ILE L 21 71.324 42.415 −15.763 1.00 31.59 ATOM CB ILE L 21 71.602 40.918 −15.467 1.00 31.26 ATOM CG2 ILE L 21 70.863 40.470 −14.234 1.00 31.18 ATOM CG1 ILE L 21 71.200 40.073 −16.680 1.00 32.87 ATOM CD1 ILE L 21 71.639 38.629 −16.607 1.00 32.99 ATOM C ILE L 21 71.802 43.294 −14.602 1.00 30.37 ATOM O ILE L 21 73.000 43.557 −14.468 1.00 26.47 ATOM N THR L 22 70.872 43.721 −13.756 1.00 29.86 ATOM CA THR L 22 71.206 44.592 −12.643 1.00 31.35 ATOM CB THR L 22 70.612 46.032 −12.903 1.00 30.91 ATOM OG1 THR L 22 71.159 46.574 −14.117 1.00 29.08 ATOM CG2 THR L 22 70.925 46.988 −11.743 1.00 31.26 ATOM C THR L 22 70.765 44.090 −11.253 1.00 31.33 ATOM O THR L 22 69.677 43.530 −11.093 1.00 31.64 ATOM N CYS L 23 71.648 44.245 −10.268 1.00 32.19 ATOM CA CYS L 23 71.351 43.899 −8.877 1.00 32.45 ATOM C CYS L 23 71.574 45.153 −8.040 1.00 33.34 ATOM O CYS L 23 72.639 45.759 −8.090 1.00 30.85 ATOM CB CYS L 23 72.213 42.738 −8.358 1.00 31.61 ATOM SG CYS L 23 71.545 41.112 −8.839 1.00 32.93 ATOM N LYS L 24 70.513 45.586 −7.370 1.00 37.25 ATOM CA LYS L 24 70.523 46.764 −6.518 1.00 42.39 ATOM CB LYS L 24 69.405 47.728 −6.922 1.00 45.13 ATOM CG LYS L 24 69.514 48.293 −8.333 1.00 50.30 ATOM CD LYS L 24 68.276 49.122 −8.680 1.00 52.53 ATOM CE LYS L 24 68.393 49.784 −10.042 1.00 54.46 ATOM NZ LYS L 24 67.154 50.539 −10.379 1.00 56.06 ATOM C LYS L 24 70.282 46.314 −5.087 1.00 44.53 ATOM O LYS L 24 69.300 45.614 −4.792 1.00 45.31 ATOM N CYS L 25 71.204 46.662 −4.205 1.00 47.46 ATOM CA CYS L 25 71.064 46.302 −2.813 1.00 50.46 ATOM CB CYS L 25 72.361 45.719 −2.262 1.00 51.49 ATOM SG CYS L 25 72.217 45.136 −0.553 1.00 55.90 ATOM C CYS L 25 70.726 47.576 −2.084 1.00 52.05 ATOM O CYS L 25 71.080 48.673 −2.527 1.00 51.90 ATOM N GLN L 26 70.002 47.434 −0.985 1.00 55.05 ATOM CA GLN L 26 69.611 48.584 −0.177 1.00 58.36 ATOM CB GLN L 26 68.491 48.207 0.811 1.00 60.14 ATOM CG GLN L 26 68.266 46.704 1.019 1.00 63.23 ATOM CD GLN L 26 67.641 46.023 −0.200 1.00 66.56 ATOM OE1 GLN L 26 68.181 45.039 −0.729 1.00 67.74 ATOM NE2 GLN L 26 66.508 46.551 −0.656 1.00 67.30 ATOM C GLN L 26 70.841 49.078 0.579 1.00 58.79 ATOM O GLN L 26 70.977 50.263 0.891 1.00 59.68 ATOM N LEU L 28 71.759 48.152 0.820 1.00 57.89 ATOM CA LEU L 28 72.977 48.441 1.547 1.00 55.81 ATOM CB LEU L 28 73.202 47.342 2.594 1.00 56.86 ATOM CG LEU L 28 71.922 46.791 3.252 1.00 57.59 ATOM CD1 LEU L 28 72.278 45.712 4.269 1.00 57.76 ATOM CD2 LEU L 28 71.117 47.912 3.921 1.00 58.04 ATOM C LEU L 28 74.139 48.487 0.568 1.00 53.54 ATOM O LEU L 28 74.132 47.788 −0.447 1.00 51.34 ATOM N SER L 29 75.117 49.338 0.858 1.00 52.55 ATOM CA SER L 29 76.292 49.456 0.007 1.00 50.75 ATOM CB SER L 29 77.226 50.551 0.521 1.00 51.65 ATOM OG SER L 29 77.860 51.233 −0.547 1.00 52.04 ATOM C SER L 29 76.979 48.093 0.021 1.00 48.93 ATOM O SER L 29 76.977 47.387 1.035 1.00 50.11 ATOM N VAL L 30 77.566 47.733 −1.106 1.00 45.38 ATOM CA VAL L 30 78.194 46.441 −1.256 1.00 43.49 ATOM CB VAL L 30 77.446 45.616 −2.348 1.00 45.26 ATOM CG1 VAL L 30 78.148 44.296 −2.627 1.00 45.55 ATOM CG2 VAL L 30 76.008 45.374 −1.926 1.00 45.67 ATOM C VAL L 30 79.633 46.609 −1.662 1.00 40.20 ATOM O VAL L 30 79.954 47.472 −2.474 1.00 40.25 ATOM N GLY L 31 80.496 45.770 −1.104 1.00 37.47 ATOM CA GLY L 31 81.902 45.830 −1.442 1.00 36.78 ATOM C GLY L 31 82.132 45.328 −2.857 1.00 36.26 ATOM O GLY L 31 82.562 46.082 −3.725 1.00 36.41 ATOM N TYR L 32 81.794 44.064 −3.096 1.00 35.02 ATOM CA TYR L 32 81.967 43.427 −4.401 1.00 33.17 ATOM CB TYR L 32 83.290 42.658 −4.431 1.00 31.32 ATOM CG TYR L 32 83.436 41.688 −3.276 1.00 33.00 ATOM CD1 TYR L 32 82.777 40.454 −3.279 1.00 33.06 ATOM CE1 TYR L 32 82.852 39.586 −2.191 1.00 32.01 ATOM CD2 TYR L 32 84.183 42.025 −2.154 1.00 33.11 ATOM CE2 TYR L 32 84.267 41.161 −1.057 1.00 33.14 ATOM CZ TYR L 32 83.595 39.945 −1.085 1.00 32.91 ATOM OH TYR L 32 83.651 39.107 0.002 1.00 30.28 ATOM C TYR L 32 80.780 42.483 −4.692 1.00 33.63 ATOM O TYR L 32 80.035 42.099 −3.771 1.00 33.48 ATOM N MET L 33 80.632 42.082 −5.954 1.00 31.62 ATOM CA MET L 33 79.532 41.209 −6.373 1.00 27.51 ATOM CB MET L 33 78.556 42.016 −7.245 1.00 27.25 ATOM CG MET L 33 77.203 41.373 −7.521 1.00 26.66 ATOM SD MET L 33 76.102 41.202 −6.088 1.00 31.44 ATOM CE MET L 33 75.676 42.936 −5.687 1.00 28.65 ATOM C MET L 33 80.048 39.999 −7.150 1.00 24.55 ATOM O MET L 33 81.115 40.062 −7.767 1.00 22.26 ATOM N HIS L 34 79.342 38.875 −7.029 1.00 22.23 ATOM CA HIS L 34 79.684 37.641 −7.754 1.00 21.25 ATOM CB HIS L 34 79.853 36.452 −6.789 1.00 19.84 ATOM CG HIS L 34 81.229 36.312 −6.199 1.00 19.58 ATOM CD2 HIS L 34 82.214 35.415 −6.443 1.00 16.56 ATOM ND1 HIS L 34 81.702 37.133 −5.195 1.00 17.59 ATOM CE1 HIS L 34 82.917 36.747 −4.847 1.00 17.33 ATOM NE2 HIS L 34 83.251 35.709 −5.591 1.00 16.19 ATOM C HIS L 34 78.489 37.349 −8.662 1.00 21.03 ATOM O HIS L 34 77.356 37.702 −8.323 1.00 22.35 ATOM N TRP L 35 78.726 36.736 −9.816 1.00 22.50 ATOM CA TRP L 35 77.634 36.390 −10.738 1.00 20.38 ATOM CB TRP L 35 77.665 37.258 −12.003 1.00 20.95 ATOM CG TRP L 35 77.300 38.704 −11.763 1.00 20.91 ATOM CD2 TRP L 35 75.977 39.281 −11.759 1.00 19.43 ATOM CE2 TRP L 35 76.123 40.660 −11.473 1.00 19.35 ATOM CE3 TRP L 35 74.689 38.768 −11.966 1.00 19.03 ATOM CD TRP L 35 78.165 39.730 −11.495 1.00 18.32 ATOM NEl TRP L 35 77.465 40.904 −11.323 1.00 17.92 ATOM CZ2 TRP L 35 75.026 41.534 −11.382 1.00 18.46 ATOM CZ3 TRP L 35 73.593 39.644 −11.877 1.00 18.57 ATOM CH2 TRP L 35 73.777 41.010 −11.584 1.00 20.31 ATOM C TRP L 35 77.747 34.922 −11.115 1.00 19.11 ATOM O TRP L 35 78.856 34.411 −11.342 1.00 17.52 ATOM N TYR L 36 76.607 34.243 −11.151 1.00 17.89 ATOM CA TYR L 36 76.554 32.824 −11.496 1.00 18.67 ATOM CE TYR L 36 76.157 31.973 −10.277 1.00 16.85 ATOM CG TYR L 36 77.103 32.151 −9.112 1.00 18.90 ATOM CD1 TYR L 36 78.206 31.301 −8.943 1.00 17.35 ATOM CE1 TYR L 36 79.138 31.515 −7.925 1.00 15.46 ATOM CD2 TYR L 36 76.948 33.215 −8.225 1.00 16.62 ATOM CE2 TYR L 36 77.870 33.435 −7.210 1.00 18.33 ATOM CZ TYR L 36 78.959 32.586 −7.072 1.00 16.23 ATOM OH TYR L 36 79.879 32.834 −6.101 1.00 16.90 ATOM C TYR L 36 75.586 32.547 −12.640 1.00 18.87 ATOM O TYR L 36 74.598 33.266 −12.833 1.00 16.77 ATOM N GLN L 37 75.912 31.511 −13.406 1.00 20.01 ATOM CA GLN L 37 75.099 31.069 −14.524 1.00 20.83 ATOM CE GLN L 37 75.938 31.002 −15.791 1.00 19.79 ATOM CG GLN L 37 75.133 30.614 −17.009 1.00 21.34 ATOM CD GLN L 37 76.012 30.207 −18.156 1.00 21.69 ATOM OE1 GLN L 37 76.829 29.295 −18.022 1.00 20.70 ATOM NE2 GLN L 37 75.862 30.880 −19.293 1.00 22.45 ATOM C GLN L 37 74.565 29.677 −14.217 1.00 17.81 ATOM O GLN L 37 75.338 28.763 −13.982 1.00 16.05 ATOM N GLN L 38 73.251 29.508 −14.231 1.00 19.04 ATOM CA GLN L 38 72.697 28.199 −13.952 1.00 19.08 ATOM CB GLN L 38 71.947 28.200 −12.625 1.00 18.05 ATOM CG GLN L 38 71.425 26.836 −12.231 1.00 16.18 ATOM CD GLN L 38 70.504 26.879 −11.020 1.00 19.78 ATOM OE1 GLN L 38 70.437 25.910 −10.242 1.00 20.20 ATOM NE2 GLN L 38 69.780 27.986 −10.854 1.00 13.17 ATOM C GLN L 38 71.799 27.644 −15.043 1.00 21.27 ATOM O GLN L 38 70.754 28.206 −15.345 1.00 19.19 ATOM N LYS L 39 72.238 26.545 −15.648 1.00 26.27 ATOM CA LYS L 39 71.463 25.856 −16.671 1.00 30.24 ATOM CB LYS L 39 72.360 24.926 −17.482 1.00 31.09 ATOM CG LYS L 39 73.184 25.657 −18.549 1.00 31.78 ATOM CD LYS L 39 72.269 26.309 −19.569 1.00 36.19 ATOM CE LYS L 39 73.016 26.722 −20.839 1.00 38.15 ATOM NZ LYS L 39 72.095 27.028 −22.005 1.00 33.68 ATOM C LYS L 39 70.411 25.081 −15.886 1.00 34.01 ATOM O LYS L 39 70.687 24.575 −14.793 1.00 31.70 ATOM N PRO L 40 69.185 24.995 −16.422 1.00 38.94 ATOM CD PRO L 40 68.854 25.278 −17.829 1.00 41.35 ATOM CA PRO L 40 68.073 24.296 −15.770 1.00 39.98 ATOM CB PRO L 40 67.076 24.070 −16.919 1.00 42.33 ATOM CG PRO L 40 67.934 24.119 −18.165 1.00 43.50 ATOM C PRO L 40 68.406 23.007 −15.020 1.00 40.98 ATOM O PRO L 40 69.001 22.066 −15.576 1.00 39.72 ATOM N GLY L 41 68.063 23.017 −13.730 1.00 41.78 ATOM CA GLY L 41 68.267 21.872 −12.861 1.00 41.84 ATOM C GLY L 41 69.698 21.410 −12.703 1.00 42.49 ATOM O GLY L 41 69.927 20.346 −12.125 1.00 45.08 ATOM N LYS L 42 70.648 22.195 −13.215 1.00 39.68 ATOM CA LYS L 42 72.073 21.891 −13.136 1.00 33.25 ATOM CB LYS L 42 72.723 22.072 −14.513 1.00 37.87 ATOM CG LYS L 42 74.156 21.538 −14.609 1.00 45.96 ATOM CD LYS L 42 75.019 22.270 −15.667 1.00 47.70 ATOM CE LYS L 42 75.041 21.551 −17.009 1.00 51.25 ATOM NZ LYS L 42 75.556 20.145 −16.892 1.00 53.52 ATOM C LYS L 42 72.667 22.867 −12.115 1.00 27.28 ATOM O LYS L 42 72.048 23.868 −11.785 1.00 22.25 ATOM N ALA L 43 73.842 22.555 −11.584 1.00 25.53 ATOM CA ALA L 43 74.485 23.416 −10.591 1.00 23.99 ATOM CB ALA L 43 75.633 22.685 −9.919 1.00 24.09 ATOM C ALA L 43 74.976 24.738 −11.178 1.00 21.59 ATOM O ALA L 43 75.360 24.796 −12.353 1.00 20.16 ATOM N PRO L 44 74.928 25.829 −10.377 1.00 18.22 ATOM CD PRO L 44 74.263 25.938 −9.068 1.00 14.64 ATOM CA PRO L 44 75.379 27.152 −10.834 1.00 18.30 ATOM CB PRO L 44 75.067 28.053 −9.637 1.00 16.73 ATOM CG PRO L 44 73.859 27.389 −9.035 1.00 15.24 ATOM C PRO L 44 76.872 27.159 −11.169 1.00 19.43 ATOM O PRO L 44 77.649 26.404 −10.573 1.00 18.33 ATOM N LYS L 45 77.238 27.955 −12.174 1.00 18.18 ATOM CA LYS L 45 78.621 28.103 −12.620 1.00 18.06 ATOM CB LYS L 45 78.747 27.822 −14.125 1.00 20.32 ATOM CG LYS L 45 80.192 27.912 −14.647 1.00 25.63 ATOM CD LYS L 45 80.284 27.852 −16.169 1.00 28.87 ATOM CE LYS L 45 79.679 29.096 −16.801 1.00 36.26 ATOM NZ LYS L 45 79.705 29.101 −18.297 1.00 37.77 ATOM C LYS L 45 79.091 29.525 −12.346 1.00 15.28 ATOM O LYS L 45 78.433 30.493 −12.719 1.00 13.64 ATOM N LEU L 46 80.222 29.646 −11.676 1.00 16.78 ATOM CA LEU L 46 80.781 30.950 −11.375 1.00 18.03 ATOM CB LEU L 46 81.979 30.795 −10.430 1.00 17.46 ATOM CG LEU L 46 82.748 32.077 −10.079 1.00 18.46 ATOM CD1 LEU L 46 81.862 33.118 −9.387 1.00 15.94 ATOM CD2 LEU L 46 83.924 31.719 −9.199 1.00 21.70 ATOM C LEU L 46 81.208 31.666 −12.662 1.00 17.99 ATOM O LEU L 46 81.974 31.122 −13.446 1.00 16.91 ATOM N LEU L 47 80.703 32.877 −12.880 1.00 19.12 ATOM CA LEU L 47 81.066 33.661 −14.068 1.00 21.92 ATOM CB LEU L 47 79.830 34.286 −14.736 1.00 23.03 ATOM CG LEU L 47 78.726 33.442 −15.371 1.00 24.65 ATOM CD1 LEU L 47 77.572 34.351 −15.770 1.00 23.61 ATOM CD2 LEU L 47 79.261 32.674 −16.578 1.00 22.42 ATOM C LEU L 47 82.008 34.816 −13.729 1.00 23.45 ATOM O LEU L 47 83.011 35.034 −14.404 1.00 24.27 ATOM N ILE L 48 81.644 35.572 −12.697 1.00 24.75 ATOM CA ILE L 48 82.388 36.748 −12.287 1.00 24.56 ATOM CB ILE L 48 81.603 38.041 −12.743 1.00 26.86 ATOM CG2 ILE L 48 82.215 39.316 −12.148 1.00 23.10 ATOM CG1 ILE L 48 81.460 38.105 −14.276 1.00 27.21 ATOM CD1 ILE L 48 82.758 38.266 −15.051 1.00 29.72 ATOM C ILE L 48 82.540 36.814 −10.763 1.00 27.68 ATOM O ILE L 48 81.572 36.581 −10.016 1.00 28.36 ATOM N TYR L 49 83.749 37.130 −10.304 1.00 27.66 ATOM CA TYR L 49 84.010 37.313 −8.879 1.00 26.50 ATOM CB TYR L 49 84.961 36.242 −8.338 1.00 25.78 ATOM CG TYR L 49 86.345 36.242 −8.942 1.00 27.79 ATOM CD1 TYR L 49 87.318 37.147 −8.510 1.00 27.87 ATOM CE1 TYR L 49 88.610 37.122 −9.023 1.00 26.39 ATOM CD2 TYR L 49 86.702 35.308 −9.913 1.00 28.91 ATOM CE2 TYR L 49 87.995 35.275 −10.437 1.00 29.68 ATOM CZ TYR L 49 88.939 36.189 −9.982 1.00 28.14 ATOM OH TYR L 49 90.205 36.178 −10.499 1.00 27.11 ATOM C TYR L 49 84.608 38.715 −8.710 1.00 28.04 ATOM O TYR L 49 84.987 39.351 −9.701 1.00 26.90 ATOM N ASP L 50 84.668 39.203 −7.471 1.00 27.93 ATOM CA ASP L 50 85.228 40.526 −7.166 1.00 30.07 ATOM CB ASP L 50 86.764 40.450 −7.231 1.00 32.48 ATOM OG ASP L 50 87.455 41.699 −6.684 1.00 34.53 ATOM OD1 ASP L 50 86.809 42.526 −5.994 1.00 33.00 ATOM OD2 ASP L 50 88.669 41.836 −6.955 1.00 34.56 ATOM C ASP L 50 84.670 41.625 −8.093 1.00 29.48 ATOM O ASP L 50 85.408 42.469 −8.621 1.00 28.02 ATOM N THR L 51 83.360 41.563 −8.312 1.00 28.37 ATOM CA THR L 51 82.637 42.514 −9.150 1.00 29.26 ATOM CB THR L 51 82.819 43.979 −8.642 1.00 29.35 ATOM OG1 THR L 51 82.378 44.070 −7.281 1.00 29.46 ATOM CG2 THR L 51 82.007 44.957 −9.474 1.00 26.57 ATOM C THR L 51 82.901 42.458 −10.657 1.00 29.27 ATOM O THR L 51 81.950 42.407 −11.448 1.00 28.35 ATOM N SER L 52 84.167 42.388 −11.057 1.00 29.47 ATOM CA SER L 52 84.492 42.413 −12.475 1.00 29.99 ATOM CB SER L 52 84.959 43.829 −12.841 1.00 32.61 ATOM OG SER L 52 85.836 44.382 −11.852 1.00 34.91 ATOM C SER L 52 85.492 41.397 −12.999 1.00 30.37 ATOM O SER L 52 85.854 41.431 −14.172 1.00 30.49 ATOM N LYS L 53 85.923 40.472 −12.159 1.00 30.92 ATOM CA LYS L 53 86.898 39.488 −12.603 1.00 33.14 ATOM CB LYS L 53 87.752 39.014 −11.427 1.00 35.84 ATOM CG LYS L 53 88.815 40.005 −10.988 1.00 37.91 ATOM CD LYS L 53 89.913 40.093 −12.024 1.00 41.62 ATOM CE LYS L 53 90.774 41.308 −11.779 1.00 45.49 ATOM NZ LYS L 53 89.949 42.558 −11.856 1.00 50.35 ATOM C LYS L 53 86.273 38.290 −13.281 2.00 33.94 ATOM O LYS L 53 85.488 37.568 −12.666 1.00 35.02 ATOM N LEU L 54 86.624 38.076 −14.544 1.00 33.95 ATOM CA LEU L 54 86.112 36.934 −15.287 1.00 35.46 ATOM CB LEU L 54 86.500 37.029 −16.770 1.00 36.70 ATOM CG LEU L 54 85.401 37.137 −17.837 1.00 37.08 ATOM CD1 LEU L 54 85.948 36.771 −19.210 1.00 33.57 ATOM CD2 LEU L 54 84.264 36.216 −17.493 1.00 36.74 ATOM C LEU L 54 86.715 35.664 −14.687 1.00 35.69 ATOM O LEU L 54 87.932 35.555 −14.545 1.00 35.01 ATOM N ALA L 55 85.860 34.714 −14.324 1.00 36.81 ATOM CA ALA L 55 86.317 33.451 −13.753 1.00 37.12 ATOM CB ALA L 55 85.154 32.709 −13.126 1.00 34.93 ATOM C ALA L 55 86.968 32.609 −14.849 1.00 38.49 ATOM O ALA L 55 86.818 32.903 −16.034 1.00 39.16 ATOM N SER L 56 87.687 31.561 −14.468 1.00 40.87 ATOM CA SER L 56 88.356 30.728 −15.461 1.00 43.84 ATOM CB SER L 56 89.365 29.779 −14.795 1.00 46.40 ATOM OG SER L 56 88.718 28.774 −14.024 1.00 50.55 ATOM C SER L 56 87.352 29.937 −16.282 1.00 44.04 ATOM O SER L 56 86.409 29.359 −15.735 1.00 44.83 ATOM N GLY L 57 87.567 29.903 −17.594 1.00 44.28 ATOM CA GLY L 57 86.666 29.176 −18.475 1.00 43.67 ATOM C GLY L 57 85.361 29.904 −18.758 1.00 42.62 ATOM O GLY L 57 84.320 29.277 −18.963 1.00 43.63 ATOM N VAL L 58 85.405 31.229 −18.758 1.00 39.62 ATOM CA VAL L 58 84.210 32.012 −19.014 1.00 38.57 ATOM CB VAL L 58 83.758 32.788 −17.742 1.00 35.08 ATOM CG1 VAL L 58 82.474 33.549 −18.020 1.00 34.33 ATOM CG2 VAL L 58 83.553 31.826 −16.585 1.00 28.89 ATOM C VAL L 58 84.481 32.972 −20.174 1.00 40.23 ATOM O VAL L 58 85.455 33.716 −20.158 1.00 40.10 ATOM N PRO L 59 83.656 32.910 −21.230 1.00 42.12 ATOM CD PRO L 59 82.539 31.958 −21.393 1.00 42.64 ATOM CA PRO L 59 83.791 33.767 −22.414 1.00 41.98 ATOM CB PRO L 59 82.505 33.470 −23.186 1.00 42.48 ATOM CG PRO L 59 82.260 32.023 −22.872 1.00 41.91 ATOM C PRO L 59 83.896 35.255 −22.083 1.00 42.11 ATOM O PRO L 59 83.106 35.782 −21.290 1.00 40.98 ATOM N SER L 60 84.818 35.942 −22.760 1.00 42.19 ATOM CA SER L 60 85.031 37.376 −22.566 1.00 42.32 ATOM CB SER L 60 86.131 37.869 −23.493 1.00 44.75 ATOM CG SER L 60 85.777 37.637 −24.846 1.00 48.53 ATOM C SER L 60 83.756 38.145 −22.867 1.00 41.50 ATOM O SER L 60 83.689 39.363 −22.684 1.00 41.56 ATOM N ARG L 61 82.772 37.411 −23.385 1.00 41.32 ATOM CA ARG L 61 81.446 37.907 −23.745 1.00 40.02 ATOM CB ARG L 61 80.649 36.727 −24.312 1.00 41.65 ATOM CG ARG L 61 79.520 37.058 −25.262 1.00 44.33 ATOM CD ARG L 61 78.721 35.782 −25.563 1.00 45.07 ATOM NE ARG L 61 79.586 34.654 −25.902 1.00 42.81 ATOM CZ ARG L 61 79.368 33.400 −25.523 1.00 41.29 ATOM NH1 ARG L 61 78.314 33.096 −24.790 1.00 39.59 ATOM NH2 ARG L 61 80.205 32.442 −25.887 1.00 42.30 ATOM C ARG L 61 80.738 38.458 −22.499 1.00 38.03 ATOM O ARG L 61 79.912 39.367 −22.583 1.00 37.15 ATOM N PHE L 62 81.052 37.876 −21.347 1.00 36.07 ATOM CA PHE L 62 80.451 38.293 −20.092 1.00 34.13 ATOM CB PHE L 62 80.242 37.079 −19.191 1.00 32.20 ATOM CG PHE L 62 79.316 36.040 −19.753 1.00 30.05 ATOM CD1 PHE L 62 79.813 34.969 −20.475 1.00 28.20 ATOM CD2 PHE L 62 77.950 36.097 −19.498 1.00 29.72 ATOM CE1 PHE L 62 78.963 33.970 −20.928 1.00 28.11 ATOM CE2 PHE L 62 77.092 35.099 −19.950 1.00 27.00 ATOM CZ PHE L 62 77.597 34.038 −20.662 1.00 24.59 ATOM C PHE L 62 81.363 39.263 −19.354 1.00 32.87 ATOM O PHE L 62 82.579 39.113 −19.382 1.00 32.64 ATOM N SER L 63 80.782 40.235 −18.670 1.00 32.15 ATOM CA SER L 63 81.572 41.176 −17.890 1.00 32.65 ATOM CB SER L 63 82.113 42.318 −18.757 1.00 32.01 ATOM OG SER L 63 81.080 43.183 −19.173 1.00 32.88 ATOM C SER L 63 80.718 41.731 −16.759 1.00 33.28 ATOM O SER L 63 79.486 41.746 −16.850 1.00 34.08 ATOM N GLY L 64 81.377 42.150 −15.682 1.00 33.66 ATOM CA GLY L 64 80.678 42.695 −14.541 1.00 30.72 ATOM C GLY L 64 81.233 44.058 −14.191 1.00 31.74 ATOM O GLY L 64 82.415 44.338 −14.403 1.00 29.96 ATOM N SER L 65 80.368 44.908 −13.653 1.00 31.35 ATOM CA SER L 65 80.743 46.249 −13.250 1.00 32.13 ATOM CB SER L 65 80.579 47.198 −14.427 1.00 33.39 ATOM OG SER L 65 81.199 48.432 −14.145 1.00 38.02 ATOM C SER L 65 79.836 46.687 −12.107 1.00 32.01 ATOM O SER L 65 78.958 45.936 −11.670 1.00 32.14 ATOM N GLY L 66 80.069 47.883 −11.587 1.00 32.03 ATOM CA GLY L 66 79.229 48.367 −10.514 1.00 31.82 ATOM C GLY L 66 79.988 48.757 −9.268 1.00 32.34 ATOM O GLY L 66 81.187 48.499 −9.149 1.00 33.45 ATOM N SER L 67 79.275 49.387 −8.342 1.00 33.28 ATOM CA SER L 67 79.829 49.819 −7.070 1.00 33.09 ATOM CB SER L 67 80.853 50.946 −7.281 1.00 34.89 ATOM OG SER L 67 80.222 52.176 −7.613 1.00 36.97 ATOM C SER L 67 78.673 50.308 −6.203 1.00 33.38 ATOM O SER L 67 77.529 50.430 −6.665 1.00 32.21 ATOM N GLY L 68 78.967 50.573 −4.939 1.00 34.02 ATOM CA GLY L 68 77.946 51.067 −4.043 1.00 35.08 ATOM C GLY L 68 76.785 50.114 −3.895 1.00 36.51 ATOM O GLY L 68 76.953 49.014 −3.381 1.00 37.01 ATOM N THR L 69 75.614 50.526 −4.362 1.00 38.06 ATOM CA THR L 69 74.413 49.706 −4.257 1.00 39.69 ATOM CB THR L 69 73.238 50.539 −3.709 1.00 41.73 ATOM OG1 THR L 69 73.143 51.764 −4.451 1.00 44.69 ATOM CG2 THR L 69 73.435 50.853 −2.226 1.00 43.12 ATOM C THR L 69 73.959 49.053 −5.568 1.00 39.10 ATOM O THR L 69 73.035 48.239 −5.559 1.00 40.25 ATOM N GLU L 70 74.596 49.393 −6.686 1.00 36.36 ATOM CA GLU L 70 74.190 48.823 −7.963 1.00 33.95 ATOM CB GLU L 70 73.480 49.869 −8.803 1.00 35.14 ATOM C GLU L 70 75.331 48.192 −8.749 1.00 32.26 ATOM O GLU L 70 76.366 48.816 −8.994 1.00 31.16 ATOM N PHE L 71 75.129 46.939 −9.141 1.00 30.51 ATOM CA PHE L 71 76.125 46.192 −9.885 1.00 29.00 ATOM CB PHE L 71 76.713 45.102 −8.983 1.00 25.95 ATOM CG PHE L 71 77.425 45.644 −7.766 1.00 26.50 ATOM CD1 PHE L 71 78.818 45.695 −7.718 1.00 23.83 ATOM CD2 PHE L 71 76.704 46.140 −6.681 1.00 23.86 ATOM CE1 PHE L 71 79.472 46.231 −6.615 1.00 23.12 ATOM CE2 PHE L 71 77.360 46.682 −5.574 1.00 25.02 ATOM CZ PHE L 71 78.743 46.726 −5.543 1.00 19.89 ATOM C PHE L 71 75.440 45.591 −11.103 1.00 31.37 ATOM O PHE L 71 74.215 45.385 −11.089 1.00 32.37 ATOM N THR L 72 76.213 45.319 −12.154 1.00 31.74 ATOM CA THR L 72 75.660 44.756 −13.381 1.00 31.21 ATOM CB THR L 72 75.437 45.846 −14.458 1.00 33.86 ATOM OG1 THR L 72 76.680 46.488 −14.753 1.00 34.13 ATOM CG2 THR L 72 74.408 46.887 −13.991 1.00 33.49 ATOM C THR L 72 76.460 43.632 −14.038 1.00 31.02 ATOM O THR L 72 77.683 43.518 −13.867 1.00 27.20 ATOM N LEU L 73 75.730 42.792 −14.768 1.00 29.35 ATOM CA LEU L 73 76.297 41.685 −15.521 1.00 30.38 ATOM CB LEU L 73 75.674 40.341 −15.120 1.00 28.33 ATOM CG LEU L 73 76.122 39.098 −15.913 1.00 28.85 ATOM CG1 LEU L 73 77.598 38.759 −15.662 1.00 26.27 ATOM CD2 LEU L 73 75.221 37.917 −15.559 1.00 26.75 ATOM C LEU L 73 75.939 41.994 −16.971 1.00 30.49 ATOM O LEU L 73 74.778 42.295 −17.282 1.00 29.18 ATOM N THR L 74 76.922 41.896 −17.855 1.00 30.05 ATOM CA THR L 74 76.682 42.181 −19.253 1.00 31.19 ATOM CB THR L 74 77.270 43.566 −19.662 1.00 31.37 ATOM OG1 THR L 74 76.667 44.597 −18.868 1.00 28.24 ATOM CG2 THR L 74 77.014 43.849 −21.158 1.00 30.50 ATOM C THR L 74 77.222 41.106 −20.172 1.00 29.92 ATOM O THR L 74 78.336 40.621 −20.002 1.00 28.40 ATOM N ILE L 75 76.373 40.714 −21.114 1.00 33.76 ATOM CA ILE L 75 76.679 39.712 −22.140 1.00 38.02 ATOM CB ILE L 75 75.587 38.579 −22.177 1.00 38.72 ATOM CG2 ILE L 75 76.058 37.421 −23.055 1.00 37.88 ATOM CG1 ILE L 75 75.312 38.071 −20.744 1.00 39.78 ATOM CD1 ILE L 75 74.105 37.164 −20.583 1.00 37.31 ATOM C ILE L 75 76.635 40.580 −23.406 1.00 38.55 ATOM O ILE L 75 75.579 41.106 −23.771 1.00 38.37 ATOM N SER L 76 77.802 40.787 −24.008 1.00 40.06 ATOM CA SER L 76 77.944 41.651 −25.170 1.00 42.95 ATOM CB SER L 76 79.420 41.847 −25.484 1.00 42.51 ATOM OG SER L 76 80.107 40.607 −25.441 1.00 47.98 ATOM C SER L 76 77.173 41.258 −26.418 1.00 44.99 ATOM O SER L 76 76.675 42.128 −27.141 1.00 47.12 ATOM N SER L 77 77.078 39.961 −26.677 1.00 43.59 ATOM CA SER L 77 76.346 39.475 −27.834 1.00 44.13 ATOM CB SER L 77 77.226 39.498 −29.075 1.00 45.12 ATOM OG SER L 77 78.508 38.981 −28.772 1.00 51.53 ATOM C SER L 77 75.870 38.069 −27.523 1.00 43.98 ATOM O SER L 77 76.590 37.086 −27.689 1.00 42.87 ATOM N LEU L 78 74.664 38.012 −26.991 1.00 43.76 ATOM CA LEU L 78 74.010 36.786 −26.591 1.00 44.13 ATOM CB LEU L 78 72.550 37.110 −26.295 1.00 45.19 ATOM CG LEU L 78 71.735 36.161 −25.433 1.00 45.72 ATOM CD1 LEU L 78 72.357 36.067 −24.054 1.00 44.08 ATOM CD2 LEU L 78 70.315 36.697 −25.359 1.00 46.47 ATOM C LEU L 78 74.076 35.704 −27.654 1.00 43.75 ATOM O LEU L 78 74.230 35.988 −28.834 1.00 45.19 ATOM N GLN L 79 74.002 34.455 −27.226 1.00 43.45 ATOM CA GLN L 79 73.989 33.350 −28.162 1.00 44.42 ATOM CB GLN L 79 75.384 32.990 −28.648 1.00 46.01 ATOM CG GLN L 79 76.334 32.491 −27.653 1.00 53.13 ATOM CD GLN L 79 77.643 32.175 −28.330 1.00 60.30 ATOM OE1 GLN L 79 78.434 33.077 −28.630 1.00 63.72 ATOM NE2 GLN L 79 77.860 30.898 −28.635 1.00 62.41 ATOM C GLN L 79 73.229 32.184 −27.551 1.00 42.80 ATOM O GLN L 79 73.019 32.155 −26.343 1.00 42.45 ATOM N PRO L 80 72.754 31.238 −28.382 1.00 42.66 ATOM CD PRO L 80 73.022 31.156 −29.831 1.00 41.71 ATOM CA PRO L 80 71.989 30.064 −27.942 1.00 40.32 ATOM CB PRO L 80 72.141 29.113 −29.123 1.00 42.49 ATOM CG PRO L 80 72.095 30.051 −30.277 1.00 42.33 ATOM C PRO L 80 72.347 29.406 −26.604 1.00 37.21 ATOM O PRO L 80 71.466 29.170 −25.774 1.00 34.11 ATOM N ASP L 81 73.631 29.153 −26.369 1.00 36.25 ATOM CA ASP L 81 74.053 28.513 −25.121 1.00 35.32 ATOM CB ASP L 81 75.428 27.880 −25.283 1.00 37.14 ATOM CG ASP L 81 75.785 26.986 −24.115 1.00 41.90 ATOM OD1 ASP L 81 76.936 27.061 −23.634 1.00 48.22 ATOM OD2 ASP L 81 74.908 26.221 −23.661 1.00 41.44 ATOM C ASP L 81 74.031 29.405 −23.879 1.00 30.85 ATOM O ASP L 81 74.419 28.986 −22.791 1.00 28.33 ATOM N ASP L 82 73.571 30.636 −24.046 1.00 30.80 ATOM CA ASP L 82 73.497 31.587 −22.943 1.00 29.65 ATOM CB ASP L 82 73.750 33.011 −23.438 1.00 29.14 ATOM CG ASP L 82 75.183 33.230 −23.872 1.00 29.25 ATOM OD1 ASP L 82 75.430 34.180 −24.636 1.00 31.44 ATOM OD2 ASP L 82 76.067 32.463 −23.438 1.00 29.20 ATOM C ASP L 82 72.151 31.494 −22.260 1.00 27.63 ATOM O ASP L 82 71.843 32.270 −21.359 1.00 27.38 ATOM N PHE L 83 71.324 30.570 −22.730 1.00 24.99 ATOM CA PHE L 83 70.025 30.371 −22.116 1.00 23.55 ATOM CB PHE L 83 69.218 29.325 −22.901 1.00 20.70 ATOM CG PHE L 83 68.164 28.651 −22.088 1.00 19.09 ATOM CG1 PHE L 83 67.068 29.359 −21.634 1.00 16.96 ATOM CD2 PHE L 83 68.306 27.313 −21.720 1.00 20.10 ATOM CE1 PHE L 83 66.133 28.753 −20.823 1.00 18.32 ATOM CE2 PHE L 83 67.368 26.694 −20.905 1.00 19.05 ATOM CZ PHE L 83 66.282 27.412 −20.455 1.00 19.06 ATOM C PHE L 83 70.368 29.850 −20.727 1.00 20.93 ATOM O PHE L 83 71.155 28.921 −20.618 1.00 22.26 ATOM N ALA L 84 69.843 30.485 −19.684 1.00 19.63 ATOM CA ALA L 84 70.095 30.070 −18.304 1.00 19.18 ATOM CB ALA L 84 71.600 29.995 −18.039 1.00 17.02 ATOM C ALA L 84 69.483 31.081 −17.357 1.00 18.18 ATOM O ALA L 84 68.926 32.085 −17.786 1.00 20.57 ATOM N THR L 85 69.513 30.778 −16.070 1.00 18.27 ATOM CA THR L 85 69.046 31.733 −15.078 1.00 18.66 ATOM CB THR L 85 68.138 31.090 −14.007 1.00 16.55 ATOM OG1 THR L 85 66.921 30.664 −14.625 1.00 19.88 ATOM CG2 THR L 85 67.776 32.102 −12.943 1.00 12.55 ATOM C THR L 85 70.328 32.298 −14.449 1.00 18.52 ATOM O THR L 85 71.240 31.533 −14.081 1.00 16.60 ATOM N TYR L 86 70.440 33.625 −14.453 1.00 17.64 ATOM CA TYR L 86 71.598 34.311 −13.895 1.00 19.24 ATOM CB TYR L 86 72.066 35.426 −14.817 1.00 18.33 ATOM CG TYR L 86 72.555 34.865 −16.118 1.00 18.76 ATOM CD1 TYR L 86 71.673 34.633 −17.172 1.00 21.98 ATOM CE1 TYR L 86 72.111 34.050 −18.360 1.00 21.65 ATOM CD2 TYR L 86 73.890 34.502 −16.283 1.00 15.25 ATOM CE2 TYR L 86 74.335 33.923 −17.456 1.00 18.24 ATOM CZ TYR L 86 73.441 33.700 −18.492 1.00 18.78 ATOM OH TYR L 86 73.879 33.135 −19.663 1.00 21.03 ATOM C TYR L 86 71.303 34.847 −12.519 1.00 19.80 ATOM O TYR L 86 70.173 35.270 −12.237 1.00 19.56 ATOM N TYR L 87 72.309 34.760 −11.645 1.00 19.65 ATOM CA TYR L 87 72.180 35.201 −10.259 1.00 19.63 ATOM CB TYR L 87 72.042 33.995 −9.324 1.00 17.97 ATOM CG TYR L 87 70.802 33.165 −9.522 1.00 15.59 ATOM CD1 TYR L 87 70.854 31.964 −10.233 1.00 14.99 ATOM CE1 TYR L 87 69.746 31.158 −10.356 1.00 14.07 ATOM CD2 TYR L 87 69.596 33.538 −8.945 1.00 15.68 ATOM CE2 TYR L 87 68.466 32.731 −9.058 1.00 16.41 ATOM CZ TYR L 87 68.548 31.542 −9.767 1.00 15.92 ATOM OH TYR L 87 67.444 30.735 −9.911 1.00 16.14 ATOM C TYR L 87 73.376 35.984 −9.773 1.00 19.98 ATOM O TYR L 87 74.518 35.626 −10.061 1.00 21.18 ATOM N CYS L 88 73.117 37.049 −9.030 1.00 19.62 ATOM CA CYS L 88 742.96 37.811 −8.445 1.00 20.76 ATOM C CYS L 88 74.219 37.345 −6.995 1.00 22.45 ATOM O CYS L 88 732.87 36.914 −6.448 1.00 22.65 ATOM CB CYS L 88 73.915 39.305 −8.494 1.00 20.25 ATOM SG CYS L 88 72.419 39.779 −7.595 1.00 23.98 ATOM N PHE L 89 75.399 37.375 −6.392 1.00 21.08 ATOM CA PHE L 89 75.556 36.982 −5.011 1.00 20.36 ATOM CB PHE L 89 76.258 35.622 −4.910 1.00 19.78 ATOM CG PHE L 89 76.577 35.202 −3.488 1.00 21.53 ATOM CD1 PHE L 89 77.898 35.078 −3.060 1.00 21.75 ATOM CD2 PHE L 89 75.553 34.945 −2.573 1.00 21.04 ATOM CE1 PHE L 89 782.89 34.709 −1.747 1.00 22.24 ATOM CE2 PHE L 89 75.838 34.577 −1.264 1.00 22.75 ATOM CZ PHE L 89 77.160 34.459 −0.849 1.00 22.39 ATOM C PHE L 89 76.387 38.044 −4.295 1.00 21.40 ATOM O PHE L 89 77.455 38.454 −4.784 1.00 19.17 ATOM N GLN L 90 75.878 38.497 −3.155 1.00 22.20 ATOM CA GLN L 90 76.567 39.480 −2.337 1.00 25.57 ATOM CB GLN L 90 75.629 40.659 −1.999 1.00 27.68 ATOM CG GLN L 90 75.673 41.205 −0.555 1.00 34.37 ATOM CD GLN L 90 76.975 41.908 −0.185 1.00 36.51 ATOM OE1 GLN L 90 78.050 41.538 −0.647 1.00 37.64 ATOM NE2 GLN L 90 76.879 42.923 0.666 1.00 42.09 ATOM C GLN L 90 77.091 38.771 −1.084 1.00 24.62 ATOM O GLN L 90 76.316 38.362 −0.220 1.00 24.09 ATOM N GLY L 91 78.405 38.560 −1.045 1.00 24.26 ATOM CA GLY L 91 79.036 37.915 0.088 1.00 25.85 ATOM C GLY L 91 80.073 38.818 0.743 1.00 27.80 ATOM O GLY L 91 80.845 38.369 1.590 1.00 28.54 ATOM N SER L 92 802.01 40.089 0.354 1.00 28.11 ATOM CA SER L 92 81.052 41.037 0.922 1.00 29.42 ATOM CB SER L 92 81.342 42.170 −0.067 1.00 27.86 ATOM OG SER L 92 80.L72 42.809 −0.525 1.00 28.57 ATOM C SER L 92 80.628 41.603 2.279 1.00 29.98 ATOM O SER L 92 81.464 42.051 3.053 1.00 29.20 ATOM N GLY L 93 79.334 41.554 2.571 1.00 31.33 ATOM CA GLY L 93 78.825 42.063 3.833 1.00 32.06 ATOM C GLY L 93 77.548 41.346 4.230 1.00 32.98 ATOM O GLY L 93 76.951 40.646 3.412 1.00 31.29 ATOM N TYR L 94 77.116 41.524 5.474 1.00 34.98 ATOM CA TYR L 94 75.907 40.862 5.956 1.00 39.24 ATOM CB TYR L 94 76.044 40.534 7.438 1.00 41.36 ATOM CG TYR L 94 77.141 39.539 7.743 1.00 45.93 ATOM CD1 TYR L 94 78.125 39.829 8.691 1.00 47.27 ATOM CE1 TYR L 94 79.121 38.916 8.996 1.00 48.93 ATOM CD2 TYR L 94 772.87 38.299 7.102 1.00 45.87 ATOM CR2 TYR L 94 78.183 37.377 7.400 1.00 47.29 ATOM CZ TYR L 94 79.147 37.692 8.348 1.00 48.81 ATOM OH TYR L 94 80.149 36.795 8.645 1.00 51.35 ATOM C TYR L 94 74.390 41.606 5.696 1.00 39.68 ATOM O TYR L 94 74.534 42.837 5.735 1.00 40.70 ATOM N PRO L 95 73.516 40.859 5.375 1.00 39.57 ATOM CG PRO L 95 72.146 41.409 5.309 1.00 40.15 ATOM CA PRO L 95 73.503 39.395 5.249 1.00 36.54 ATOM CB PRO L 95 72.055 39.050 5.573 1.00 36.84 ATOM CG PRO L 95 71.308 40.192 4.948 1.00 38.59 ATOM C PRO L 95 73.877 38.944 3.835 1.00 33.17 ATOM O PRO L 95 73.645 39.662 2.863 1.00 32.32 ATOM N PHE L 96 74.469 37.762 3.726 1.00 32.39 ATOM CA PHE L 96 74.850 37.231 2.421 1.00 33.60 ATOM CB PHE L 96 75.661 35.947 2.576 1.00 30.98 ATOM CG PHE L 96 76.991 36.139 3.242 1.00 33.91 ATOM CD1 PHE L 96 77.518 37.416 3.432 1.00 33.81 ATOM CD2 PHE L 96 77.733 35.033 3.662 1.00 36.87 ATOM CE1 PHE L 96 78.759 37.595 4.027 1.00 36.46 ATOM CE2 PHE L 96 78.987 35.196 4.266 1.00 38.28 ATOM CZ PHE L 96 79.500 36.481 4.447 1.00 37.60 ATOM C PHE L 96 73.558 36.938 1.685 1.00 29.65 ATOM O PHE L 96 72.661 36.310 2.241 1.00 29.87 ATOM N THR L 97 73.447 37.377 0.442 1.00 27.80 ATOM CA THR L 97 72.217 37.154 −0.294 1.00 27.85 ATOM CB THR L 97 71.252 38.356 −0.119 1.00 31.07 ATOM OG1 THR L 97 71.957 39.581 −0.373 1.00 34.91 ATOM CG2 THR L 97 70.670 38.394 1.283 1.00 34.02 ATOM C THR L 97 72.421 36.964 −1.780 1.00 25.56 ATOM O THR L 97 73.385 37.468 −2.354 1.00 25.97 ATOM N PHE L 98 71.493 36.243 −2.395 1.00 23.93 ATOM CA PHE L 98 71.494 36.003 −3.837 1.00 22.96 ATOM CB PHE L 98 71.203 34.545 −4.157 1.00 20.08 ATOM CG PHE L 98 72.257 33.586 −4.165 1.00 17.47 ATOM CD1 PHE L 98 72.517 32.782 −3.068 1.00 18.73 ATOM CD2 PHE L 98 73.109 33.517 −5.252 1.00 15.42 ATOM CE1 PHE L 98 73.616 31.930 −3.053 1.00 18.52 ATOM CE2 PHE L 98 74.207 32.664 −5.239 1.00 17.15 ATOM CZ PHE L 98 74.159 31.874 −4.138 1.00 16.08 ATOM C PHE L 98 70.424 36.910 −4.436 1.00 23.92 ATOM O PHE L 98 69.522 37.385 −3.734 1.00 26.57 ATOM N GLY L 99 70.537 37.190 −5.723 1.00 24.88 ATOM CA GLY L 99 69.512 37.977 −6.370 1.00 24.29 ATOM C GLY L 99 68.379 37.008 −6.685 1.00 24.25 ATOM O GLY L 99 68.569 35.778 −6.622 1.00 22.05 ATOM N GLY L 100 67.213 37.553 −7.032 1.00 22.89 ATOM CA GLY L 100 66.059 36.732 −7.357 1.00 19.67 ATOM C GLY L 100 66.275 35.998 −8.683 1.00 20.73 ATOM O GLY L 100 65.395 35.082 −8.959 1.00 18.00 ATOM N GLY L 101 67.116 36.420 −9.521 1.00 19.87 ATOM CA GLY L 101 67.306 35.765 −10.797 1.00 19.54 ATOM C GLY L 101 66.184 36.508 −12.017 1.00 20.81 ATOM O GLY L 101 65.922 37.391 −11.930 1.00 20.98 ATOM N THR L 102 67.389 36.176 −13.151 1.00 21.18 ATOM CA THR L 102 67.038 36.707 −14.459 1.00 22.07 ATOM CD THR L 102 68.080 37.735 −14.978 1.00 22.40 ATOM OG1 THR L 102 68.114 38.880 −14.116 1.00 23.14 ATOM CG2 THR L 102 67.721 38.190 −16.378 1.00 22.44 ATOM C THR L 102 67.085 35.483 −15.379 1.00 22.40 ATOM O THR L 102 68.170 34.937 −15.636 1.00 20.43 ATOM N LYS L 103 65.913 34.990 −15.782 1.00 22.47 ATOM CA LYS L 103 65.851 33.843 −16.684 1.00 23.31 ATOM CB LYS L 103 64.583 33.021 −16.478 1.00 21.12 ATOM CG LYS L 103 64.550 31.824 −17.392 1.00 22.43 ATOM CD LYS L 103 63.660 30.711 −16.876 1.00 24.88 ATOM CE LYS L 103 63.733 29.481 −17.797 1.00 23.83 ATOM NZ LYS L 103 63.023 28.313 −17.241 1.00 21.06 ATOM G LYS L 103 65.908 34.396 −18.093 1.00 25.31 ATOM O LYS L 103 65.044 35.172 −18.512 1.00 26.75 ATOM N LEU L 104 66.930 33.987 −18.824 1.00 25.69 ATOM CA LEU L 104 67.161 34.469 −20.168 1.00 27.01 ATOM CD LEU L 104 68.650 34.808 −20.298 1.00 27.67 ATOM CG LEU L 104 69.152 35.661 −21.448 1.00 27.93 ATOM CD1 LEU L 104 68.423 36.985 −21.446 1.00 29.85 ATOM CD2 LEU L 104 70.630 35.881 −21.265 1.00 29.69 ATOM C LEU L 104 66.754 33.473 −21.244 1.00 28.40 ATOM O LEU L 104 67.285 32.364 −21.301 1.00 30.35 ATOM N GLU L 105 65.813 33.874 −22.092 1.00 28.05 ATOM CA GLU L 105 65.343 33.039 −23.191 1.00 29.59 ATOM CB GLU L 105 63.823 33.113 −23.325 1.00 32.46 ATOM CG GLU L 105 63.264 32.079 −24.291 1.00 39.22 ATOM CD GLU L 105 62.213 32.632 −25.237 1.00 41.09 ATOM OE1 GLU L 105 62.584 33.444 −26.101 1.00 43.86 ATOM OE2 GLU L 105 61.028 32.240 −25.138 1.00 39.88 ATOM C GLU L 105 65.965 33.593 −24.456 1.00 28.60 ATOM O GLU L 105 66.142 34.797 −24.581 1.00 28.67 ATOM N ILE L 106 66.272 32.716 −25.399 1.00 29.12 ATOM CA ILE L 106 66.870 33.111 −26.670 1.00 30.41 ATOM CB ILE L 106 68.039 32.149 −27.066 1.00 30.16 ATOM CG2 ILE L 106 68.710 32.616 −28.340 1.00 32.05 ATOM CG1 ILE L 106 69.056 32.011 −25.928 1.00 29.52 ATOM CD1 ILE L 106 69.615 33.317 −25.418 1.00 30.24 ATOM C ILE L 106 65.792 33.091 −27.773 1.00 31.27 ATOM O ILE L 106 65.043 32.116 −27.916 1.00 32.16 ATOM N LYS L 107 65.676 34.187 −28.514 1.00 30.72 ATOM CA LYS L 107 64.69B 34.265 −29.585 1.00 32.13 ATOM CB LYS L 107 64.400 35.716 −29.968 1.00 32.27 ATOM CG LYS L 107 63.701 36.569 −28.945 1.00 34.00 ATOM CD LYS L 107 63.503 37.967 −29.540 1.00 34.55 ATOM CE LYS L 107 62.918 38.935 −28.536 1.00 37.68 ATOM NZ LYS L 107 61.661 38.391 −27.962 1.00 40.96 ATOM C LYS L 107 65.270 33.593 −30.817 1.00 31.68 ATOM O LYS L 107 66.462 33.684 −31.074 1.00 32.74 ATOM N ARG L 108 64.413 32.937 −31.586 1.00 31.51 ATOM CA ARG L 108 64.821 32.295 −32.824 1.00 29.52 ATOM CB ARG L 108 65.265 30.861 −32.591 1.00 29.77 ATOM CG ARG L 108 64.243 29.994 −31.905 1.00 30.89 ATOM CD ARG L 108 64.344 28.565 −32.408 1.00 30.81 ATOM NE ARG L 108 64.038 28.496 −33.829 1.00 30.96 ATOM CZ ARG L 108 64.564 27.618 −34.674 1.00 31.44 ATOM NH1 ARG L 108 65.440 26.716 −34.250 1.00 27.52 ATOM NH2 ARG L 108 64.205 27.646 −35.952 1.00 29.16 ATOM C ARG L 108 63.636 32.342 −33.771 1.00 28.69 ATOM O ARG L 108 62.572 32.852 −33.421 1.00 28.53 ATOM N THR L 109 63.832 31.858 −34.985 1.00 29.11 ATOM CA THR L 109 62.168 31.858 −35.976 1.00 30.78 ATOM CB THR L 109 63.315 31.518 −37.370 1.00 32.45 ATOM OG1 THR L 109 64.064 30.299 −37.309 1.00 35.48 ATOM CG2 THR L 109 64.223 32.635 −37.874 1.00 30.66 ATOM C THR L 109 61.693 30.850 −35.595 1.00 31.46 ATOM O THR L 109 61.937 29.954 −34.795 1.00 31.24 ATOM N VAL L 110 60.496 31.009 −36.146 1.00 31.64 ATOM CA VAL L 110 59.417 30.086 −35.836 1.00 31.60 ATOM CB VAL L 110 58.057 30.560 −36.394 1.00 32.31 ATOM CG1 VAL L 110 56.964 29.541 −36.066 1.00 31.80 ATOM CG2 VAL L 110 57.692 31.919 −35.807 1.00 31.73 ATOM C VAL L 110 59.760 28.722 −36.400 1.00 30.86 ATOM O VAL L 110 60.394 28.614 −37.451 1.00 30.96 ATOM N ALA L 111 59.434 27.693 −35.634 1.00 29.60 ATOM CA ALA L 111 59.680 26.318 −36.032 1.00 28.26 ATOM CB ALA L 111 60.901 25.755 −35.316 1.00 26.88 ATOM C ALA L 111 58.431 25.567 −35.618 1.00 27.23 ATOM O ALA L 111 57.993 25.646 −34.466 1.00 25.20 ATOM N ALA L 112 57.807 24.910 −36.581 1.00 26.83 ATOM CA ALA L 112 56.602 24.153 −36.308 1.00 26.48 ATOM CB ALA L 112 55.840 23.880 −37.610 1.00 27.20 ATOM C ALA L 112 56.943 22.843 −35.606 1.00 23.94 ATOM O ALA L 112 57.988 22.244 −35.855 1.00 23.22 ATOM N PRO L 113 56.075 22.409 −34.691 1.00 22.26 ATOM CD PRO L 113 54.924 23.154 −34.147 1.00 20.36 ATOM CA PRO L 113 56.286 21.161 −33.957 1.00 23.79 ATOM CB PRO L 113 55.244 21.249 −32.838 1.00 22.36 ATOM CG PRO L 113 54.149 22.066 −33.453 1.00 23.79 ATOM C PRO L 113 56.013 19.922 −34.794 1.00 23.47 ATOM O PRO L 113 55.136 19.931 −35.655 1.00 25.95 ATOM N SER L 114 56.769 18.863 −34.535 1.00 21.45 ATOM CA SER L 114 56.557 17.580 −35.194 1.00 21.91 ATOM CB SER L 114 57.871 16.823 −35.335 1.00 24.05 ATOM OG SER L 114 58.789 17.547 −36.137 1.00 28.55 ATOM C SER L 114 55.670 16.904 −34.157 1.00 20.29 ATOM O SER L 114 56.077 16.777 −32.997 1.00 21.52 ATOM N VAL L 115 54.463 16.509 −34.552 1.00 17.56 ATOM CA VAL L 115 53.500 15.914 −33.621 1.00 17.02 ATOM CB VAL L 115 52.110 16.578 −33.810 1.00 16.79 ATOM CG1 VAL L 115 51.120 16.067 −32.800 1.00 14.41 ATOM CG2 VAL L 115 52.244 18.092 −33.709 1.00 16.01 ATOM C VAL L 115 53.379 14.394 −33.693 1.00 17.60 ATOM O VAL L 115 53.355 13.818 −34.786 1.00 20.11 ATOM N PHE L 116 53.347 13.746 −32.528 1.00 15.99 ATOM CA PHE L 116 53.226 12.289 −32.439 1.00 17.49 ATOM CB PHE L 116 54.562 11.646 −32.059 1.00 15.67 ATOM CG PHE L 116 55.701 12.057 −32.926 1.00 16.56 ATOM CD1 PHE L 116 56.376 13.258 −32.687 1.00 15.63 ATOM CD2 PHE L 116 56.115 11.246 −33.984 1.00 17.82 ATOM CE1 PHE L 116 57.452 13.652 −33.489 1.00 18.32 ATOM CE2 PHE L 116 57.186 11.627 −34.792 1.00 18.08 ATOM CZ PHE L 116 57.860 12.839 −34.542 1.00 17.81 ATOM C PHE L 116 52.219 11.915 −31.355 1.00 19.64 ATOM O PHE L 116 52.139 12.586 −30.321 1.00 20.26 ATOM N ILE L 117 51.447 10.858 −31.585 1.00 18.75 ATOM CA ILE L 117 50.490 10.392 −30.585 1.00 19.77 ATOM CB ILE L 117 49.029 10.490 −31.075 1.00 20.51 ATOM CG2 ILE L 117 48.815 9.610 −32.295 1.00 18.97 ATOM CG1 ILE L 117 48.071 10.086 −29.946 1.00 18.35 ATOM CG1 ILE L 117 45.635 10.459 −30.206 1.00 17.73 ATOM C ILE L 117 50.833 8.941 −30.213 1.00 20.69 ATOM O ILE L 117 51.222 8.143 −31.076 1.00 20.52 ATOM N PHE L 118 50.741 8.611 −28.929 1.00 19.61 ATOM CA PHE L 118 51.047 7.262 −28.477 1.00 17.90 ATOM CB PHE L 118 52.268 7.252 −27.557 1.00 16.09 ATOM CG PHE L 118 53.491 7.832 −28.175 1.00 18.71 ATOM CD1 PHE L 118 53.868 9.141 −27.902 1.00 18.19 ATOM CD2 PHE L 118 54.283 7.069 −29.034 1.00 17.56 ATOM CE1 PHE L 118 55.014 9.686 −28.471 1.00 19.36 ATOM CE2 PHE L 118 55.436 7.613 −29.608 1.00 20.45 ATOM CZ PHE L 118 55.799 8.917 −29.328 1.00 18.79 ATOM C PHE L 118 49.883 6.662 −27.714 1.00 18.98 ATOM O PHE L 118 49.391 7.261 −26.759 1.00 18.51 ATOM N PRO L 119 49.363 5.519 −28.193 1.00 19.68 ATOM CD PRO L 119 49.626 4.897 −29.503 1.00 19.95 ATOM CA PRO L 119 48.254 4.839 −27.527 1.00 19.86 ATOM CB PRO L 119 47.843 3.789 −28.562 1.00 16.77 ATOM CG PRO L 119 49.099 3.521 −29.297 1.00 19.18 ATOM C PRO L 119 48.778 4.176 −26.243 1.00 18.58 ATOM O PRO L 119 49.997 4.040 −26.050 1.00 15.88 ATOM N PRO L 120 47.872 3.839 −25.312 1.00 20.20 ATOM CD PRO L 120 46.416 4.079 −25.288 1.00 19.97 ATOM CA PRO L 120 48.314 3.193 −24.073 1.00 20.19 ATOM CB PRO L 120 47.030 3.132 −23.245 1.00 19.86 ATOM CG PRO L 120 45.958 3.059 −24.282 1.00 19.24 ATOM C PRO L 120 48.826 1.788 −24.393 1.00 23.23 ATOM O PRO L 120 48.385 1.155 −25.371 1.00 23.12 ATOM N SER L 121 49.770 1.309 −23.593 1.00 23.42 ATOM CA SER L 121 50.327 −0.018 −23.803 1.00 21.02 ATOM CB SER L 121 51.678 −0.139 −23.087 1.00 21.17 ATOM OG SER L 121 51.545 0.081 −21.687 1.00 21.28 ATOM C SER L 121 49.346 −1.019 −23.229 1.00 20.91 ATOM O SER L 121 48.540 −0.664 −22.356 1.00 17.96 ATOM N ASP L 122 49.380 −2.251 −23.734 1.00 20.98 ATOM CA ASP L 122 48.493 −3.292 −23.213 1.00 23.86 ATOM CB ASP L 122 48.631 −4.578 −24.018 1.00 24.89 ATOM CG ASP L 122 48.131 −4.424 −25.433 1.00 27.96 ATOM OD1 ASP L 122 47.303 −3.524 −25.681 1.00 27.84 ATOM OD2 ASP L 122 48.576 −5.193 −26.305 1.00 32.19 ATOM C ASP L 122 48.845 −3.544 −21.757 1.00 23.60 ATOM O ASP L 122 47.977 −3.813 −20.932 1.00 21.88 ATOM N GLU L 123 50.130 −3.411 −21.454 1.00 23.93 ATOM CA GLU L 123 50.642 −3.585 −20.109 1.00 27.91 ATOM CD GLU L 123 52.163 −3.426 −20.122 1.00 32.19 ATOM CG GLU L 123 52.830 −3.698 −18.791 1.00 40.41 ATOM CD GLU L 123 54.258 −3.194 −18.748 1.00 47.82 ATOM OE1 GLU L 123 55.115 −3.894 −18.169 1.00 53.21 ATOM OE2 GLU L 123 54.527 −2.092 −19.280 1.00 51.56 ATOM C GLU L 123 50.001 −2.588 −19.117 1.00 27.85 ATOM O GLU L 123 49.575 −2.977 −18.019 1.00 27.68 ATOM N GLN L 124 49.938 −1.308 −19.480 1.00 24.64 ATOM CA GLN L 124 49.332 −0.337 −18.578 1.00 23.22 ATOM CB GLN L 124 49.514 1.088 −19.072 1.00 20.28 ATOM CG GLN L 124 49.008 2.087 −18.064 1.00 14.77 ATOM CD GLN L 124 48.953 3.485 −18.578 1.00 14.59 ATOM OE1 GLN L 124 48.958 3.730 −19.780 1.00 17.10 ATOM NE2 GLN L 124 48.861 4.424 −17.665 1.00 15.03 ATOM C GLN L 124 47.842 −0.597 −18.400 1.00 25.72 ATOM O GLN L 124 47.315 −0.529 −17.285 1.00 26.05 ATOM N LEU L 125 47.155 −0.864 −19.504 1.00 27.91 ATOM CA LEU L 125 45.723 −1.132 −19.467 1.00 30.96 ATOM CB LEU L 125 45.219 −1.558 −20.847 1.00 28.53 ATOM CG LEU L 125 45.112 −0.447 −21.887 1.00 27.48 ATOM CE1 LEU L 125 44.392 −0.998 −23.088 1.00 28.97 ATOM CD2 LEU L 125 44.352 0.738 −21.318 1.00 27.09 ATOM C LEU L 125 45.416 −2.208 −18.439 1.00 33.69 ATOM O LEU L 125 44.440 −2.107 −17.698 1.00 34.97 ATOM N LYS L 126 46.286 −3.207 −18.357 1.00 36.13 ATOM CA LYS L 126 46.107 −4.282 −17.401 1.00 39.52 ATOM CB LYS L 126 47.296 −5.246 −17.441 1.00 45.42 ATOM CG LYS L 126 46.968 −6.615 −16.849 1.00 52.87 ATOM CD LYS L 126 48.168 −7.301 −16.193 1.00 55.14 ATOM CE LYS L 126 47.770 −8.667 −15.616 1.00 56.30 ATOM NZ LYS L 126 46.588 −8.603 −14.695 1.00 56.59 ATOM C LYS L 126 45.958 −3.715 −15.989 1.00 39.37 ATOM O LYS L 126 45.105 −4.170 −15.232 1.00 40.56 ATOM N SER L 127 46.745 −2.686 −15.667 1.00 38.46 ATOM CA SER L 127 46.730 −2.052 −14.343 1.00 36.08 ATOM CB SER L 127 47.994 −1.191 −14.125 1.00 36.59 ATOM OG SER L 127 47.895 0.119 −14.693 1.00 38.49 ATOM C SER L 127 45.478 −1.227 −14.072 1.00 33.85 ATOM O SER L 127 45.333 −0.633 −13.000 1.00 36.40 ATOM N GLY L 128 44.583 −1.166 −15.048 1.00 31.83 ATOM CA GLY L 128 43.354 −0.414 −14.865 1.00 28.09 ATOM C GLY L 128 43.336 1.015 −15.374 1.00 28.23 ATOM O GLY L 128 42.290 1.666 −15.312 1.00 27.58 ATOM N THR L 129 44.454 1.513 −15.894 1.00 26.97 ATOM CA THR L 129 44.486 2.883 −16.390 1.00 26.43 ATOM CB THR L 129 45.222 3.804 −15.424 1.00 28.39 ATOM OG1 THR L 129 44.466 3.862 −14.194 1.00 32.69 ATOM OG2 THR L 129 45.325 5.214 −15.997 1.00 29.42 ATOM C THR L 129 45.071 3.015 −17.774 1.00 23.68 ATOM O THR L 129 45.875 2.192 −18.194 1.00 25.37 ATOM N ALA L 130 44.625 4.044 −18.487 1.00 20.97 ATOM CA ALA L 130 45.069 4.323 −19.639 1.00 19.62 ATOM CB ALA L 130 43.909 4.148 −20.807 1.00 18.49 ATOM C ALA L 130 45.637 5.739 −19.961 1.00 19.53 ATOM O ALA L 130 44.955 6.718 −19.646 1.00 19.42 ATOM N SER L 131 46.909 5.832 −20.347 1.00 16.98 ATOM CA SER L 131 47.656 7.114 −20.553 1.00 16.02 ATOM CB SER L 131 48.899 7.186 −19.834 1.00 14.60 ATOM OG SER L 131 48.729 7.094 −18.434 1.00 16.28 ATOM C SER L 131 47.760 7.262 −22.048 1.00 15.07 ATOM O SER L 131 48.211 6.333 −22.708 1.00 15.64 ATOM N VAL L 132 47.325 8.389 −22.593 1.00 15.03 ATOM CA VAL L 132 47.475 8.667 −24.010 1.00 16.30 ATOM CB VAL L 132 46.116 9.021 −24.691 1.00 15.74 ATOM CG1 VAL L 132 46.291 9.031 −26.210 1.00 14.83 ATOM CG2 VAL L 132 45.014 8.034 −24.255 1.00 12.79 ATOM C VAL L 132 48.420 9.861 −24.039 1.00 16.78 ATOM O VAL L 132 48.193 10.852 −23.349 1.00 15.30 ATOM N VAL L 133 49.601 9.736 −24.796 1.00 14.90 ATOM CA VAL L 133 50.497 10.786 −24.853 1.00 16.13 ATOM CB VAL L 133 51.901 10.246 −24.396 1.00 15.26 ATOM CG1 VAL L 133 52.953 11.362 −24.412 1.00 14.56 ATOM CG2 VAL L 133 51.794 9.620 −23.018 1.00 13.03 ATOM C VAL L 133 50.622 11.409 −26.226 1.00 14.37 ATOM O VAL L 133 50.629 10.721 −27.251 1.00 13.58 ATOM N CYS L 134 50.734 12.727 −26.222 1.00 16.21 ATOM CA CYS L 134 50.906 13.508 −27.433 1.00 16.73 ATOM C CYS L 134 52.188 14.309 −27.250 1.00 17.07 ATOM O CYS L 134 52.391 14.974 −26.229 1.00 16.97 ATOM CB CYS L 134 49.727 14.456 −27.645 1.00 18.80 ATOM SG CYS L 134 49.723 15.237 −29.291 1.00 24.75 ATOM N LEU L 135 53.075 14.186 −28.216 1.00 16.87 ATOM CA LEU L 135 54.339 14.872 −28.187 1.00 17.83 ATOM CB LEU L 135 55.458 13.849 −28.433 1.00 14.08 ATOM CG LEU L 135 56.857 14.414 −28.734 1.00 16.16 ATOM CD1 LEU L 135 57.424 15.070 −27.488 1.00 13.93 ATOM CD2 LEU L 135 57.794 13.329 −29.223 1.00 14.15 ATOM C LEU L 135 54.364 15.922 −29.294 1.00 19.16 ATOM O LEU L 135 53.898 15.648 −30.401 1.00 18.16 ATOM N LEU L 136 54.826 17.136 −28.974 1.00 19.85 ATOM CA LEU L 136 55.005 18.200 −29.973 1.00 18.72 ATOM CB LEU L 136 54.371 19.523 −29.578 1.00 16.93 ATOM CG LEU L 136 53.008 19.601 −28.922 1.00 22.19 ATOM CD1 LEU L 136 52.444 20.977 −29.261 1.00 20.90 ATOM CD2 LEU L 136 52.077 18.504 −29.370 1.00 16.66 ATOM C LEU L 136 56.494 18.330 −29.821 1.00 18.78 ATOM O LEU L 136 56.968 18.683 −28.745 1.00 19.77 ATOM N ASN L 137 57.231 18.044 −30.878 1.00 17.88 ATOM CA ASN L 137 58.677 18.051 −30.811 1.00 17.03 ATOM CB ASN L 137 59.198 16.728 −31.408 1.00 18.02 ATOM CG ASN L 137 60.452 16.198 −30.714 1.00 19.89 ATOM OD1 ASN L 137 60.761 16.559 −29.569 1.00 21.01 ATOM ND2 ASN L 137 61.160 15.309 −31.396 1.00 17.37 ATOM C ASN L 137 59.382 19.211 −31.487 1.00 17.90 ATOM O ASN L 137 59.030 19.624 −32.601 1.00 19.36 ATOM N ASN L 138 60.371 19.745 −30.786 1.00 18.41 ATOM CA ASN L 138 61.225 20.806 −31.298 1.00 19.22 ATOM CB ASN L 138 62.269 20.191 −32.234 1.00 19.52 ATOM CG ASN L 138 63.097 19.099 −31.563 1.00 19.73 ATOM OD1 ASN L 138 63.268 19.078 −30.340 1.00 19.78 ATOM ND2 ASN L 138 63.612 18.186 −32.364 1.00 23.67 ATOM C ASN L 138 60.576 21.998 −31.987 1.00 20.58 ATOM O ASN L 138 60.845 22.240 −33.153 1.00 22.46 ATOM N PHE L 139 59.841 22.811 −31.232 1.00 21.42 ATOM CA PHE L 139 59.142 23.976 −31.777 1.00 21.68 ATOM CB PHE L 139 57.630 23.775 −31.654 1.00 18.86 ATOM CG PHE L 139 57.128 23.694 −30.227 1.00 17.94 ATOM CD1 PHE L 139 56.634 24.822 −29.582 1.00 17.65 ATOM CD2 PHE L 139 57.081 22.478 −29.556 1.00 17.82 ATOM CE1 PHE L 139 56.091 24.744 −28.299 1.00 15.73 ATOM CE2 PHE L 139 56.540 22.399 −28.272 1.00 18.39 ATOM CZ PHE L 139 56.042 23.541 −27.646 1.00 15.75 ATOM C PHE L 139 59.902 25.314 −31.137 1.00 20.62 ATOM O PHE L 139 60.190 25.369 −30.129 1.00 20.00 ATOM N TYR L 140 59.018 26.390 −31.738 1.00 21.80 ATOM CA TYR L 140 59.239 27.746 −31.232 1.00 25.88 ATOM CB TYR L 140 60.712 28.166 −31.365 1.00 28.61 ATOM CG TYR L 140 61.014 29.491 −30.677 1.00 32.85 ATOM CG1 TYR L 140 60.690 30.704 −31.285 1.00 32.88 ATOM CE1 TYR L 140 60.943 31.915 −30.648 1.00 33.51 ATOM CD2 TYR L 140 61.607 29.532 −29.408 1.00 31.57 ATOM CE2 TYR L 140 61.866 30.740 −28.772 1.00 29.63 ATOM CE TYR L 140 61.530 31.922 −29.394 1.00 31.58 ATOM OH TYR L 140 61.766 33.127 −28.777 1.00 32.96 ATOM C TYR L 140 58.344 28.729 −31.992 1.00 25.00 ATOM O TYR L 140 58.228 28.649 −33.216 1.00 26.01 ATOM N PRO L 141 57.716 29.682 −31.290 1.00 25.66 ATOM CD PRO L 141 56.823 30.618 −31.995 1.00 26.17 ATOM CA PRO L 141 57.729 29.979 −29.855 1.00 26.74 ATOM CB PRO L 141 56.894 31.257 −29.772 1.00 26.54 ATOM CG PRO L 141 55.924 31.091 −30.885 1.00 25.01 ATOM C PRO L 141 57.149 28.887 −28.972 1.00 27.91 ATOM O PRO L 141 56.590 27.910 −29.468 1.00 27.79 ATOM N ARG L 142 57.267 29.086 −27.661 1.00 28.05 ATOM CA ARG L 142 56.781 28.140 −26.660 1.00 29.58 ATOM CB ARG L 142 57.336 28.500 −25.282 1.00 32.03 ATOM CG ARG L 142 57.042 27.480 −24.205 1.00 36.16 ATOM CD ARG L 142 57.579 27.937 −22.862 1.00 43.89 ATOM NE ARG L 142 56.887 27.256 −21.769 1.00 52.50 ATOM CZ ARG L 142 55.698 27.622 −21.285 1.00 56.42 ATOM NH1 ARG L 142 55.061 28.684 −21.787 1.00 57.72 ATOM NH2 ARG L 142 55.115 26.889 −20.337 1.00 56.76 ATOM C ARG L 142 55.264 27.995 −26.579 1.00 29.52 ATOM O ARG L 142 54.771 26.935 −26.189 1.00 31.05 ATOM N GLU L 143 54.523 29.044 −26.925 1.00 27.77 ATOM CA GLU L 143 53.064 28.994 −26.878 1.00 29.28 ATOM CB GLU L 143 52.461 30.381 −27.143 1.00 33.40 ATOM CG GLU L 143 51.192 30.739 −26.316 1.00 43.31 ATOM CD GLU L 143 49.989 29.789 −26.518 1.00 49.45 ATOM OE1 GLU L 143 49.242 29.944 −27.521 1.00 5L.48 ATOM OE2 GLU L 143 49.767 28.909 −25.643 1.00 51.44 ATOM CG GLU L 143 52.529 27.985 −27.900 1.00 28.06 ATOM O GLU L 143 52.854 28.036 −29.094 1.00 27.27 ATOM N ALA L 144 51.722 27.054 −27.419 1.00 26.94 ATOM CA ALA L 144 51.138 26.036 −28.272 1.00 28.67 ATOM CB ALA L 144 52.129 24.898 −28.509 1.00 25.66 ATOM C ALA L 144 49.514 25.527 −27.546 1.00 29.63 ATOM O ALA L 144 49.903 25.442 −26.311 1.00 30.81 ATOM N LYS L 145 48.860 25.259 −28.307 1.00 30.65 ATOM CA LYS L 145 47.623 24.756 −27.734 1.00 30.11 ATOM CB LYS L 145 46.446 25.673 −28.075 1.00 33.51 ATOM CG LYS L 145 45.168 25.314 −27.333 1.00 38.19 ATOM CD LYS L 145 44.013 25.039 −28.287 1.00 44.45 ATOM CE LYS L 145 43.662 26.272 −29.116 1.00 45.04 ATOM NZ LYS L 145 42.426 26.059 −29.917 1.00 45.43 ATOM C LYS L 145 47.362 23.357 −28.251 1.00 28.14 ATOM O LYS L 145 47.377 23.103 −29.461 1.00 26.62 ATOM N VAL L 146 47.171 22.437 −27.325 1.00 28.70 ATOM CA VAL L 146 46.907 21.065 −27.690 1.00 30.08 ATOM CB VAL L 146 48.104 20.097 −27.325 1.00 30.21 ATOM CG1 VAL L 146 49.130 20.784 −26.451 1.00 30.48 ATOM CG2 VAL L 146 47.606 18.807 −26.701 1.00 29.81 ATOM C VAL L 146 45.593 20.657 −27.057 1.00 29.32 ATOM O VAL L 146 45.391 20.831 −25.860 1.00 29.58 ATOM N GLN L 147 44.661 20.233 −27.902 1.00 30.06 ATOM CA GLN L 147 43.346 19.802 −27.455 1.00 30.42 ATOM CB GLN L 147 42.236 20.636 −28.113 1.00 35.67 ATOM CG GLN L 147 42.091 22.049 −27.550 1.00 40.36 ATOM CD GLN L 147 40.817 22.745 −28.005 1.00 43.14 ATOM CE1 GLN L 147 39.992 23.141 −27.186 1.00 43.76 ATOM NE2 GLN L 147 40.856 22.903 −29.314 1.00 43.31 ATOM C GLN L 147 43.117 18.330 −27.745 1.00 28.02 ATOM O GLN L 147 43.417 17.837 −28.838 1.00 25.81 ATOM N TRP L 148 42.622 17.624 −26.742 1.00 25.59 ATOM CA TRP L 148 42.333 16.213 −26.882 1.00 25.12 ATOM CB TRP L 148 42.574 15.493 −25.573 1.00 23.52 ATOM CG TRP L 148 44.015 15.322 −25.266 1.00 22.59 ATOM CD2 TRP L 148 44.870 14.282 −25.753 1.00 21.52 ATOM CE2 TRP L 148 46.114 14.439 −25.122 1.00 17.40 ATOM CE3 TRP L 148 44.898 13.226 −26.660 1.00 21.73 ATOM CD1 TRP L 148 44.760 16.063 −24.401 1.00 19.92 ATOM NEl TRP L 148 46.020 15.532 −24.304 1.00 18.98 ATOM CZ2 TRP L 148 47.185 13.579 −25.359 1.00 19.15 ATOM CZ3 TRP L 148 45.767 12.372 −26.900 1.00 19.55 ATOM CH2 TRP L 148 46.993 12.555 −26.249 1.00 17.26 ATOM C TRP L 148 40.897 16.050 −27.267 1.00 27.24 ATOM O TRP L 148 40.021 16.706 −26.704 1.00 29.09 ATOM N LYS L 149 40.842 15.170 −28.218 1.00 27.78 ATOM CA LYS L 149 39.286 14.927 −28.655 1.00 28.56 ATOM CB LYS L 149 39.065 15.540 −30.043 1.00 33.33 ATOM CG LYS L 149 39.014 17.083 −30.049 1.00 40.99 ATOM CD LYS L 149 39.056 17.665 −31.460 1.00 45.80 ATOM CE LYS L 149 40.413 17.409 −32.118 1.00 50.94 ATOM NZ LYS L 149 40.478 17.798 −33.568 1.00 52.55 ATOM C LYS L 149 39.064 13.431 −28.673 1.00 27.65 ATOM O LYS L 149 39.836 12.686 −29.274 1.00 26.68 ATOM N VAL L 150 38.064 12.979 −27.932 1.00 28.55 ATOM CA VAL L 150 37.736 11.555 −27.890 1.00 30.17 ATOM CB VAL L 150 37.694 11.019 −26.437 1.00 29.56 ATOM CG1 VAL L 150 37.346 9.542 −26.446 1.00 31.46 ATOM CG2 VAL L 150 39.049 11.233 −25.747 1.00 28.62 ATOM C VAL L 150 36.376 11.403 −28.584 1.00 32.05 ATOM O VAL L 150 35.356 11.919 −28.106 1.00 31.85 ATOM N ASP L 151 36.380 10.737 −29.736 1.00 33.92 ATOM CA ASP L 151 35.177 10.553 −30.555 1.00 34.55 ATOM CB ASP L 151 34.146 9.661 −29.863 1.00 34.11 ATOM CG ASP L 151 34.488 8.190 −29.982 1.00 35.60 ATOM OD1 ASP L 151 35.120 7.820 −30.992 1.00 34.60 ATOM OD2 ASP L 151 34.129 7.405 −29.076 1.00 38.15 ATOM C ASP L 151 34.601 11.916 −30.912 1.00 34.81 ATOM O ASP L 151 33.396 12.141 −30.887 1.00 35.02 ATOM N ASN L 152 35.513 12.837 −31.189 1.00 34.49 ATOM CA ASN L 152 35.190 14.191 −31.574 1.00 35.32 ATOM CB ASN L 152 34.202 14.168 −32.734 1.00 39.44 ATOM CG ASN L 152 34.735 13.365 −33.910 1.00 44.85 ATOM OD1 ASN L 152 34.762 12.136 −33.877 1.00 46.35 ATOM ND2 ASN L 152 35.233 14.059 −34.922 1.00 48.06 ATOM C ASN L 152 34.729 15.076 −30.435 1.00 33.57 ATOM O ASN L 152 34.545 16.275 −30.619 1.00 36.79 ATOM N ALA L 153 34.614 14.506 −29.243 1.00 31.08 ATOM CA ALA L 153 34.207 15.266 −28.073 1.00 28.26 ATOM CB ALA L 153 33.481 14.371 −27.116 1.00 28.75 ATOM C ALA L 153 35.439 15.875 −27.403 1.00 28.92 ATOM O ALA L 153 36.384 15.155 −27.053 1.00 26.45 ATOM N LEU L 154 35.422 17.195 −27.221 1.00 29.49 ATOM CA LEU L 154 36.532 17.924 −26.606 1.00 30.90 ATOM CB LEU L 154 36.386 19.416 −26.835 1.00 33.24 ATOM CG LEU L 154 37.433 20.289 −26.146 1.00 36.75 ATOM CD1 LEU L 154 38.831 19.982 −26.665 1.00 38.15 ATOM CD2 LEU L 154 37.086 21.748 −26.380 1.00 39.59 ATOM C LEU L 154 36.645 17.642 −25.117 1.00 31.55 ATOM O LEU L 154 35.690 17.838 −24.362 1.00 31.00 ATOM N GLN L 155 37.840 17.209 −24.713 1.00 31.11 ATOM CA GLN L 155 38.151 16.846 −23.336 1.00 28.18 ATOM CB GLN L 155 39.328 15.878 −23.317 1.00 25.72 ATOM CG GLN L 155 39.079 14.638 −24.112 1.00 23.68 ATOM CD GLN L 155 37.881 13.888 −23.604 1.00 25.63 ATOM OE1 GLN L 155 37.975 13.140 −22.639 1.00 26.96 ATOM NE2 GLN L 155 36.737 14.094 −24.237 1.00 25.22 ATOM C GLN L 155 38.485 18.050 −22.492 1.00 29.16 ATOM O GLN L 155 39.007 19.047 −22.995 1.00 28.96 ATOM N SER L 156 38.231 17.931 −21.196 1.00 29.53 ATOM CA SER L 156 38.498 19.015 −20.273 1.00 30.80 ATOM CB SER L 156 37.260 19.914 −20.143 1.00 34.66 ATOM OG SER L 156 36. 60 20.429 −21.409 1.00 43.01 ATOM C SER L 156 38.838 18.467 −18.907 1.00 29.08 ATOM O SER L 156 38.103 17.641 −18.368 1.00 29.54 ATOM N GLY L 157 39.972 18.901 −18.368 1.00 28.54 ATOM CA GLY L 157 40.372 18.490 −17.038 1.00 26.39 ATOM C GLY L 157 40.936 17.101 −16.850 1.00 26.37 ATOM O GLY L 157 41.120 16.671 −15.715 1.00 29.38 ATOM N ASN L 158 41.216 16.385 −17.928 1.00 23.45 ATOM CA ASN L 158 41.770 15.049 −17.777 1.00 21.09 ATOM CB ASN L 158 40.764 13.989 −18.244 1.00 19.33 ATOM CG ASN L 158 40.216 14.252 −19.630 1.00 17.19 ATOM OG1 ASN L 158 40.588 15.213 −20.302 1.00 18.35 ATOM ND2 ASN L 158 39.331 13.387 −20.066 1.00 18.99 ATOM C ASN L 158 43.136 14.867 −18.440 1.00 19.26 ATOM O ASN L 158 43.534 13.753 −18.767 1.00 21.16 ATOM N SER L 159 43.874 15.959 −18.600 1.00 18.71 ATOM CA SER L 159 45.187 15.890 −19.218 1.00 20.76 ATOM CB SER L 159 45.077 16.188 −20.714 1.00 18.72 ATOM OG SER L 159 44.532 17.477 −20.945 1.00 20.62 ATOM C SER L 159 46.131 16.882 −18.553 1.00 23.10 ATOM O SER L 159 45.685 17.868 −17.957 1.00 24.15 ATOM N GLN L 160 47.427 16.585 −18.592 1.00 21.31 ATOM CA GLN L 160 48.442 17.471 −18.021 1.00 21.04 ATOM CB GLN L 160 49.069 16.879 −16.736 1.00 23.45 ATOM OG GLN L 160 48.154 16.872 −15.510 1.00 27.10 ATOM CD GLN L 160 48.835 16.394 −14.231 1.00 28.51 ATOM GE1 GLN L 160 49.047 15.187 −14.036 1.00 24.70 ATOM NE2 GLN L 160 49.135 17.334 −13.329 1.00 25.84 ATOM C GLN L 160 49.532 17.659 −19.066 1.00 20.99 ATOM O GLN L 160 49.863 16.734 −19.816 1.00 21.59 ATOM N GLU L 161 50.098 18.853 −19.124 1.00 20.61 ATOM CA GLU L 161 51.172 19.106 −20.072 1.00 20.46 ATOM CB GLU L 161 50.901 20.359 −20.890 1.00 20.91 ATOM CG GLU L 161 49.611 20.349 −21.674 1.00 24.55 ATOM CD GLU L 161 49.542 21.528 −22.619 1.00 26.26 ATOM OE1 GLU L 161 50.300 22.486 −22.485 1.00 29.28 ATOM OE2 GLU L 161 48.648 21.497 −23.507 1.00 28.66 ATOM C GLU L 161 52.476 19.303 −19.328 1.00 19.83 ATOM O GLU L 161 52.493 19.602 −18.134 1.00 20.07 ATOM N SER L 162 53.569 19.107 −20.036 1.00 17.23 ATOM CA SER L 162 54.865 19.323 −19.455 1.00 17.53 ATOM CB SER L 162 55.447 18.035 −18.889 1.00 14.42 ATOM OG SER L 162 56.762 18.252 −18.431 1.00 18.03 ATOM C SER L 162 55.709 19.870 −20.579 1.00 16.58 ATOM O SER L 162 55.655 19.376 −21.705 1.00 17.04 ATOM N VAL L 163 56.386 20.975 −20.311 1.00 19.21 ATOM CA VAL L 163 57.226 21.568 −21.323 1.00 18.37 ATOM CB VAL L 163 56.819 23.039 −21.669 1.00 18.75 ATOM CG1 VAL L 163 56.923 23.931 −20.442 2.00 20.07 ATOM CG2 VAL L 163 57.696 23.590 −22.802 1.00 13.07 ATOM C VAL L 163 58.686 21.463 −20.921 1.00 19.06 ATOM O VAL L 163 59.071 21.541 −19.744 1.00 16.78 ATOM N THR L 164 59.484 21.211 −21.936 1.00 18.83 ATOM CA THR L 164 60.915 21.063 −21.827 1.00 19.31 ATOM CE THR L 164 61.331 20.278 −23.114 1.00 19.43 ATOM OG1 THR L 164 61.683 18.919 −22.809 1.00 22.69 ATOM CG2 THR L 164 62.355 20.966 −23.872 1.00 16.60 ATOM C THR L 164 61.579 22.474 −21.698 1.00 19.84 ATOM O THR L 164 60.976 23.506 −22.053 1.00 17.28 ATOM N GLU L 165 62.756 22.535 −21.083 1.00 19.36 ATOM CA GLU L 165 63.471 23.800 −20.983 1.00 19.55 ATOM CB GLU L 165 64.575 23.736 −19.925 1.00 23.79 ATOM CG GLU L 165 64.076 23.813 −18.473 1.00 31.50 ATOM CD GLU L 165 63.482 25.178 −18.114 1.00 38.33 ATOM OE1 GLU L 165 64.068 26.216 −18.506 1.00 42.53 ATOM OE2 GLU L 165 62.426 25.220 −17.441 1.00 42.33 ATOM C GLU L 165 64.063 24.052 −22.364 1.00 17.91 ATOM O GLU L 165 64.328 23.115 −23.111 1.00 16.78 ATOM N GLN L 166 64.261 25.311 −22.715 1.00 19.48 ATOM CA GLN L 166 64.794 25.653 −24.030 1.00 22.17 ATOM CB GLN L 166 65.000 27.162 −24.135 1.00 23.76 ATOM CG GLN L 166 65.302 27.660 −25.525 1.00 22.40 ATOM CD GLN L 166 65.300 29.163 −25.585 1.00 24.53 ATOM OE1 GLN L 166 65.665 29.834 −24.615 1.00 23.40 ATOM NE2 GLN L 166 64.862 29.710 −26.710 1.00 22.79 ATOM C GLN L 166 66.082 24.923 −24.354 1.00 22.88 ATOM O GLN L 166 66.968 24.829 −23.514 1.00 23.51 ATOM N ASP L 167 66.277 24.395 −25.570 1.00 24.27 ATOM CA ASP L 167 67.363 23.665 −25.995 1.00 24.79 ATOM CB ASP L 167 67.086 22.929 −27.307 1.00 25.67 ATOM CG ASP L 167 68.201 21.975 −27.691 1.00 26.79 ATOM OD1 ASP L 167 68.072 20.765 −27.439 1.00 29.58 ATOM OD2 ASP L 167 69.206 22.429 −28.260 1.00 28.02 ATOM C ASP L 167 68.528 24.647 −26.147 1.00 25.55 ATOM O ASP L 167 68.392 25.708 −26.753 1.00 23.48 ATOM N SER L 168 69.675 24.277 −25.597 1.00 27.95 ATOM CA SER L 168 70.860 25.120 −25.625 1.00 29.28 ATOM CB SER L 168 71.831 24.670 −24.531 1.00 28.03 ATOM OG SER L 168 71.341 24.844 −23.243 1.00 28.54 ATOM C SER L 168 71.554 25.200 −26.987 1.00 31.24 ATOM O SER L 168 72.477 25.993 −27.164 1.00 33.45 ATOM N LYS L 169 71.122 24.369 −27.935 1.00 32.30 ATOM CA LYS L 169 71.692 24.370 −29.287 1.00 32.24 ATOM CB LYS L 169 71.975 22.947 −29.796 1.00 33.42 ATOM CG LYS L 169 73.305 22.207 −29.102 1.00 41.01 ATOM CD LYS L 169 72.677 21.620 −27.743 1.00 50.52 ATOM CE LYS L 169 71.807 20.369 −27.899 1.00 53.08 ATOM NZ LYS L 169 70.996 20.036 −26.688 1.00 53.75 ATOM C LYS L 169 70.744 25.064 −30.261 1.00 31.01 ATOM O LYS L 169 71.098 26.081 −30.867 1.00 30.68 ATOM N ASP L 170 69.534 24.522 −30.407 1.00 28.81 ATOM CA ASP L 170 68.577 25.097 −31.337 1.00 25.15 ATOM CB ASP L 170 67.953 24.024 −32.229 1.00 26.91 ATOM CG ASP L 170 67.157 22.996 −31.460 1.00 28.83 ATOM OD1 ASP L 170 66.590 23.320 −30.406 1.00 30.B3 ATOM OD2 ASP L 170 67.082 21.846 −31.927 1.00 33.97 ATOM C ASP L 170 67.515 26.027 −30.786 1.00 25.54 ATOM O ASP L 170 66.600 26.397 −31.512 1.00 25.89 ATOM N SER L 171 67.607 26.368 −29.504 1.00 24.11 ATOM CA SER L 171 66.662 27.300 −28.878 1.00 25.64 ATOM CB SER L 171 66.966 28.712 −29.391 1.00 25.56 ATOM OG SER L 171 68.371 28.936 −29.352 1.00 28.30 ATOM C SER L 171 65.175 26.947 −29.074 1.00 23.90 ATOM O SER L 171 64.279 27.800 −29.011 1.00 25.67 ATOM N THR L 172 64.929 25.653 −29.168 1.00 23.05 ATOM CA THR L 172 63.609 25.103 −29.394 1.00 22.83 ATOM CB THR L 172 63.769 24.085 −30.562 1.00 24.46 ATOM OG1 THR L 172 62.989 24.482 −31.695 1.00 28.40 ATOM CG2 THR L 172 63.498 22.695 −30.140 1.00 18.05 ATOM C THR L 172 63.030 24.465 −28.099 1.00 23.36 ATOM O THR L 172 63.743 24.308 −27.094 1.00 20.90 ATOM N TYR L 173 61.735 24.141 −28.123 1.00 23.45 ATOM CA TYR L 173 61.033 23.508 −26.999 1.00 21.92 ATOM CB TYR L 173 59.935 24.431 −26.453 1.00 22.23 ATOM CG TYR L 173 60.430 25.740 −25.917 1.00 24.83 ATOM CD1 TYR L 173 61.023 25.808 −24.664 1.00 25.38 ATOM CE1 TYR L 173 61.483 26.991 −24.161 1.00 24.43 ATOM CD2 TYR L 173 60.311 26.912 −26.659 1.00 25.09 ATOM CE2 TYR L 173 60.774 28.115 −26.160 1.00 26.35 ATOM CZ TYR L 173 61.559 28.143 −24.903 1.00 25.86 ATOM OH TYR L 173 61.799 29.324 −24.366 1.00 26.61 ATOM C TYR L 173 60.325 22.231 −27.463 1.00 20.70 ATOM O TYR L 173 60.063 22.049 −28.648 1.00 18.08 ATOM N SER L 174 60.025 21.354 −26.515 1.00 18.47 ATOM CA SER L 174 59.275 20.134 −26.785 1.00 17.88 ATOM CB SER L 174 60.178 18.904 −26.831 1.00 15.91 ATOM OG SER L 174 60.833 18.848 −28.095 1.00 17.19 ATOM C SER L 174 58.212 20.047 −25.692 1.00 17.46 ATOM O SER L 174 58.445 20.462 −24.555 1.00 16.26 ATOM N LEU L 175 57.035 19.548 −26.036 1.00 17.03 ATOM CA LEU L 175 55.952 19.487 −25.076 1.00 17.80 ATOM CB LEU L 175 54.352 20.613 −25.378 1.00 16.17 ATOM CG LEU L 175 53.705 20.835 −24.513 1.00 19.25 ATOM CD1 LEU L 175 53.316 22.301 −24.587 1.00 19.61 ATOM CD2 LEU L 175 52.537 19.964 −24.943 1.00 18.86 ATOM C LEU L 175 55.233 18.154 −25.138 1.00 18.23 ATOM O LEU L 175 55.153 17.549 −26.207 1.00 18.92 ATOM N SER L 176 54.150 17.691 −23.985 1.00 17.34 ATOM CA SER L 176 53.983 16.460 −23.912 1.00 16.51 ATOM CB SER L 176 54.722 15.383 −23.107 1.00 16.81 ATOM OG SER L 176 54.108 15.643 −21.710 1.00 18.80 ATOM C SER L 176 52.648 16.785 −23.236 1.00 18.21 ATOM O SER L 176 52.599 17.593 −22.291 1.00 17.16 ATOM N SER L 177 51.563 16.269 −23.804 1.00 16.60 ATOM CA SER L 177 50.242 16.426 −23.221 1.00 15.84 ATOM CB SER L 177 49.266 17.107 −24.170 1.00 17.29 ATOM OG SER L 177 47.980 17.148 −23.580 1.00 18.53 ATOM C SER L 177 49.830 14.986 −22.963 1.00 16.07 ATOM O SER L 177 49.953 14.120 −23.843 1.00 15.65 ATOM N THR L 178 49.399 14.706 −21.740 1.00 15.55 ATOM CA THR L 178 49.039 13.355 −21.395 1.00 14.30 ATOM CB THR L 178 50.000 12.811 −20.331 1.00 15.61 ATOM OG1 THR L 178 51.350 12.944 −20.813 1.00 15.71 ATOM CG2 THR L 178 49.686 11.333 −20.008 1.00 15.89 ATOM C THR L 178 47.626 13.286 −20.905 1.00 16.11 ATOM O THR L 178 47.253 14.017 −19.981 1.00 14.99 ATOM N LEU L 179 46.843 12.431 −21.562 1.00 16.21 ATOM CA LEU L 179 45.428 12.195 −21.247 1.00 17.85 ATOM CB LEU L 179 44.639 12.046 −22.551 1.00 16.22 ATOM CG LEU L 179 43.152 11.701 −22.489 1.00 16.81 ATOM CD1 LEU L 179 42.374 12.854 −21.907 1.00 15.95 ATOM CD2 LEU L 179 42.664 11.397 −23.890 1.00 17.04 ATOM C LEU L 179 45.305 10.909 −20.424 1.00 19.34 ATOM O LEU L 179 45.805 9.862 −20.843 1.00 19.74 ATOM N THR L 180 44.686 10.984 −19.245 1.00 19.39 ATOM CA THR L 180 44.528 9.800 −18.402 1.00 20.40 ATOM CB THR L 180 45.074 10.010 −16.980 1.00 21.84 ATOM OG1 THR L 180 46.378 10.611 −17.036 1.00 22.46 ATOM CG2 THR L 180 45.181 8.668 −16.261 1.00 20.50 ATOM C THR L 180 43.061 9.406 −18.294 1.00 23.01 ATOM O THR L 180 42.192 10.237 −17.975 1.00 21.76 ATOM N LEU L 181 42.797 8.132 −18.553 1.00 23.18 ATOM CA LEU L 181 41.456 7.579 −18.503 1.00 24.23 ATOM CB LEU L 181 40.928 7.330 −19.917 1.00 25.07 ATOM CG LEU L 181 40.619 8.578 −20.729 1.00 26.14 ATOM CD1 LEU L 181 40.168 8.204 −22.132 1.00 28.53 ATOM CD2 LEU L 181 39.545 9.361 −19.998 1.00 30.01 ATOM C LEU L 181 41.504 6.256 −17.784 1.00 24.92 ATOM O LEU L 181 42.558 5.637 −17.691 1.00 25.25 ATOM N SER L 182 40.364 5.848 −17.237 1.00 27.27 ATOM CA SER L 182 40.250 4.567 −16.563 1.00 25.98 ATOM CB SER L 182 38.940 4.502 −15.780 1.00 28.54 ATOM OG SER L 182 37.810 4.674 −16.630 1.00 27.58 ATOM C SER L 182 40.176 3.594 −17.715 1.00 26.31 ATOM O SER L 182 39.793 3.991 −18.826 1.00 25.06 ATOM N LYS L 183 40.556 2.341 −17.477 1.00 25.27 ATOM CA LYS L 183 40.489 1.336 −18.526 1.00 29.03 ATOM CB LYS L 183 40.914 −0.032 −17.992 1.00 30.64 ATOM CG LYS L 183 40.694 −1.155 −18.969 1.00 32.86 ATOM CD LYS L 183 41.393 −2.411 −18.519 1.00 38.66 ATOM CE LYS L 183 41.157 −3.533 −19.526 1.00 43.79 ATOM NZ LYS L 183 42.049 −4.722 −19.316 1.00 50.95 ATOM C LYS L 183 39.049 1.276 −19.027 1.00 31.27 ATOM O LYS L 183 38.800 1.120 −20.227 1.00 32.73 ATOM N ALA L 184 38.110 1.419 −18.093 1.00 32.33 ATOM CA ALA L 184 36.683 1.402 −18.389 1.00 32.00 ATOM CB ALA L 184 35.885 1.598 −17.112 1.00 32.27 ATOM C ALA L 184 36.316 2.476 −19.395 1.00 31.78 ATOM O ALA L 184 35.759 2.179 −20.453 1.00 34.22 ATOM N ASP L 185 36.660 3.719 −19.086 1.00 31.26 ATOM CA ASP L 185 36.335 4.827 −19.976 1.00 33.90 ATOM CB ASP L 185 36.558 6.151 −19.268 1.00 38.89 ATOM CG ASP L 185 35.528 6.392 −18.184 1.00 45.46 ATOM OD1 ASP L 185 34.316 6.444 −18.507 1.00 48.98 ATOM OD2 ASP L 185 35.919 6.493 −17.006 1.00 50.41 ATOM C ASP L 185 37.042 4.801 −21.315 1.00 32.24 ATOM O ASP L 185 36.468 5.185 −22.333 1.00 31.83 ATOM N TYR L 186 38.283 4.327 −21.311 1.00 31.61 ATOM CA TYR L 186 39.078 4.226 −22.520 1.00 28.14 ATOM CB TYR L 186 40.493 3.754 −22.174 1.00 24.69 ATOM CG TYR L 186 41.352 3.542 −23.390 1.00 21.62 ATOM CD1 TYR L 186 41.837 4.623 −24.114 1.00 22.76 ATOM CE1 TYR L 186 42.592 4.437 −25.250 1.00 20.71 ATOM CD2 TYR L 186 41.652 2.260 −23.841 1.00 20.70 ATOM CE2 TYR L 186 42.411 2.064 −24.981 1.00 20.68 ATOM CZ TYR L 186 42.874 3.164 −25.673 1.00 20.70 ATOM OH TYR L 186 43.646 2.996 −26.787 1.00 26.48 ATOM C TYR L 186 38.420 3.256 −23.500 1.00 30.06 ATOM O TYR L 186 38.380 3.506 −24.708 1.00 27.70 ATOM N GLU L 187 37.885 2.157 −22.973 1.00 33.21 ATOM CA GLU L 187 37.236 1.147 −23.803 1.00 35.81 ATOM CB GLU L 187 37.307 −0.211 −23.122 1.00 37.97 ATOM CG GLU L 187 38.738 −0.704 −23.053 1.00 43.63 ATOM CD GLU L 187 38.909 −1.895 −22.158 1.00 47.42 ATOM OE1 GLU L 187 39.179 −2.736 −22.466 1.00 49.65 ATOM OE2 GLU L 187 38.185 −1.984 −21.143 1.00 50.40 ATOM C GLU L 187 35.816 1.495 −24.207 1.00 35.32 ATOM O GLU L 187 35.171 0.766 −24.948 1.00 35.82 ATOM N LYS L 188 35.361 2.650 −23.747 1.00 36.88 ATOM CA LYS L 188 34.034 3.159 −24.049 1.00 36.72 ATOM CB LYS L 188 33.581 4.028 −22.867 1.00 40.35 ATOM CG LYS L 188 32.390 4.606 −22.957 1.00 48.51 ATOM CD LYS L 188 31.859 5.399 −21.684 1.00 55.80 ATOM CE LYS L 188 30.375 5.811 −21.620 1.00 58.80 ATOM NZ LYS L 188 29.969 6.745 −22.711 1.00 61.10 ATOM C LYS L 188 34.121 4.004 −25.333 1.00 35.19 ATOM O LYS L 188 33.099 4.440 −25.875 1.00 33.77 ATOM N HIS L 189 35.338 4.222 −25.832 1.00 31.64 ATOM CA HIS L 189 35.517 5.062 −27.014 1.00 30.51 ATOM CB HIS L 189 35.936 6.465 −26.585 1.00 31.61 ATOM CG HIS L 189 35.092 7.012 −25.479 1.00 33.55 ATOM CD2 HIS L 189 35.356 7.192 −24.162 1.00 34.11 ATOM ND1 HIS L 189 33.766 7.340 −25.652 1.00 33.12 ATOM CE1 HIS L 189 33.246 7.690 −24.489 1.00 34.25 ATOM NE2 HIS L 189 34.190 7.608 −23.570 1.00 35.58 ATOM C HIS L 189 36.447 4.525 −28.081 1.00 29.17 ATOM O HIS L 189 37.263 3.650 −27.821 1.00 26.39 ATOM N LYS L 190 36.310 5.087 −29.283 1.00 30.68 ATOM CA LYS L 190 37.075 4.672 −30.455 1.00 32.94 ATOM CB LYS L 190 36.120 4.481 −31.650 1.00 36.49 ATOM CG LYS L 190 36.776 4.064 −32.983 1.00 39.14 ATOM CD LYS L 190 37.615 2.800 −32.838 1.00 41.61 ATOM CE LYS L 190 36.773 1.619 −32.404 1.00 43.23 ATOM NZ LYS L 190 37.611 0.436 −32.111 1.00 44.23 ATOM C LYS L 190 38.240 5.571 −30.867 1.00 31.98 ATOM O LYS L 190 39.395 5.159 −30.759 1.00 32.68 ATOM N VAL L 191 37.956 6.776 −31.363 1.00 29.70 ATOM CA VAL L 191 39.040 7.635 −31.805 1.00 27.93 ATOM CB VAL L 191 38.770 8.312 −33.177 1.00 27.89 ATOM CG1 VAL L 191 37.581 7.663 −33.876 1.00 30.46 ATOM CG2 VAL L 191 38.601 9.791 −33.042 1.00 30.08 ATOM C VAL L 191 39.569 8.620 −30.783 1.00 25.97 ATOM O VAL L 191 38.816 9.303 −30.081 1.00 25.01 ATOM N TYR L 192 40.891 8.605 −30.668 1.00 25.08 ATOM CA TYR L 192 41.644 9.461 −29.756 1.00 21.91 ATOM CB TYR L 192 42.505 8.596 −28.825 1.00 19.53 ATOM CG TYR L 192 41.653 7.806 −27.853 1.00 20.50 ATOM CD1 TYR L 192 41.307 8.349 −26.619 1.00 21.28 ATOM CE1 TYR L 192 40.415 7.714 −25.773 1.00 20.30 ATOM CD2 TYR L 192 41.082 6.575 −28.211 1.00 22.35 ATOM CE2 TYR L 192 40.176 5.930 −27.359 1.00 21.21 ATOM CZ TYR L 192 39.853 6.517 −26.144 1.00 23.15 ATOM OH TYR L 192 38.963 5.935 −25.280 1.00 26.13 ATOM C TYR L 192 42.478 10.352 −30.665 1.00 19.39 ATOM O TYR L 192 43.240 9.869 −31.490 1.00 16.16 ATOM N ALA L 193 42.243 11.652 −30.574 1.00 17.37 ATOM CA ALA L 193 42.925 12.609 −31.416 1.00 1 .38 ATOM CB ALA L 193 41.951 13.200 −32.422 1.00 14.68 ATOM C ALA L 193 43.546 13.714 −30.591 1.00 19.81 ATOM O ALA L 193 42.991 14.144 −29.568 1.00 19.87 ATOM N CYS L 194 44.721 14.143 −31.029 1.00 19.00 ATOM CA CYS L 194 45.446 15.212 −30.390 1.00 20.02 ATOM C CYS L 194 45.533 16.306 −31.451 1.00 22.09 ATOM O CYS L 194 46.104 16.099 −32.526 1.00 23.10 ATOM CB CYS L 194 46.836 14.736 −29.982 1.00 20.62 ATOM SG CYS L 194 47.887 16.076 −29.359 1.00 27.82 ATOM N GLU L 195 44.897 17.438 −31.198 1.00 21.48 ATOM CA GLU L 195 44.922 18.522 −32.155 1.00 26.37 ATOM CB GLU L 195 43.508 19.070 −32.380 1.00 30.62 ATOM CG GLU L 195 43.452 20.166 −33.425 1.00 39.13 ATOM CD GLU L 195 42.043 20.556 −33.786 1.00 46.06 ATOM OE1 GLU L 195 41.281 20.924 −32.866 1.00 49.26 ATOM OE2 GLU L 195 41.697 20.467 −34.992 1.00 50.81 ATOM C GLU L 195 45.870 19.607 −31.669 1.00 25.13 ATOM O GLU L 195 45.711 20.140 −30.571 1.00 24.45 ATOM N VAL L 196 46.825 19.965 −32.519 1.00 24.78 ATOM CA VAL L 196 47.839 20.960 −32.187 1.00 26.26 ATOM CB VAL L 196 49.255 20.369 −32.373 1.00 23.55 ATOM CG1 VAL L 196 50.325 21.443 −32.160 1.00 23.61 ATOM CG2 VAL L 196 49.454 19.172 −31.429 1.00 20.96 ATOM C VAL L 196 47.749 22.271 −32.965 1.00 28.29 ATOM O VAL L 196 47.776 22.287 −34.200 1.00 28.62 ATOM N THR L 197 47.664 23.369 −32.225 1.00 28.72 ATOM CA THR L 197 47.612 24.694 −32.820 1.00 31.05 ATOM CB THR L 197 46.441 25.524 −32.232 1.00 30.50 ATOM OG1 THR L 197 45.202 24.869 −32.519 1.00 31.44 ATOM CG2 THR L 197 46.399 26.909 −32.834 1.00 30.89 ATOM C THR L 197 48.952 25.356 −32.472 1.00 32.18 ATOM O THR L 197 49.396 25.309 −31.313 1.00 31.68 ATOM N HIS L 198 49.612 25.938 −33.468 1.00 32.23 ATOM CA HIS L 198 50.884 26.602 −33.225 1.00 32.28 ATOM CB HIS L 198 52.018 25.577 −33.141 1.00 31.15 ATOM CG HIS L 198 53.331 26.168 −32.727 1.00 30.40 ATOM CD2 HIS L 198 53.626 26.466 −31.500 1.00 29.70 ATOM ND1 HIS L 198 54.299 26.545 −33.635 1.00 27.78 ATOM CE1 HIS L 198 55.332 27.052 −32.984 1.00 29.10 ATOM NE2 HIS L 198 55.071 27.014 −31.688 1.00 28.06 ATOM C HIS L 198 51.186 27.622 −34.313 1.00 33.18 ATOM O HIS L 198 50.840 27.421 −35.471 1.00 33.74 ATOM N GLN L 199 51.877 28.691 −33.933 1.00 35.27 ATOM CA GLN L 199 52.247 29.767 −34.846 1.00 36.38 ATOM CB GLN L 199 53.225 30.727 −34.156 1.00 37.34 ATOM CG GLN L 199 53.508 31.989 −34.964 1.00 43.51 ATOM CD GLN L 199 54.222 33.074 −34.174 1.00 45.57 ATOM OE1 GLN L 199 54.997 33.848 −34.733 1.00 47.22 ATOM NE2 GLN L 199 53.943 33.153 −32.879 1.00 46.45 ATOM C GLN L 199 52.833 29.255 −36.162 1.00 35.85 ATOM O GLN L 199 52.477 29.725 −37.233 1.00 36.61 ATOM N GLY L 200 53.706 28.263 −36.083 1.00 35.48 ATOM CA GLY L 200 54.310 27.734 −37.291 1.00 35.01 ATOM C GLY L 200 53.403 26.833 −38.102 1.00 35.20 ATOM O GLY L 200 53.837 26.247 −39.087 1.00 35.29 ATOM N LEU L 201 52.152 26.699 −37.682 1.00 35.81 ATOM CA LEU L 201 51.198 25.857 −38.393 1.00 36.05 ATOM CB LEU L 201 50.543 24.862 −37.433 1.00 33.90 ATOM CG LEU L 201 51.478 23.925 −36.668 1.00 33.97 ATOM CD1 LEU L 201 50.674 23.147 −35.641 1.00 32.30 ATOM CD2 LEU L 201 52.204 22.978 −37.632 1.00 31.98 ATOM C LEU L 201 50.133 26.743 −39.033 1.00 36.97 ATOM O LEU L 201 49.499 27.558 −38.346 1.00 36.27 ATOM N SER L 202 49.968 26.609 −40.349 1.00 38.32 ATOM CA SER L 202 48.973 27.388 −41.085 1.00 40.35 ATOM CB SER L 202 49.179 27.229 −42.588 1.00 39.68 ATOM OG SER L 202 49.055 25.874 −42.981 1.00 43.15 ATOM C SER L 202 47.580 26.907 −40.688 1.00 41.57 ATOM O SER L 202 46.599 27.656 −40.750 1.00 43.86 ATOM N SER L 203 47.512 25.653 −40.261 1.00 40.52 ATOM CA SER L 203 46.269 25.049 −39.824 1.00 40.76 ATOM CB SER L 203 45.526 24.478 −41.028 1.00 42.78 ATOM OG SER L 203 46.420 23.731 −41.838 1.00 50.38 ATOM C SER L 203 46.623 23.942 −38.834 1.00 39.15 ATOM O SER L 203 47.654 23.273 −38.992 1.00 38.36 ATOM N PRO L 204 45.801 23.774 −37.778 1.00 37.58 ATOM CD PRO L 204 44.653 24.641 −37.453 1.00 36.52 ATOM CA PRO L 204 45.983 22.764 −36.731 1.00 36.27 ATOM CB PRO L 204 44.648 22.806 −35.989 1.00 36.27 ATOM CG PRO L 204 44.336 24.256 −36.011 1.00 37.26 ATOM C PRO L 204 46.274 21.379 −37.270 1.00 34.75 ATOM O PRO L 204 45.661 20.931 −38.238 1.00 33.73 ATOM N VAL L 205 47.260 20.733 −36.663 1.00 34.45 ATOM CA VAL L 205 47.652 19.390 −37.047 1.00 31.64 ATOM CB VAL L 205 49.170 19.203 −36.935 1.00 29.36 ATOM CG1 VAL L 205 49.545 17.778 −37.215 1.00 28.96 ATOM CG2 VAL L 205 49.855 20.097 −37.919 1.00 31.43 ATOM C VAL L 205 46.952 18.438 −36.099 1.00 31.45 ATOM O VAL L 205 46.809 18.732 −34.919 1.00 31.91 ATOM N THR L 206 46.480 17.315 −36.618 1.00 30.31 ATOM CA THR L 206 45.812 16.348 −35.776 1.00 27.81 ATOM CB THR L 206 44.286 16.304 −36.030 1.00 28.22 ATOM OG1 THR L 206 43.699 17.541 −35.612 1.00 30.85 ATOM CG2 THR L 206 43.639 15.180 −35.227 1.00 25.07 ATOM C THR L 206 46.403 14.969 −35.954 1.00 26.65 ATOM O THR L 206 46.585 14.49B −37.075 1.00 26.93 ATOM N LYS L 207 46.801 14.375 −34.834 1.00 26.50 ATOM CA LYS L 207 47.340 13.013 −34.803 1.00 24.40 ATOM CB LYS L 207 48.719 12.976 −34.138 1.00 22.17 ATOM CG LYS L 207 49.800 13.584 −35.000 1.00 22.70 ATOM CD LYS L 207 49.682 13.080 −36.420 1.00 25.39 ATOM CE LYS L 207 50.876 13.490 −37.283 1.00 27.96 ATOM NZ LYS L 207 50.979 14.962 −37.448 1.00 32.56 ATOM C LYS L 207 46.332 12.152 −34.041 1.00 21.89 ATOM O LYS L 207 45.836 12.552 −32.990 1.00 29.91 ATOM N SER L 208 46.002 10.986 −34.573 1.00 20.67 ATOM CA SER L 208 45.023 10.160 −33.895 1.00 22.53 ATOM CB SER L 208 43.607 10.641 −34.229 1.00 23.05 ATOM OG SER L 208 43.309 10.503 −35.605 1.00 22.35 ATOM C SER L 208 45.152 8.692 −34.236 1.00 21.41 ATOM O SER L 208 45.917 8.323 −35.128 1.00 23.53 ATOM N PHE L 209 44.414 7.867 −33.503 1.00 20.17 ATOM CA PHE L 209 44.384 6.428 −33.709 1.00 19.98 ATOM CB PHE L 209 45.499 5.733 −32.917 1.00 27.21 ATOM CG PHE L 209 45.340 5.830 −31.421 1.00 17.15 ATOM CG1 PHE L 209 45.980 6.838 −30.705 1.00 15.87 ATOM CD2 PHE L 209 44.544 4.926 −30.735 1.00 14.47 ATOM CE1 PHE L 209 45.826 6.945 −29.335 1.00 13.72 ATOM CE2 PHE L 209 44.379 5.024 −29.363 1.00 15.39 ATOM CZ PHE L 209 45.024 6.039 −28.659 1.00 15.16 ATOM C PHE L 209 43.027 5.919 −33.241 1.00 20.93 ATOM O PHE L 209 42.326 6.582 −32.474 1.00 20.26 ATOM N ASN L 210 42.643 4.745 −33.709 1.00 23.29 ATOM CA ASN L 210 41.384 4.167 −33.285 1.00 25.15 ATOM CB ASN L 210 40.588 3.627 −34.469 1.00 27.36 ATOM CG ASN L 210 40.138 4.709 −35.406 1.00 28.83 ATOM OG1 ASN L 210 39.666 5.761 −34.986 1.00 30.55 ATOM ND2 ASN L 210 40.284 4.459 −36.691 1.00 32.86 ATOM C ASN L 210 41.735 3.020 −32.361 1.00 25.95 ATOM O ASN L 210 42.595 2.177 −32.691 1.00 23.37 ATOM N ARG L 211 41.107 3.016 −31.190 1.00 24.99 ATOM CA ARG L 211 41.310 1.973 −30.200 1.00 26.72 ATOM CB ARG L 211 40.272 2.126 −29.096 1.00 29.08 ATOM CG ARG L 211 40.439 1.203 −27.920 1.00 32.37 ATOM CD ARG L 211 39.260 1.337 −26.982 1.00 38.35 ATOM NE ARG L 211 38.303 0.250 −27.164 1.00 44.72 ATOM CZ ARG L 211 37.227 0.300 −27.942 1.00 47.51 ATOM NE1 ARG L 211 36.934 1.387 −28.635 1.00 50.78 ATOM NH2 ARG L 211 36.460 −0.770 −28.060 1.00 52.10 ATOM C ARG L 211 41.086 0.649 −30.920 1.00 27.05 ATOM O ARG L 211 40.070 0.488 −31.598 1.00 25.38 ATOM N GLY L 212 42.075 −0.240 −30.863 1.00 25.25 ATOM CA GLY L 212 41.935 −1.528 −31.512 1.00 27.36 ATOM C GLY L 212 42.467 −1.669 −32.931 1.00 28.73 ATOM O GLY L 212 42.374 −2.753 −33.500 1.00 30.55 ATOM N GLU L 213 43.013 −0.603 −33.519 1.00 28.63 ATOM CA GLU L 213 43.559 −0.706 −34.878 1.00 28.38 ATOM CB GLU L 213 43.809 0.676 −35.485 1.00 27.47 ATOM CG GLU L 213 44.767 1.547 −34.702 1.00 30.90 ATOM CD GLU L 213 45.140 2.811 −35.442 1.00 32.32 . ATOM OE1 GLU L 213 44.256 3.660 −35.697 1.00 28.43 ATOM OE2 GLU L 213 46.337 2.951 −35.777 1.00 38.75 ATOM C GLU L 213 44.848 −1.545 −34.912 1.00 27.34 ATOM O GLU L 213 45.340 −1.905 −35.984 1.00 27.73 ATOM N CYS L 214 45.386 −1.824 −33.730 1.00 23.79 ATOM CA CYS L 214 46.588 −2.617 −33.568 1.00 24.14 ATOM CB CYS L 214 47.832 −1.793 −33.929 1.00 21.09 ATOM SG CYS L 214 49.402 −2.696 −33.720 1.00 21.16 ATOM C CYS L 214 46.655 −3.098 −32.113 1.00 25.60 ATOM O CYS L 214 46.497 −4.317 −31.886 1.00 26.55 ATOM OXT CYS L 214 46.812 −2.250 −31.208 1.00 25.04 ATOM CB GLN H 1 89.041 17.551 −11.026 1.00 38.73 ATOM CG GLN H 1 89.504 16.894 −12.327 1.00 43.69 ATOM CD GLN H 1 90.587 17.700 −13.054 1.00 47.34 ATOM OEl GLN H 1 91.700 17.172 −13.322 1.00 49.92 ATOM NE2 GLN H 1 90.284 18.983 −13.367 1.00 44.36 ATOM C GLN H 1 89.366 17.829 −8.582 1.00 32.86 ATOM O GLN H 1 89.282 16.917 −7.752 1.00 32.27 ATOM N GLN H 1 90.700 16.216 −9.797 1.00 36.03 ATOM CA GLN H 1 90.081 17.570 −9.909 1.00 35.50 ATOM N VAL H 2 88.863 19.049 −8.385 1.00 31.14 ATOM CA VAL H 2 88.124 19.398 −7.168 1.00 27.15 ATOM CB VAL H 2 88.139 20.922 −6.901 1.00 28.34 ATOM CG1 VAL H 2 87.231 21.267 −5.723 1.00 25.54 ATOM CG2 VAL H 2 89.545 21.385 −6.600 1.00 31.24 ATOM C VAL H 2 86.677 18.955 −7.400 1.00 24.53 ATOM O VAL H 2 86.089 19.295 −8.435 1.00 23.94 ATOM N THR H 3 86.120 18.198 −6.452 1.00 20.44 ATOM CA THR H 3 84.749 17.696 −6.557 1.00 21.79 ATOM CB THR H 3 84.695 16.180 −7.087 1.00 21.21 ATOM OG1 THR H 3 85.135 15.276 −6.066 1.00 24.96 ATOM CG2 THR H 3 85.595 15.968 −8.301 1.00 19.19 ATOM C THR H 3 84.047 17.771 −5.198 1.00 19.89 ATOM O THR H 3 84.687 17.698 −4.146 1.00 20.44 ATOM N LEU H 4 82.737 17.982 −5.222 1.00 21.46 ATOM CA LEU H 4 81.932 18.026 −3.996 1.00 21.29 ATOM CB LEU H 4 81.412 19.433 −3.711 1.00 20.12 ATOM CG LEU H 4 82.224 20.719 −3.514 1.00 23.52 ATOM CD1 LEU H 4 82.836 20.766 −2.153 1.00 21.59 ATOM CD2 LEU H 4 83.219 20.968 −4.618 1.00 22.05 ATOM C LEU H 4 80.726 17.137 −4.299 1.00 20.12 ATOM O LEU H 4 80.291 17.071 −5.447 1.00 20.31 ATOM N ARG H 5 80.207 16.432 −3.299 1.00 19.84 ATOM CA ARG H 5 79.032 15.574 −3.504 1.00 19.68 ATOM CB ARG H 5 79. 57 14.128 −3.746 1.00 25.17 ATOM CG ARG H 5 78.424 13.305 −4.463 1.00 29.51 ATOM CD ARG H 5 78.626 11.812 −4.206 1.00 38.74 ATOM NE ARG H 5 78.217 11.422 −2.851 1.00 46.80 ATOM CZ ARG H 5 79.055 11.063 −1.879 1.00 49.80 ATOM NH1 ARG H 5 80.369 11.032 −2.093 1.00 51.08 ATOM NH2 ARG H 5 78.574 10.751 −0.682 1.00 51.13 ATOM C ARG H 5 78.100 15.618 −2.301 1.00 15.95 ATOM O ARG H 5 78.504 15.298 −1.190 1.00 15.47 ATOM N GLU H 6 76.842 15.968 −2.533 1.00 16.47 ATOM CA GLU H 6 75.860 16.042 −1.450 1.00 15.47 ATOM CB GLU H 6 74.865 17.196 −1.654 1.00 15.61 ATOM CG GLU H 6 75.459 18.549 −1.986 1.00 13.15 ATOM CD GLU H 6 75.769 18.732 −3.474 1.00 14.34 ATOM OE1 GLU H 6 75.679 17.763 −4.264 1.00 14.15 ATOM OE2 GLU H 6 76.100 19.869 −3.860 1.00 16.39 ATOM C GLU H 6 75.077 14.735 −1.382 1.00 14.85 ATOM O GLU H 6 74.811 14.095 −2.405 1.00 13.49 ATOM N SER H 7 74.730 14.335 −0.169 1.00 16.74 ATOM CA SER H 7 73.953 13.131 0.045 1.00 16.80 ATOM CB SER H 7 74.876 11.897 0.097 1.00 18.29 ATOM OG SER H 7 75.885 12.018 1.085 1.00 20.20 ATOM C SER H 7 73.087 13.260 1.302 1.00 14.45 ATOM O SER H 7 73.379 14.039 2.220 1.00 12.60 ATOM N GLY H 8 71.972 12.556 1.292 1.00 13.11 ATOM CA GLY H 8 71.061 12.581 2.411 1.00 13.45 ATOM C GLY H 8 69.796 11.883 1.963 1.00 15.80 ATOM O GLY H 8 69.751 11.362 0.840 1.00 16.91 ATOM N PRO H 9 68.786 11.766 2.827 1.00 15.87 ATOM CD PRO H 9 68.706 12.263 4.210 1.00 16.52 ATOM CA PRO H 9 67. 36 11.105 2.419 1.00 16.14 ATOM CB PRO H 9 66.747 11.050 3.718 1.00 15.96 ATOM CG PRO H 9 67.217 12.297 4.431 1.00 19.96 ATOM C PRO H 9 66.820 11.970 1.378 1.00 16.98 ATOM O PRO H 9 66.961 13.204 1.366 1.00 15.45 ATOM N ALA H 10 66.069 11.337 0.491 1.00 16.97 ATOM CA ALA H 10 65.359 12.091 −0.536 1.00 17.03 ATOM CB ALA H 10 65.148 11.232 −1.762 1.00 17.55 ATOM C ALA H 10 64.016 12.627 −0.042 1.00 16.22 ATOM O ALA H 10 63.475 13.574 −0.607 1.00 14.92 ATOM N LEU H 11 63.517 12.059 1.049 1.00 16.76 ATOM CA LEU H 11 62.231 12.444 1.590 1.00 17.28 ATOM CB LEU H 11 61.224 11.333 1.282 1.00 20.63 ATOM CG LEU H 11 59.722 11.535 1.042 1.00 23.90 ATOM CD1 LEU H 11 59.037 10.144 1.116 1.00 17.36 ATOM CD2 LEU H 11 59.111 12.498 2.054 1.00 26.18 ATOM C LEU H 11 62.409 12.524 3.083 1.00 18.81 ATOM O LEU H 11 63.081 11.682 3.670 1.00 20.70 ATOM N VAL H 12 61.817 13.535 3.697 1.00 18.51 ATOM CA VAL H 12 61.890 13.700 5.137 1.00 19.38 ATOM CB VAL H 12 63.009 14.740 5.513 1.00 21.22 ATOM CG1 VAL H 12 62.819 16.018 4.757 1.00 22.31 ATOM CG2 VAL H 12 63.045 15.008 6.991 1.00 22.98 ATOM C VAL H 12 60.472 14.120 5.559 1.00 17.45 ATOM O VAL H 12 59.737 14.698 4.769 1.00 19.16 ATOM N LYS H 13 60.044 13.757 6.753 1.00 16.45 ATOM CA LYS H 13 S8.70S 14.125 7.193 1.00 19.16 ATOM CB LYS H 13 58.119 13.002 8.045 1.00 19.92 ATOM CG LYS H 13 57.944 11.718 7.279 1.00 21.38 ATOM CD LYS H 13 57.493 10.592 8.168 1.00 23.63 ATOM CE LYS H 13 57.213 9.342 7.3S0 1.00 26.68 ATOM NZ LYS H 13 55.952 9.380 6.548 1.00 29.7S ATOM C LYS H 13 58.678 15.447 7.959 1.00 21.82 ATOM O LYS H 13 59.659 15.813 8.630 1.00 23.05 ATOM N PRO H 14 57.564 16.202 7.852 1.00 20.98 ATOM CD PRO H 14 56.341 15.940 7.068 1.00 20.16 ATOM CA PRO H 14 57.468 17.480 8.564 1.00 20.48 ATOM CB PRO H 14 55.980 17.813 8.457 1.00 20.21 ATOM CG PRO H 14 55.622 17.275 7.117 1.00 19.19 ATOM C PRO H 14 57.908 17.318 10.020 1.00 19.76 ATOM O PRO H 14 57.703 16.263 10.616 1.00 19.05 ATOM N THR H 15 58.572 18.345 10.543 1.00 22.03 ATOM CA THR H 15 59.089 18.410 11.917 1.00 22.23 ATOM CB THR H 15 58.010 18.048 13.007 1.00 22.84 ATOM OG1 THR H 15 57.795 16.628 13.049 1.00 21.55 ATOM CG2 THR H 15 56.672 18.786 12.719 1.00 23.91 ATOM C THR H 15 60.356 17.613 12.182 1.00 22.65 ATOM O THR H 15 61.010 17.825 13.208 1.00 21.92 ATOM N GLN H 16 60.695 16.687 11.284 1.00 22.77 ATOM CA GLN H 16 61.911 15.889 11.442 1.00 20.54 ATOM CB GLN H 16 61.865 14.639 10.571 1.00 22.36 ATOM CG GLN H 16 60.807 13.651 11.000 1.00 25.78 ATOM CD GLN H 16 60.906 12.346 10.260 1.00 26.82 ATOM OE1 GLN H 16 61.223 12.305 9.063 1.00 26.33 ATOM NE2 GLN H 16 60.636 11.262 10.962 1.00 27.32 ATOM C GLN H 16 63.178 16.681 11.141 1.00 18.94 ATOM O GLN H 16 63.131 17.828 10.702 1.00 16.50 ATOM N THR H 17 64.318 16.077 11.435 1.00 19.96 ATOM CA THR H 17 65.582 16.737 11.197 1.00 20.38 ATOM CB THR H 17 66.533 16.591 12.400 1.00 22.26 ATOM OG1 THR H 17 65.940 17.211 13.549 1.00 24.95 ATOM CG2 THR H 17 67.886 17.266 12.106 1.00 24.40 ATOM C THR H 17 66.244 16.162 9.969 1.00 19.47 ATOM O THR H 17 66.210 14.940 9.746 1.00 21.06 ATOM N LEU H 18 66.776 17.056 9.141 1.00 17.08 ATOM CA LEU H 18 67.481 16.660 7.934 1.00 18.72 ATOM CB LEU H 18 67.118 17.590 6.771 1.00 16.71 ATOM CG LEU H 18 67.911 17.343 5.481 1.00 17.37 ATOM CD1 LEU H 18 67.516 16.008 4.874 1.00 17.23 ATOM CD2 LEU H 18 67.684 18.478 4.489 1.00 16.91 ATOM C LEU H 18 68.993 16.734 8.176 1.00 17.32 ATOM O LEU H 18 69.488 17.704 8.724 1.00 16.61 ATOM N THR H 19 69.707 15.683 7.803 1.00 18.33 ATOM CA THR H 19 71.157 15.663 7.923 1.00 17.82 ATOM CB THR H 19 71.628 14.541 8.862 1.00 18.17 ATOM OG1 THR H 19 71.181 14.838 10.188 1.00 19.18 ATOM CG2 THR H 19 73.162 14.394 8.833 1.00 16.07 ATOM C THR H 19 71.728 15.472 6.511 1.00 17.19 ATOM O THR H 19 71.464 14.460 5.846 1.00 17.03 ATOM N LEU H 20 72.412 16.503 6.023 1.00 15.96 ATOM CA LEU H 20 73.021 16.477 4.705 1.00 16.02 ATOM CB LEU H 20 72.693 17.760 3.935 1.00 12.09 ATOM CG LEU H 20 71.242 17.974 3.533 1.00 14.01 ATOM CG1 LEU H 20 71.021 19.422 3.324 1.00 15.03 ATOM CG2 LEU H 20 70.877 17.173 2.312 1.00 14.28 ATOM C LEU H 20 74.531 16.353 4.858 1.00 16.97 ATOM O LEU H 20 75.122 16.960 5.754 1.00 17.31 ATOM N THR H 21 75.151 15.586 3.972 1.00 15.60 ATOM CA THR H 21 76.587 15.414 4.024 1.00 16.81 ATOM CB THR H 21 76.941 13.958 4.332 1.00 15.79 ATOM OG1 THR H 21 76.304 13.571 5.561 1.00 14.35 ATOM OG2 THR H 21 78.458 13.798 4.472 1.00 14.58 ATOM C THR H 21 77.219 15.863 2.714 1.00 15.76 ATOM O THR H 21 76.689 15.595 1.646 1.00 15.65 ATOM N CYS H 22 78.292 16.635 2.806 1.00 15.22 ATOM CA CYS H 22 79.007 17.100 1.624 1.00 16.61 ATOM C CYS H 22 80.386 16.462 1.661 1.00 17.70 ATOM O CYS H 22 81.212 16.808 2.509 1.00 17.86 ATOM CB CYS H 22 79.164 18.622 1.624 1.00 16.86 ATOM SG CYS H 22 80.150 19.286 0.243 1.00 14.84 ATOM N THR H 23 80.609 15.512 0.760 1.00 18.33 ATOM CA THR H 23 81.879 14.812 0.670 1.00 19.26 ATOM CB THR H 23 81.662 13.312 0.509 1.00 19.33 ATOM OG1 THR H 23 80.879 12.853 1.613 1.00 22.21 ATOM CG2 THR H 23 82.974 12.586 0.528 1.00 22.05 ATOM C THR H 23 82.640 15.389 −0.495 1.00 18.33 ATOM O THR H 23 82.122 15.497 −1.610 1.00 17.83 ATOM N PHE H 24 83.875 15.782 −0.236 1.00 19.13 ATOM CA PHE H 24 84.656 16.408 −1.288 1.00 22.34 ATOM CB PHE H 24 84.806 17.918 −0.994 1.00 21.75 ATOM CG PHE H 24 85.421 18.218 0.347 1.00 20.43 ATOM CD1 PHE H 24 86.808 18.263 0.496 1.00 22.58 ATOM CD2 PHE H 24 84.623 18.387 1.467 1.00 19.58 ATOM CE1 PHE H 24 87.383 18.462 1.743 1.00 21.78 ATOM CE2 PHE H 24 85.182 18.585 2.713 1.00 18.19 ATOM CZ PHE H 24 86.564 18.621 2.859 1.00 21.55 ATOM C PHE H 24 86.020 15.778 −1.498 1.00 23.38 ATOM O PHE H 24 86.434 14.911 −0.743 1.00 24.19 ATOM N SER H 25 86.685 16.209 −2.559 1.00 25.12 ATOM CA SER H 25 88.021 15.754 −2.885 1.00 27.58 ATOM CB SER H 25 88.004 14.355 −3.510 1.00 25.80 ATOM OG SER H 25 87.469 14.384 −4.822 1.00 28.75 ATOM C SER H 25 88.628 16.788 −3.837 1.00 28.21 ATOM O SER H 25 87.931 17.666 −4.365 1.00 26.90 ATOM NH GLY H 26 89.936 16.692 −4.035 1.00 30.76 ATOM CA GLY H 26 90.625 17.627 −4.900 1.00 27.87 ATOM C GLY H 26 91.146 18.782 −4.070 1.00 29.61 ATOM O GLY H 26 91.781 19.678 −4.611 1.00 30.97 ATOM N PHE H 27 90.888 18.761 −2.761 1.00 26.72 ATOM CA PHE H 27 91.332 19.830 −1.884 1.00 27.11 ATOM CB PHE H 27 90.600 21.166 −2.190 1.00 27.71 ATOM CG PHE H 27 89.159 21.233 −1.700 1.00 26.87 ATOM CD1 PHE H 27 88.858 21.733 −0.431 1.00 24.48 ATOM CD2 PHE H 27 88.110 20.820 −2.513 1.00 27.17 ATOM CE1 PHE H 27 87.537 21.817 0.020 1.00 25.75 ATOM CE2 PHE H 27 86.787 20.905 −2.067 1.00 25.89 ATOM CZ PHE H 27 86.506 21.402 −0.801 1.00 24.60 ATOM C PHE H 27 91.133 19.435 −0.438 1.00 26.87 ATOM O PHE H 27 90.467 18.439 −0.150 1.00 27.66 ATOM N SER H 28 91.714 20.223 0.464 1.00 26.42 ATOM CA SER H 28 91.612 19.970 1.890 1.00 24.77 ATOM CB SER H 28 92.976 19.626 2.481 1.00 21.30 ATOM OG SER H 28 92.934 19.678 3.901 1.00 22.82 ATOM C SER H 28 91.053 21.162 2.625 1.00 25.66 ATOM O SER H 28 91.508 22.292 2.433 1.00 27.14 ATOM N LEU H 29 90.131 20.888 3.540 1.00 26.30 ATOM CA LEU H 29 89.508 21.926 4.334 1.00 26.90 ATOM CB LEU H 29 88.237 21.399 5.013 1.00 27.65 ATOM CG LEU H 29 86.958 22.199 4.723 1.00 27.49 ATOM CD1 LEU H 29 85.790 21.609 5.467 1.00 25.56 ATOM CD2 LEU H 29 87.123 23.664 5.097 1.00 26.24 ATOM C LEU H 29 90.478 22.442 5.378 1.00 28.20 ATOM O LEU H 29 90.104 23.243 6.225 1.00 30.84 ATOM N SER H 30 91.699 21.917 5.381 1.00 29.52 ATOM CA SER H 30 92.696 22.371 6.336 1.00 30.23 ATOM CB SER H 30 93.591 21.223 6.779 1.00 32.80 ATOM OG SER H 30 92.878 20.324 7.605 1.00 40.53 ATOM C SER H 30 93.533 23.473 5.719 1.00 28.60 ATOM O SER H 30 94.197 24.228 6.426 1.00 30.68 ATOM N THR H 31 93.507 23.553 4.399 1.00 25.79 ATOM CA THR H 31 94.251 24.574 3.689 1.00 25.17 ATOM CB THR H 31 94.168 24.342 2.185 1.00 22.82 ATOM OG1 THR H 31 94.642 23.026 1.884 1.00 21.22 ATOM CG2 THR H 31 94.992 25.387 1.430 1.00 25.49 ATOM C THR H 31 93.706 25.975 4.008 1.00 26.42 ATOM O THR H 31 92.515 26.265 3.804 1.00 25.36 ATOM N SER H 32 94.586 26.835 4.510 1.00 25.43 ATOM CA SER H 32 94.243 28.204 4.846 1.00 22.79 ATOM CB SER H 32 95.532 29.001 5.032 1.00 25.70 ATOM OG SER H 32 95.273 30.390 5.103 1.00 28.76 ATOM C SER H 32 93.391 28.837 3.744 1.00 21.57 ATOM O SER H 32 93.675 28.691 2.548 1.00 17.71 ATOM N GLY H 33 92.324 29.510 4.160 1.00 20.10 ATOM CA GLY H 33 91.419 30.167 3.225 1.00 18.48 ATOM C GLY H 33 90.306 29.308 2.637 1.00 18.96 ATOM O GLY H 33 89.391 29.840 1.992 1.00 17.36 ATOM N MET H 34 90.367 27.993 2.846 1.00 18.43 ATOM CA MET H 34 89.353 27.091 2.301 1.00 21.06 ATOM CB MET H 34 89.896 25.660 2.232 1.00 23.04 ATOM CG MET H 34 89.583 24.932 0.932 1.00 24.08 ATOM SD MET H 34 90.321 25.677 −0.522 1.00 29.23 ATOM CE MET H 34 91.809 24.779 −0.645 1.00 28.50 ATOM C MET H 34 88.032 27.140 3.088 1.00 20.35 ATOM O MET H 34 88.023 27.277 4.321 1.00 20.61 ATOM N SER H 35 86.921 27.022 2.367 1.00 18.89 ATOM CA SER H 35 85.595 27.082 2.970 1.00 17.02 ATOM CB SER H 35 85.119 28.554 2.963 1.00 16.91 ATOM OG SER H 35 83.744 28.731 3.303 1.00 15.81 ATOM C SER H 35 84.630 26.226 2.148 1.00 16.42 ATOM O SER H 35 84.839 26.014 0.954 1.00 13.99 ATOM N VAL H 35A 83.609 25.695 2.813 1.00 17.17 ATOM CA VAL H 35A 82.561 24.928 2.145 1.00 18.21 ATOM CB VAL H 35A 82.627 23.410 2.457 1.00 10.71 ATOM CG1 VAL H 35A 81.375 22.712 1.965 1.00 19.97 ATOM CG2 VAL H 35A 83.834 22.791 1.780 1.00 19.38 ATOM C VAL H 35A 81.230 25.524 2.621 1.00 17.91 ATOM O VAL H 35A 81.013 25.716 3.821 1.00 17.18 ATOM N GLY H 35B 80.400 25.934 1.668 1.00 19.58 ATOM CA GLY H 35B 79.101 26.501 1.997 1.00 17.30 ATOM C GLY H 35B 77.953 25.659 1.464 1.00 13.26 ATOM O GLY H 35B 78.140 24.770 0.641 1.00 7.81 ATOM N TRP H 36 76.760 25.939 1.961 1.00 16.00 ATOM CA TRP H 36 75.554 25.254 1.546 1.00 14.93 ATOM CB TRP H 36 74.910 24.504 2.711 1.00 12.98 ATOM CG TRP H 36 75.636 23.264 3.120 1.00 14.47 ATOM CD2 TRP H 36 75.431 21.931 2.608 1.00 14.01 ATOM CE2 TRP H 36 76.264 21.066 3.353 1.00 12.94 ATOM CE3 TRP H 36 74.619 21.388 1.598 1.00 11.52 ATOM CD1 TRP H 36 76.574 23.150 4.115 1.00 14.35 ATOM NEl TRP H 36 76.945 21.834 4.262 1.00 15.17 ATOM CZ2 TRP H 36 76.311 19.687 3.123 1.00 13.17 ATOM CZ3 TRP H 36 74.666 20.008 1.367 1.00 14.14 ATOM CH2 TRP H 36 75.508 19.176 2.130 1.00 13.90 ATOM C TRP H 36 74.587 26.298 0.998 1.00 15.07 ATOM O TRP H 36 74.433 27.393 1.569 1.00 14.43 ATOM N ILE H 37 73.999 25.957 −0.145 1.00 14.15 ATOM CA ILE H 37 73.028 26.769 −0.862 1.00 14.19 ATOM CB ILE H 37 73.644 27.357 −2.191 1.00 13.79 ATOM CG2 ILE H 37 72.623 28.239 −2.912 1.00 10.80 ATOM CG1 ILE H 37 74.924 28.157 −1.906 1.00 12.98 ATOM CD1 ILE H 37 76.391 27.361 −2.001 1.00 9.84 ATOM C ILE H 37 71.857 25.834 −1.255 1.00 14.48 ATOM O ILE H 37 72.059 24.660 −1.573 1.00 14.48 ATOM N ARG H 38 70.632 26.337 −1.187 1.00 15.05 ATOM CA ARG H 38 69.490 25.537 −1.594 1.00 13.99 ATOM CB ARG H 38 68.654 25.107 −0.400 1.00 12.72 ATOM CG ARG H 38 67.837 26.195 0.206 1.00 11.35 ATOM CD ARG H 38 66.955 25.629 1.271 1.00 12.76 ATOM NE ARG H 38 66.226 26.687 1.942 1.00 17.72 ATOM CZ ARG H 38 65.375 26.498 2.942 1.00 16.18 ATOM NH1 ARG H 38 65.136 25.280 3.392 1.00 9.66 ATOM NH2 ARG H 38 64.786 27.544 3.501 1.00 14.95 ATOM C ARG H 38 68.622 26.289 −2.601 1.00 13.81 ATOM O ARG H 38 68.718 27.514 −2.765 1.00 11.23 ATOM N GLN H 39 67.776 25.544 −3.285 1.00 12.87 ATOM CA GLN H 39 66.919 26.147 −4.265 1.00 14.66 ATOM CB GLN H 39 67.527 26.167 −5.612 1.00 16.19 ATOM CG GLN H 39 66.876 26.910 −6.694 1.00 15.68 ATOM CD GLN H 39 67.681 27.024 −7.956 1.00 15.98 ATOM OE1 GLN H 39 67.798 28.106 −8.538 1.00 17.80 ATOM NE2 GLN H 39 68.259 25.910 −8.390 1.00 16.85 ATOM C GLN H 39 65.600 25.396 −4.367 1.00 15.76 ATOM O GLN H 39 65.556 24.249 −4.835 1.00 14.34 ATOM N PRO H 40 64.512 26.015 −3.868 1.00 17.06 ATOM CD PRO H 40 64.495 27.302 −3.152 1.00 15.97 ATOM CA PRO H 40 63.173 25.436 −3.899 1.00 15.94 ATOM CB PRO H 40 62.335 26.497 −3.198 1.00 16.60 ATOM CG PRO H 40 63.286 27.140 −2.272 1.00 17.11 ATOM C PRO H 40 62.768 25.339 −5.350 1.00 17.70 ATOM O PRO H 40 63.214 26.134 −6.162 1.00 16.65 ATOM N PRO H 41 61.958 24.334 −5.710 1.00 20.76 ATOM CD PRO H 41 61.398 23.245 −4.889 1.00 22.23 ATOM CA PRO H 41 61.336 24.210 −7.108 1.00 20.87 ATOM CB PRO H 41 60.416 23.185 −7.025 1.00 22.27 ATOM CG PRO H 41 60.893 22.279 −5.936 1.00 23.84 ATOM C PRO H 41 61.017 25.555 −7.609 1.00 20.24 ATOM O PRO H 41 60.256 26.225 −6.917 1.00 22.84 ATOM N GLY H 42 61.540 25.993 −8.744 1.00 21.26 ATOM CA GLY H 42 61.119 27.248 −9.331 1.00 20.76 ATOM C GLY H 42 61.459 28.521 −8.583 1.00 21.38 ATOM O GLY H 42 60.877 29.562 −8.877 1.00 23.41 ATOM N LYS H 43 62.367 28.474 −7.614 1.00 21.11 ATOM CA LYS H 43 62.721 29.693 −6.885 1.00 21.46 ATOM CB LYS H 43 62.341 29.597 −5.402 1.00 24.52 ATOM CG LYS H 43 60.863 29.358 −5.133 1.00 26.93 ATOM CD LYS H 43 60.568 29.524 −3.660 1.00 33.74 ATOM CE LYS H 43 59.089 29.328 −3.340 1.00 38.50 ATOM NZ LYS H 43 58.826 29.556 −1.884 1.00 39.74 ATOM C LYS H 43 64.210 29.976 −7.021 1.00 20.27 ATOM O LYS H 43 64.348 29.184 −7.599 1.00 20.32 ATOM N ALA H 44 64.646 31.106 −6.487 1.00 19.41 ATOM CA ALA H 44 66.051 31.491 −6.557 1.00 19.41 ATOM CB ALA H 44 66.189 32.990 −6.372 1.00 19.26 ATOM C ALA H 44 66.925 30.764 −5.538 1.00 19.34 ATOM O ALA H 44 66.435 30.088 −4.620 1.00 19.44 ATOM N LEU H 45 68.232 30.901 −5.717 1.00 17.25 ATOM CA LEU H 45 69.196 30.299 −4.815 1.00 15.89 ATOM CB LEU H 45 70.620 30.447 −5.373 1.00 10.63 ATOM CD LEU H 45 70.953 29.865 −6.735 1.00 12.90 ATOM CD1 LEU H 45 72.289 30.431 −7.221 1.00 8.13 ATOM CD2 LEU H 45 71.013 28.351 −6.645 1.00 10.96 ATOM C LEU H 45 69.105 31.048 −3.488 1.00 24.70 ATOM O LEU H 45 68.854 32.254 −3.465 1.00 17.03 ATOM N GLU H 46 69.320 30.326 −2.398 1.00 15.19 ATOM CA GLU H 46 69.317 30.877 −1.058 1.00 14.24 ATOM CB GLU H 46 68.054 30.488 −0.307 1.00 13.44 ATOM CG GLU H 46 68.093 30.929 1.136 1.00 14.99 ATOM CD GLU H 46 66.813 30.604 1.879 1.00 20.34 ATOM OE1 GLU H 46 66.322 29.460 1.784 1.00 20.65 ATOM OE2 GLU H 46 66.295 31.499 2.563 1.00 22.75 ATOM C GLU H 46 70.504 30.332 −0.300 1.00 13.87 ATOM O GLU H 46 70.608 29.121 −0.094 1.00 14.81 ATOM N TRP H 47 71.368 31.228 0.161 1.00 15.80 ATOM CA TRP H 47 72.548 30.846 0.923 1.00 15.32 ATOM CB TRP H 47 73.496 32.034 1.070 1.00 15.93 ATOM CG TRP H 47 74.728 31.714 1.868 1.00 18.77 ATOM CD2 TRP H 47 74.966 32.053 3.238 1.00 18.77 ATOM CE2 TRP H 47 76.256 31.564 3.575 1.00 19.72 ATOM CE3 TRP H 47 74.221 32.729 4.215 1.00 16.45 ATOM CG1 TRP H 47 75.848 31.041 1.435 1.00 17.15 ATOM NE1 TRP H 47 76.767 30.952 2.459 1.00 19.64 ATOM CZ2 TRP H 47 76.814 31.733 4.846 1.00 16.17 ATOM CZ3 TRP H 47 74.783 32.895 5.476 1.00 18.48 ATOM CH2 TRP H 47 76.067 32.398 5.777 1.00 17.28 ATOM C TRP H 47 72.095 30.349 2.293 1.00 15.44 ATOM O TRP H 47 71.236 30.960 2.922 1.00 14.94 ATOM N LEU H 48 72.674 29.240 2.742 1.00 13.88 ATOM CA LEU H 48 72.311 28.639 4.021 1.00 14.64 ATOM CB LEU H 48 72.057 27.151 3.829 1.00 15.18 ATOM CG LEU H 48 70.642 26.595 3.685 1.00 19.59 ATOM CD1 LEU H 48 69.668 27.639 3.236 1.00 19.86 ATOM CD2 LEU H 48 70.658 25.396 2.779 1.00 14.67 ATOM C LEU H 48 73.348 28.813 5.122 1.00 16.42 ATOM O LEU H 48 73.030 29.297 6.217 1.00 16.87 ATOM N ALA H 49 74.588 28.416 4.834 1.00 17.65 ATOM CA ALA H 49 75.660 28.485 5.819 1.00 15.42 ATOM CB ALA H 49 75.326 27.536 7.008 1.00 10.92 ATOM C ALA H 49 77.000 28.083 5.197 1.00 15.85 ATOM O ALA H 49 77.051 27.654 4.046 1.00 11.51 ATOM N ASP H 50 78.085 28.311 5.941 1.00 17.23 ATOM CA ASP H 50 79.427 27.915 5.526 1.00 19.09 ATOM CB ASP H 50 80.068 28.898 4.515 1.00 21.53 ATOM CG ASP H 50 80.480 30.247 5.125 1.00 28.53 ATOM OD1 ASP H 50 80.865 30.328 6.307 1.00 32.68 ATOM OD2 ASP H 50 80.448 31.257 4.392 1.00 31.09 ATOM C ASP H 50 80.315 27.663 6.746 1.00 18.22 ATOM O ASP H 50 79.981 28.049 7.867 1.00 17.40 ATOM N ILE H 51 81.426 26.982 6.525 1.00 18.70 ATOM CA ILE H 51 82.3,6 126.68 37.588 1.00 18.57 ATOM CB ILE H 51 82.191 25.214 8.098 1.00 16.66 ATOM CG2 ILE H 51 82.568 24.215 6.992 1.00 15.80 ATOM CG1 ILE H 51 83.005 24.994 9.387 1.00 14.81 ATOM CD1 ILE H 51 82.725 23.688 10.108 1.00 10.85 ATOM C ILE H 51 83.757 26.900 6.994 1.00 20.10 ATOM O ILE H 51 84.028 26.479 5.850 1.00 20.16 ATOM N TRP H 52 84.613 27.592 7.750 1.00 17.80 ATOM CA TRP H 52 85.976 27.885 7.322 1.00 18.52 ATOM CB TRP H 52 86.438 29.230 7.882 1.00 17.60 ATOM CG TRP H 52 85.852 30.427 7.186 1.00 18.48 ATOM CD2 TRP H 52 86.315 31.773 7.275 1.00 18.83 ATOM CE2 TRP H 52 85.460 32.568 6.470 1.00 17.83 ATOM CE3 TRP H 52 87.372 32.393 7.960 1.00 20.10 ATOM CD1 TRP H 52 84.765 30.454 6.346 1.00 18.77 ATOM NE1 TRP H 52 84.525 31.739 5.915 1.00 19.18 ATOM CZ2 TRP H 52 85.628 33.943 6.336 1.00 17.47 ATOM CZ3 TRP H 52 87.536 33.759 7.823 1.00 16.79 ATOM CH2 TRP H 52 86.668 34.520 7.018 1.00 17.22 ATOM C TRP H 52 86.951 26.806 7.758 1.00 20.38 ATOM O TRP H 52 86.658 26.004 8.640 1.00 18.84 ATOM N TRP H 52A 88.135 26.830 7.159 1.00 23.43 ATOM CA TRP H 52A 89.203 25.877 7.463 1.00 24.45 ATOM CB TRP H 52A 90.459 26.230 6.661 1.00 23.73 ATOM CG TRP H 52A 91.148 27.485 7.136 1.00 23.91 ATOM CD2 TRP H 52A 90.769 28.845 6.861 1.00 22.37 ATOM CE2 TRP H 52A 91.713 29.677 7.500 1.00 24.65 ATOM CE3 TRP H 52A 89.731 29.437 6.132 1.00 21.82 ATOM CG1 TRP H 52A 92.266 27.551 7.912 1.00 25.27 ATOM NE1 TRP H 52A 92.612 28.863 8.134 1.00 26.22 ATOM CZ2 TRP H 52A 91.652 31.068 7.435 1.00 21.13 ATOM CZ3 TRP H 52A 89.669 30.822 6.066 1.00 22.40 ATOM CH2 TRP H 52A 90.627 31.622 6.716 1.00 24.82 ATOM C TRP H 52A 89.537 25.895 8.952 1.00 25.32 ATOM O TRP H 52A 89.974 24.886 9.509 1.00 27.89 ATOM N ASP H 52B 89.338 27.046 9.584 1.00 24.77 ATOM CA ASP H 52B 89.624 27.204 10.998 1.00 26.84 ATOM CB ASP H 52B 90.186 28.606 11.274 1.00 27.51 ATOM CG ASP H 52B 89.193 29.722 10.979 1.00 31.35 ATOM OG1 ASP H 52B 87.991 29.447 10.793 1.00 31.83 ATOM OG2 ASP H 52B 89.619 30.898 10.942 1.00 33.88 ATOM C ASP H 52B 88.418 26.911 11.893 1.00 27.40 ATOM O ASP H 52B 88.410 27.245 13.072 1.00 26.88 ATOM N ASP H 52C 87.392 26.313 11.305 1.00 28.03 ATOM CA ASP H 52C 86.163 25.955 11.998 1.00 26.36 ATOM CB ASP H 52C 86.446 25.160 13.274 1.00 28.42 ATOM CG ASP H 52C 85.327 24.180 13.603 1.00 33.76 ATOM OD1 ASP H 52C 84.868 24.153 14.764 1.00 36.60 ATOM OD2 ASP H 52C 84.902 23.430 12.697 1.00 34.49 ATOM C ASP H 52C 85.184 27.093 12.269 1.00 25.03 ATOM O ASP H 52C 84.178 26.896 12.958 1.00 26.18 ATOM N LYS H 53 85.440 28.274 11.713 1.00 23.11 ATOM CA LYS H 53 84.492 29.376 11.893 1.00 24.05 ATOM CB LYS H 53 85.050 30.712 11.388 1.00 25.09 ATOM CG LYS H 53 84.286 31.929 11.912 1.00 24.49 ATOM CD LYS H 53 84.751 33.225 11.245 1.00 25.32 ATOM CE LYS H 53 84.428 33.243 9.741 1.00 27.10 ATOM NZ LYS H 53 82.961 33.405 9.382 1.00 25.06 ATOM C LYS H 53 83.237 29.016 11.078 1.00 24.81 ATOM O LYS H 53 83.328 28.634 9.900 1.00 22.11 ATOM N LYS H 54 82.076 29.153 11.706 1.00 24.62 ATOM CA LYS H 54 80.798 28.831 11.085 1.00 23.21 ATOM CB LYS H 54 80.045 27.879 11.995 1.00 20.83 ATOM CG LYS H 54 80.861 26.659 12.357 1.00 20.72 ATOM CG LYS H 54 80.211 25.853 13.454 1.00 20.64 ATOM CE LYS H 54 81.055 24.631 13.802 1.00 22.89 ATOM NZ LYS H 54 82.409 25.036 14.297 1.00 23.84 ATOM C LYS H 54 79.975 30.090 10.870 1.00 23.07 ATOM O LYS H 54 79.984 30.988 11.704 1.00 24.80 ATOM N ASP H 55 79.286 30.171 9.740 1.00 23.45 ATOM CA ASP H 55 78.452 31.331 9.448 1.00 23.61 ATOM CB ASP H 55 79.083 32.190 8.358 1.00 29.01 ATOM CG ASP H 55 78.710 33.653 8.481 1.00 33.21 ATOM OD1 ASP H 55 79.219 34.452 7.674 1.00 36.92 ATOM OD2 ASP H 55 77.911 34.015 9.375 1.00 37.49 ATOM C ASP H 55 77.085 30.801 9.028 1.00 22.55 ATOM O ASP H 55 77.000 29.775 8.357 1.00 22.79 ATOM N TYR H 56 76.023 31.495 9.418 1.00 21.97 ATOM CA TYR H 56 74.675 31.022 9.154 1.00 22.29 ATOM CB TYR H 56 74.051 30.491 10.449 1.00 19.74 ATOM CG TYR H 56 74.749 29.308 11.084 1.00 18.86 ATOM CG1 TYR H 56 74.608 28.034 10.554 1.00 19.13 ATOM CE1 TYR H 56 75.211 26.947 11.141 1.00 19.36 ATOM CD2 TYR H 56 75.522 29.462 12.227 1.00 14.87 ATOM CE2 TYR H 56 76.127 28.379 12.821 1.00 15.48 ATOM CZ TYR H 56 75.971 27.126 12.281 1.00 17.68 ATOM OH TYR H 56 76.565 26.031 12.868 1.00 20.54 ATOM C TYR H 56 73.736 32.071 8.662 1.00 22.36 ATOM O TYR H 56 73.833 33.228 9.047 1.00 22.95 ATOM N ASN H 57 72.780 31.643 7.849 1.00 24.93 ATOM CA ASN H 57 71.742 32.543 7.357 1.00 27.64 ATOM CB ASN H 57 70.862 31.833 6.315 1.00 28.33 ATOM CG ASN H 57 69.825 32.756 5.693 1.00 29.14 ATOM OD1 ASN H 57 68.986 33.312 6.385 1.00 31.07 ATOM ND2 ASN H 57 69.874 32.909 4.386 1.00 29.86 ATOM C ASN H 57 70.929 32.879 8.617 1.00 27.04 ATOM O ASN H 57 70.524 31.981 9.357 1.00 23.79 ATOM N PRO H 58 70.762 34.176 8.921 1.00 28.56 ATOM CD PRO H 58 71.297 35.280 8.113 1.00 28.44 ATOM CA PRO H 58 70.025 34.708 10.077 1.00 29.68 ATOM CB PRO H 58 70.043 36.205 9.816 1.00 31.68 ATOM CG PRO H 58 71.336 36.388 9.102 1.00 32.72 ATOM C PRO H 58 68.595 34.207 10.165 1.00 30.03 ATOM O PRO H 58 68.138 33.842 11.241 1.00 32.06 ATOM N SER H 59 67.902 34.203 9.028 1.00 30.81 ATOM CA SER H 59 66.521 33.739 8.924 1.00 33.61 ATOM CB SER H 59 66.045 33.796 7.464 1.00 33.98 ATOM OG SER H 59 66.414 35.012 6.825 1.00 42.18 ATOM C SER H 59 66.398 32.292 9.371 1.00 34.64 ATOM O SER H 59 65.354 31.878 9.882 1.00 37.21 ATOM N LEU H 60 67.461 31.521 9.142 1.00 34.74 ATOM CA LEU H 60 67.485 30.100 9.463 1.00 33.58 ATOM CB LEU H 60 67.896 29.314 8.205 1.00 32.72 ATOM CG LEU H 60 66.922 28.895 7.093 1.00 34.81 ATOM CD1 LEU H 60 65.565 29.513 7.313 1.00 36.52 ATOM CD2 LEU H 60 67.479 29.259 5.716 1.00 30.66 ATOM C LEU H 60 68.406 29.661 10.606 1.00 34.55 ATOM O LEU H 60 68.276 28.523 11.082 1.00 32.36 ATOM N LYS H 61 69.321 30.539 11.062 1.00 35.17 ATOM CA LYS H 61 70.2 2 30.163 12.092 1.00 35.08 ATOM CB LYS H 61 70.959 31.376 12.750 1.00 36.66 ATOM CG LYS H 61 72.030 30.921 13.748 1.00 42.58 ATOM CD LYS H 61 72.964 32.023 14.233 1.00 47.58 ATOM CE LYS H 61 74.154 31.417 15.007 1.00 48.86 ATOM NZ LYS H 61 75.157 32.426 15.480 1.00 51.14 ATOM C LYS H 61 69.830 29.172 13.163 1.00 34.17 ATOM O LYS H 61 70.520 28.174 13.423 1.00 29.94 ATOM N SER H 62 68.646 29.426 13.726 1.00 30.94 ATOM CA SER H 62 68.051 28.597 14.770 1.00 28.25 ATOM CB SER H 62 66.650 29.117 15.072 1.00 30.62 ATOM CG SER H 62 65.918 29.317 13.866 1.00 33.57 ATOM C SER H 62 67.946 27.110 14.440 1.00 28.84 ATOM O SER H 62 68.078 26.252 15.317 1.00 28.71 ATOM N ARG H 63 67.708 26.807 13.171 1.00 26.01 ATOM CA ARG H 63 67.528 25.432 12.743 1.00 23.24 ATOM CB ARG H 63 66.394 25.407 11.739 1.00 24.03 ATOM CG ARG H 63 65.149 26.109 12.252 1.00 27.07 ATOM CD ARG H 63 64.142 26.336 11.146 1.00 30.24 ATOM NE ARG H 63 63.910 25.102 10.417 1.00 29.49 ATOM CZ ARG H 63 63.630 25.049 9.127 1.00 24.96 ATOM NH1 ARG H 63 63.535 26.166 8.415 1.00 23.27 ATOM ND2 ARG H 63 63.471 23.873 8.556 1.00 24.48 ATOM C ARG H 63 68.741 24.751 12.145 1.00 22.40 ATOM O ARG H 63 68.731 23.546 11.929 1.00 21.50 ATOM N LEU H 64 69.804 25.518 11.941 1.00 22.16 ATOM CA LEU H 64 71.023 25.034 11.296 1.00 21.65 ATOM CB LEU H 64 71.466 26.058 10.243 1.00 19.30 ATOM CG LEU H 64 70.890 26.155 8.832 1.00 20.78 ATOM CD1 LEU H 64 69.545 25.524 8.719 1.00 20.71 ATOM CD2 LEU H 64 70.879 27.617 8.396 1.00 15.66 ATOM C LEU H 64 72.234 24.732 12.156 1.00 19.31 ATOM O LEU H 64 72.564 25.472 13.070 1.00 20.05 ATOM N THR H 65 72.941 23.676 11.785 1.00 19.59 ATOM CA THR H 65 74.185 23.294 12.442 1.00 20.65 ATOM CB THR H 65 73.998 22.193 13.493 1.00 20.20 ATOM OG1 THR H 65 72.990 22.595 14.428 1.00 24.09 ATOM CG2 THR H 65 75.315 21.946 14.225 1.00 19.32 ATOM C THR H 65 75.144 22.768 11.378 1.00 19.21 ATOM O THR H 65 74.857 21.778 10.702 1.00 21.02 ATOM N ILE H 66 76.262 23.452 11.204 1.00 19.16 ATOM CA ILE H 66 77.254 23.021 10.240 1.00 17.30 ATOM CB ILE H 66 77.546 24.145 9.217 1.00 16.44 ATOM CG2 ILE H 66 78.223 25.316 9.884 1.00 17.96 ATOM CG1 ILE H 66 78.367 23.611 8.048 1.00 16.66 ATOM CD1 ILE H 66 78.283 24.492 6.803 1.00 16.98 ATOM C ILE H 66 78.509 22.541 10.984 1.00 17.84 ATOM O ILE H 66 78.856 23.062 12.040 1.00 18.17 ATOM N SER H 67 79.131 21.486 10.482 1.00 18.11 ATOM CA SER H 67 80.321 20.948 11.105 1.00 20.14 ATOM CB SER H 67 79.934 19.982 12.222 1.00 19.34 ATOM OG SER H 67 79.148 18.916 11.722 1.00 22.34 ATOM C SER H 67 81.129 20.235 10.042 1.00 21.51 ATOM O SER H 67 80.617 19.939 8.963 1.00 23.77 ATOM N LYS H 68 82.389 19.945 10.326 1.00 22.37 ATOM CA LYS H 68 83.220 19.276 9.337 1.00 24.76 ATOM CB LYS H 68 84.170 20.268 8.653 1.00 24.88 ATOM CG LYS H 68 85.243 20.860 9.600 1.00 26.98 ATOM CD LYS H 68 86.178 21.863 8.913 1.00 24.59 ATOM CE LYS H 68 87.077 22.575 9.923 1.00 25.04 ATOM NZ LYS H 68 87.950 21.660 10.691 1.00 22.91 ATOM C LYS H 68 84.065 18.220 9.995 1.00 2 .60 ATOM O LYS H 68 84.222 18.194 11.211 1.00 26.90 ATOM N ASP H 69 84.609 17.350 9.162 1.00 30.57 ATOM CA ASP H 69 85.497 16.301 9.603 1.00 32.63 ATOM CB ASP H 69 84.751 14.987 9.808 1.00 32.99 ATOM CG ASP H 69 85.630 13.919 10.414 1.00 34.81 ATOM OD1 ASP H 69 85.157 13.155 11.274 1.00 36.75 ATOM OD2 ASP H 69 86.800 13.839 10.027 1.00 31.40 ATOM C ASP H 69 86.530 16.184 8.487 1.00 34.03 ATOM O ASP H 69 86.370 15.392 7.547 1.00 32.76 ATOM N THR H 70 87.571 17.008 8.594 1.00 36.91 ATOM CA THR H 70 88.660 17.047 7.624 1.00 38.63 ATOM CB THR H 70 89.797 17.966 8.100 1.00 37.90 ATOM OG1 THR H 70 89.244 19.134 8.721 1.00 40.53 ATOM CG2 THR H 70 90.630 18.400 6.924 1.00 41.19 ATOM C THR H 70 89.193 15.640 7.441 1.00 39.84 ATOM O THR H 70 89.470 15.209 6.323 1.00 40.13 ATOM N SER H 71 89.243 14.904 8.546 1.00 40.90 ATOM CA SER H 71 89.711 13.526 8.543 1.00 42.40 ATOM CB SER H 71 89.550 12.917 9.938 1.00 42.28 ATOM OG SER H 71 89.247 13.928 10.895 1.00 46.77 ATOM C SER H 71 88.900 12.714 7.539 1.00 42.54 ATOM O SER H 71 89.441 11.844 6.858 1.00 45.17 ATOM N LYS H 72 87.610 13.028 7.429 1.00 39.45 ATOM CA LYS H 72 86.728 12.317 6.517 1.00 36.17 ATOM CB LYS H 72 85.4.5 411.88 67.253 1.00 35.09 ATOM C LYS H 72 86.394 13.122 5.253 1.00 34.32 ATOM O LYS H 72 85.624 12.670 4.404 1.00 36.05 ATOM N ASN H 73 86.985 14.303 5.110 1.00 30.90 ATOM CA ASN H 73 86.725 15.122 3.935 1.00 28.57 ATOM CB ASN H 73 87.339 14.479 2.698 1.00 30.95 ATOM CG ASN H 73 88.753 14.930 2.459 1.00 32.43 ATOM OD1 ASN H 73 89.410 15.448 3.356 1.00 33.76 ATOM ND2 ASN H 73 89.217 14.781 1.231 1.00 33.57 ATOM C ASN H 73 85.235 15.368 3.706 1.00 27.51 ATOM O ASN H 73 84.723 15.252 2.581 1.00 24.45 ATOM N GLN H 74 84.535 15.700 4.783 1.00 26.55 ATOM CA GLN H 74 83.120 15.977 4.680 1.00 25.83 ATOM CB GLN H 74 82.305 14.693 4.841 1.00 27.06 ATOM CG GLN H 74 82.244 14.191 6.232 1.00 29.34 ATOM CD GLN H 74 81.624 12.830 6.295 1.00 32.28 ATOM OE1 GLN H 74 81.764 12.043 5.367 1.00 29.45 ATOM NE2 GLN H 74 80.935 12.535 7.398 1.00 32.68 ATOM C GLN H 74 82.649 17.068 5.638 1.00 23.47 ATOM O GLN H 74 83.254 17.328 6.684 1.00 19.87 ATOM N VAL H 75 81.633 17.784 5.185 1.00 20.78 ATOM CA VAL H 75 81.016 18.858 5.934 1.00 18.65 ATOM CG VAL H 75 81.073 20.188 5.119 1.00 19.56 ATOM CG1 VAL H 75 80.267 21.297 5.808 1.00 17.72 ATOM CG2 VAL H 75 82.528 20.639 4.948 1.00 16.40 ATOM C VAL H 75 79.583 18.378 6.069 1.00 17.42 ATOM O VAL H 75 79.042 17.751 5.185 1.00 18.13 ATOM N VAL H 76 78.982 18.619 7.242 1.00 17.43 ATOM CA VAL H 76 77.615 18.177 7.491 1.00 17.51 ATOM CB VAL H 76 77.579 17.122 8.652 1.00 18.76 ATOM CG1 VAL H 76 76.140 16.849 9.115 1.00 16.58 ATOM CG2 VAL H 76 78.239 15.822 8.202 1.00 16.10 ATOM C VAL H 76 76.753 19.363 7.872 1.00 16.23 ATOM O VAL H 76 77.217 20.261 8.559 1.00 16.73 ATOM N LEU H 77 75.523 19.387 7.375 1.00 15.92 ATOM CA LEU H 77 74.573 20.441 7.701 1.00 17.74 ATOM CB LEU H 77 74.182 21.259 6.454 1.00 17.08 ATOM CG LEU H 77 73.669 22.718 6.499 1.00 18.21 ATOM CD1 LEU H 77 72.305 22.832 5.904 1.00 18.50 ATOM CD2 LEU H 77 73.717 23.340 7.886 1.00 20.05 ATOM C LEU H 77 73.347 19.700 8.233 1.00 19.52 ATOM O LEU H 77 72.890 18.745 7.606 1.00 18.14 ATOM N LYS H 78 72.894 20.072 9.432 1.00 19.66 ATOM CA LYS H 78 71.709 19.478 10.039 1.00 21.64 ATOM CB LYS H 78 72.019 18.898 11.420 1.00 24.63 ATOM CG LYS H 78 72.773 17.585 11.372 1.00 29.51 ATOM CD LYS H 78 72.910 17.009 12.771 1.00 35.12 ATOM CE LYS H 78 73.805 15.761 12.808 1.00 38.85 ATOM NZ LYS H 78 73.139 14.504 12.308 1.00 43.57 ATOM C LYS H 78 70.667 20.580 10.147 1.00 18.69 ATOM O LYS H 78 70.941 21.647 10.687 1.00 21.34 ATOM N VAL H 79 69.498 20.338 9.573 1.00 18.22 ATOM CA VAL H 79 68.408 21.305 9.561 1.00 17.88 ATOM CB VAL H 79 67.869 21.543 8.126 1.00 15.85 ATOM CG1 VAL H 79 66.903 22.712 8.117 1.00 18.65 ATOM CG2 VAL H 79 69.058 21.782 7.149 1.00 13.37 ATOM C VAL H 79 67.288 20.688 10.373 1.00 19.10 ATOM O VAL H 79 66.766 19.628 10.020 1.00 19.43 ATOM N THR H 80 66.910 21.343 11.455 1.00 20.81 ATOM CA THR H 80 65.866 20.808 12.315 1.00 21.37 ATOM CB THR H 80 66.162 21.141 13.782 1.00 17.57 ATOM OG1 THR H 80 66.408 22.543 13.898 1.00 20.71 ATOM CG2 THR H 80 67.380 20.380 14.248 1.00 21.24 ATOM C THR H 80 64.476 21.295 11.945 1.00 18.46 ATOM O THR H 80 64.323 22.234 11.161 1.00 18.70 ATOM N ASN H 81 63.480 20.594 12.471 1.00 19.47 ATOM CA ASN H 81 62.081 20.917 12.263 1.00 20.71 ATOM CB ASN H 81 61.693 22.053 13.203 1.00 23.15 ATOM CG ASN H 81 60.208 22.296 13.243 1.00 26.34 ATOM OD1 ASN H 81 59.409 21.384 13.099 1.00 28.57 ATOM ND2 ASN H 81 59.830 23.541 13.429 1.00 28.83 ATOM C ASN H 81 61.728 21.235 10.800 1.00 20.55 ATOM O ASN H 81 61.222 22.316 10.475 1.00 18.95 ATOM N MET H 82 61.995 20.268 9.925 1.00 19.37 ATOM CA MET H 82 61.731 20.396 8.500 1.00 19.90 ATOM CB MET H 82 62.119 19.104 7.775 1.00 20.79 ATOM CG MET H 82 63.643 18.886 7.651 1.00 19.47 ATOM SD MET H 82 64.499 20.227 6.746 1.00 21.79 ATOM CE MET H 82 64.228 19.776 5.039 1.00 15.01 ATOM C MET H 82 60.276 20.755 8.216 1.00 22.71 ATOM O MET H 82 59.360 20.168 8.793 1.00 24.24 ATOM N ASP H 83 60.080 21.683 7.284 1.00 22.76 ATOM CA ASP H 83 58.759 22.184 6.888 1.00 23.77 ATOM CB ASP H 83 58.714 23.696 7.144 1.00 25.06 ATOM CG ASP H 83 57.367 24.298 6.842 1.00 28.59 ATOM OD1 ASP H 83 56.478 24.190 7.701 1.00 32.41 ATOM OD2 ASP H 83 57.178 24.852 5.742 1.00 29.90 ATOM C ASP H 83 58.596 21.944 5.395 1.00 22.22 ATOM O ASP H 83 59.590 21.841 4.699 1.00 23.36 ATOM N PRO H 84 57.350 21.834 4.882 1.00 20.50 ATOM CD PRO H 84 56.066 21.715 5.600 1.00 20.73 ATOM CA PRO H 84 57.143 21.619 3.446 1.00 18.92 ATOM CB PRO H 84 55.641 21.822 3.305 1.00 18.31 ATOM CG PRO H 84 55.129 21.194 4.526 1.00 18.56 ATOM C PRO H 84 57.916 22.652 2.619 1.00 19.61 ATOM O PRO H 84 58.437 22.349 1.553 1.00 20.74 ATOM N ALA H 85 58.004 23.872 3.132 1.00 19.68 ATOM CA ALA H 85 58.720 24.946 2.465 1.00 21.18 ATOM CB ALA H 85 58.457 26.256 3.166 1.00 22.00 ATOM C ALA H 85 60.235 24.709 2.362 1.00 22.08 ATOM O ALA H 85 60.949 25.498 1.735 1.00 24.05 ATOM N ASP H 86 60.740 23.682 3.032 1.00 18.30 ATOM CA ASP H 86 62.152 23.379 2.952 1.00 17.61 ATOM CB ASP H 86 62.664 22.784 4.262 1.00 16.88 ATOM CG ASP H 86 62.547 23.752 5.417 1.00 22.66 ATOM OD1 ASP H 86 62.032 23.343 6.483 1.00 19.55 ATOM OD2 ASP H 86 62.954 24.932 5.257 1.00 24.22 ATOM C ASP H 86 62.415 22.421 1.791 1.00 17.63 ATOM O ASP H 86 63.568 22.018 1.574 1.00 17.70 ATOM N THR H 87 61.360 22.018 1.074 1.00 15.36 ATOM CA THR H 87 61.526 21.122 −0.066 1.00 14.35 ATOM CB THR H 87 60.183 20.740 −0.680 1.00 13.84 ATOM OG1 THR H 87 59.454 19.945 0.257 1.00 15.44 ATOM CG2 THR H 87 60.387 19.913 −1.948 1.00 15.26 ATOM C THR H 87 62.370 21.895 −1.069 1.00 15.26 ATOM O THR H 87 62.031 23.023 −1.444 1.00 12.69 ATOM N ALA H 88 63.507 21.317 −1.446 1.00 16.68 ATOM CA ALA H 88 64.422 21.994 −2.352 1.00 16.96 ATOM CB ALA H 88 64.946 23.281 −1.663 1.00 15.82 ATOM C ALA H 88 65. 01 21.115 −2.711 1.00 15.92 ATOM O ALA H 88 65.736 19.998 −2.218 1.00 15.04 ATOM N THR H 89 66.429 21.627 −3.610 1.00 14.79 ATOM CA THR H 89 67.655 20.971 −4.010 1.00 14.63 ATOM CB THR H 89 67.923 21.180 −5.485 1.00 15.26 ATOM OG1 THR H 89 66.989 20.403 −6.232 1.00 17.61 ATOM CG2 THR H 89 69.360 20.774 −5.854 1.00 13.56 ATOM C THR H 89 68.738 21.675 −3.190 1.00 14.21 ATOM O THR H 89 68.802 22.907 −3.156 1.00 14.78 ATOM N TYR H 90 69.651 20.894 −2.494 1.00 15.66 ATOM CA TYR H 90 70.605 21.418 −1.638 1.00 13.86 ATOM CB TYR H 90 70.527 20.751 −0.254 1.00 12.67 ATOM CG TYR H 90 69.304 21.132 0.547 1.00 11.49 ATOM CD1 TYR H 90 68.Q35 20.632 0.227 1.00 12.32 ATOM CE1 TYR H 90 66.907 21.050 0.926 1.00 12.25 ATOM CD2 TYR H 90 69.405 22.037 1.585 1.00 8.94 ATOM CE2 TYR H 90 68.293 22.458 2.286 1.00 13.05 ATOM CZ TYR H 90 67.053 21.967 1.951 1.00 13.38 ATOM OH TYR H 90 65.981 22.433 2.651 1.00 16.83 ATOM C TYR H 90 71.966 21.156 −2.262 1.00 14.93 ATOM O TYR H 90 72.273 20.023 −2.664 1.00 12.21 ATOM N TYR H 91 72.778 22.211 −2.319 1.00 14.42 ATOM CA TYR H 91 74.122 22.158 −2.893 1.00 13.29 ATOM CB TYR H 91 74.260 23.169 −4.047 1.00 13.73 ATOM CG TYR H 91 73.312 23.032 −5.214 1.00 15.62 ATOM CD1 TYR H 91 72.169 23.826 −5.309 1.00 17.17 ATOM CE1 TYR H 91 71.343 23.766 −6.438 1.00 17.39 ATOM CD2 TYR H 91 73.600 22.168 −6.271 1.00 14.12 ATOM CE2 TYR H 91 72.774 22.102 −7.402 1.00 14.64 ATOM CZ TYR H 91 71.662 22.899 −7.471 1.00 17.01 ATOM OH TYR H 91 70.867 22.826 −8.572 1.00 19.82 ATOM C TYR H 91 75.189 22.562 −1.881 1.00 11.93 ATOM O TYR H 91 74.949 23.392 −1.016 1.00 11.94 ATOM N CYS H 92 76.375 21.990 −1.989 1.00 12.26 ATOM CA CYS H 92 77.470 22.439 −1.144 1.00 12.39 ATOM C CYS H 92 78.467 22.930 −2.191 1.00 13.50 ATOM O CYS H 92 78.452 22.480 −3.358 1.00 11.63 ATOM CB CYS H 92 78.043 21.338 −0.249 1.00 12.10 ATOM SG CYS H 92 78.729 19.877 −1.079 1.00 15.31 ATOM N ALA H 93 79.242 23.935 −1.826 1.00 14.24 ATOM CA ALA H 93 80.178 24.503 −2.755 1.00 15.22 ATOM CB ALA H 93 79.506 25.690 −3.505 1.00 12.31 ATOM C ALA H 93 81.456 24.952 −2.051 1.00 15.72 ATOM O ALA H 93 81.436 25.311 −0.872 1.00 14.75 ATOM N ARG H 94 82.559 24.936 −2.795 1.00 16.63 ATOM CA ARG H 94 83.849 25.353 −2.268 1.00 15.90 ATOM CB ARG H 94 84.963 24.513 −2.909 1.00 15.45 ATOM CG ARG H 94 86.371 24.681 −2.281 1.00 13.98 ATOM CD ARG H 94 87.148 25.873 −2.794 1.00 13.40 ATOM NE ARG H 94 87.492 25.804 −4.213 1.00 16.03 ATOM CZ ARG H 94 88.506 25.108 −4.717 1.00 18.37 ATOM NH1 ARG H 94 89.289 24.390 −3.932 1.00 18.16 ATOM NH2 ARG H 94 88.783 25.180 −6.006 1.00 18.51 ATOM C ARG H 94 84.089 26.850 −2.519 1.00 13.99 ATOM O ARG H 94 83.743 27.379 −3.576 1.00 13.67 ATOM N SER H 95 84.679 27.521 −1.536 1.00 16.14 ATOM CA SER H 95 85.011 28.939 −1.639 1.00 15.68 ATOM CB SER H 95 84.065 29.810 −0.780 1.00 15.30 ATOM OG SER H 95 82.715 29.760 −1.213 1.00 13.60 ATOM C SER H 95 86.451 29.119 −1.144 1.00 15.90 ATOM O SER H 95 86.965 28.290 −0.372 1.00 15.38 ATOM N MET H 96 87.095 30.191 −1.599 1.00 17.08 ATOM CA MET H 96 88.465 30.527 −1.201 1.00 19.15 ATOM CB MET H 96 89.439 30.332 −2.370 1.00 19.64 ATOM CG MET H 96 89.701 28.849 −2.678 1.00 25.79 ATOM SD MET H 96 90.549 28.511 −4.238 1.00 29.25 ATOM CE MET H 96 91.543 27.150 −3.780 1.00 30.33 ATOM C MET H 96 88.418 31.977 −0.727 1.00 16.53 ATOM O MET H 96 88.319 32.907 −1.522 1.00 17.07 ATOM N ILE H 97 88.419 32.128 0.593 1.00 16.76 ATOM CA ILE H 97 88.320 33.415 1.268 1.00 14.34 ATOM CB ILE H 97 88.410 33.245 2.802 1.00 13.83 ATOM CG2 ILE H 97 88.001 34.513 3.491 1.00 10.54 ATOM CG1 ILE H 97 87.524 32.085 3.272 1.00 16.40 ATOM CD1 ILE H 97 86.055 32.197 2.875 1.00 16.82 ATOM C ILE H 97 89.381 34.388 0.774 1.00 15.53 ATOM O ILE H 97 90.555 34.047 0.695 1.00 :6.36 ATOM N THR H 98 88.917 35.599 0.466 1.00 14.74 ATOM CA THR H 98 89.661 36.739 −0.068 1.00 12.35 ATOM CB THR H 98 90.976 37.091 0.680 1.00 10.22 ATOM OG1 THR H 98 92.000 36.156 0.326 1.00 10.30 ATOM CG2 THR H 98 90.766 37.122 2.191 1.00 7.62 ATOM C THR H 98 89.923 36.565 −1.556 1.00 13.74 ATOM O THR H 98 90.549 37.415 −2.187 1.00 17.87 ATOM N ASN H 99 89.402 35.481 −2.124 1.00 14.64 ATOM CA ASN H 99 89.551 35.205 −3.541 1.00 15.20 ATOM CB ASN H 99 90.448 33.998 −3.760 1.00 16.40 ATOM CG ASN H 99 91.902 34.344 −3.591 1.00 17.20 ATOM OD1 ASN H 99 92.388 35.290 −4.214 1.00 15.38 ATOM ND2 ASN H 99 92.594 33.626 −2.720 1.00 15.23 ATOM C ASN H 99 88.213 35.049 −4.259 1.00 17.88 ATOM O ASN H 99 87.855 35.899 −5.083 1.00 18.92 ATOM N TRP H 100 87.441 34.017 −3.928 1.00 17.14 ATOM CA TRP H 100 86.145 33.834 −4.591 1.00 18.19 ATOM CB TRP H 100 86.341 33.387 −6.047 1.00 19.31 ATOM CG TRP H 100 87.406 32.345 −6.185 1.00 19.32 ATOM CD2 TRP H 100 88.710 32.538 −6.722 1.00 19.62 ATOM CE2 TRP H 100 89.396 31.306 −6.597 1.00 22.56 ATOM CE3 TRP H 100 89.373 33.635 −7.294 1.00 17.80 ATOM CD1 TRP H 100 87.343 31.044 −5.773 1.00 19.51 ATOM NE1 TRP H 100 88.531 30.415 −6.011 1.00 21.48 ATOM CZ2 TRP H 100 90.729 31.131 −7.027 1.00 21.08 ATOM CZ3 TRP H 100 90.690 33.470 −7.722 1.00 20.58 ATOM CH2 TRP H 100 91.356 32.218 −7.583 1.00 23.10 ATOM C TRP H 100 85.183 32.874 −3.908 1.00 16.39 ATOM O TRP H 100 85.584 31.928 −3.245 1.00 15.36 ATOM N TYR H 100A 83.901 33.129 −4.105 1.00 15.37 ATOM CA TYR H 100 82.862 32.289 −3.555 1.00 16.59 ATOM CB TYR H 100 81.656 33.136 −3.135 1.00 16.72 ATOM CG TYR H 100 81.746 33.717 −1.749 1.00 22.50 ATOM CD1 TYR H 100 81.600 35.098 −1.553 1.00 23.43 ATOM CE1 TYR H 100 81.645 35.637 −0.273 1.00 22.21 ATOM CD2 TYR H 100 81.744 32.883 −0.626 1.00 24.26 ATOM CE2 TYR H 100 81.793 33.405 0.659 1.00 27.56 ATOM CZ TYR H 100 81.840 34.783 0.829 1.00 29.81 ATOM OH TYR H 100 81.860 35.292 2.103 1.00 34.18 ATOM C TYR H 100 82.385 31.279 −4.587 1.00 14.72 ATOM O TYR H 100 82.272 31.596 −5.772 1.00 14.44 ATOM N PHE H 100B 82.115 30.070 −4.118 1.00 14.18 ATOM CA PHE H 100 81.552 28.985 −4.923 1.00 15.04 ATOM CB PHE H 100 80.018 29.135 −4.968 1.00 11.93 ATOM CG PHE H 100 79.433 29.732 −3.719 1.00 10.44 ATOM CD1 PHE H 100 78.547 30.789 −3.798 1.00 12.27 ATOM CD2 PHE H 100 79.803 29.258 −2.469 1.00 10.01 ATOM CE1 PHE H 100 78.027 31.378 −2.647 1.00 14.34 ATOM CE2 PHE H 100 79.304 29.823 −1.308 1.00 10.04 ATOM CZ PHE H 100 78.411 30.889 −1.386 1.00 13.85 ATOM C PHE H 100 82.095 28.814 −6.341 1.00 16.03 ATOM O PHE H 100 81.350 28.924 −7.316 1.00 16.54 ATOM N ASP H 101 83.381 28.510 −6.459 1.00 15.78 ATOM CA ASP H 101 83.966 28.305 −7.776 1.00 17.03 ATOM CB ASP H 101 85.467 28.643 −7.788 1.00 16.29 ATOM CG ASP H 101 86.280 27.761 −6.876 1.00 17.74 ATOM OD1 ASP H 101 87.419 27.421 −7.233 1.00 23.19 ATOM OD2 ASP H 101 85.815 27.429 −5.782 1.00 18.97 ATOM C ASP H 101 83.710 26.868 −8.224 1.00 17.89 ATOM O ASP H 101 83.770 26.569 −9.414 1.00 18.15 ATOM N VAL H 102 83.420 25.977 −7.277 1.00 16.57 ATOM CA VAL H 102 83.120 24.589 −7.613 1.00 18.26 ATOM CB VAL H 102 84.332 23.662 −7.370 1.00 17.45 ATOM CG1 VAL H 102 84.069 22.280 −7.969 1.00 15.35 ATOM CG2 VAL H 102 85.804 24.285 −7.957 1.00 16.60 ATOM C VAL H 102 81.940 24.118 −6.753 1.00 18.17 ATOM O VAL H 102 81.984 24.245 −5.532 1.00 19.18 ATOM N TRP H 103 80.908 23.565 −7.392 1.00 17.66 ATOM CA TRP H 103 79.695 23.070 −6.714 1.00 16.97 ATOM CB TRP H 103 78.450 23.733 −7.307 1.00 14.66 ATOM CG TRP H 103 78.402 25.206 −7.217 1.00 13.16 ATOM CD2 TRP H 103 77.335 25.990 −6.683 1.00 13.16 ATOM CE2 TRP H 103 77.674 27.346 −6.885 1.00 11.97 ATOM CE3 TRP H 103 76.116 25.680 −6.053 1.00 14.23 ATOM CG1 TRP H 103 79.327 26.091 −7.698 1.00 12.35 ATOM NE1 TRP H 103 78.897 27.374 −7.503 1.00 10.43 ATOM CZ2 TRP H 103 76.839 28.396 −6.485 1.00 11.68 ATOM CZ3 TRP H 103 75.287 26.723 −5.652 1.00 12.59 ATOM CH2 TRP H 103 75.652 28.066 −5.870 1.00 12.82 ATOM C TRP H 103 79.470 21.562 −6.876 1.00 18.07 ATOM O TRP H 103 79.944 20.953 −7.839 1.00 19.15 ATOM N GLY H 104 78.716 20.973 −5.950 1.00 16.51 ATOM CA GLY H 104 78.372 19.568 −6.057 1.00 15.81 ATOM C GLY H 104 77.235 19.521 −7.080 1.00 17.22 ATOM O GLY H 104 76.809 20.561 −7.578 1.00 16.55 ATOM N ALA H 105 76.699 18.340 −7.373 1.00 18.21 ATOM CA ALA H 105 75.623 18.238 −8.359 1.00 15.09 ATOM CB ALA H 105 75.555 16.842 −8.906 1.00 17.38 ATOM C ALA H 105 74.283 18.634 −7.752 1.00 15.46 ATOM O ALA H 105 73.356 19.008 −8.470 1.00 15.25 ATOM N GLY H 106 74.202 18.570 −6.425 1.00 13.51 ATOM CA GLY H 106 72.984 18.921 −5.713 1.00 14.41 ATOM C GLY H 106 72.153 17.692 −5.417 1.00 14.89 ATOM O GLY H 106 72.152 16.742 −6.204 1.00 16.09 ATOM N THR H 107 71.498 17.668 −4.261 1.00 15.25 ATOM CA THR H 107 70.647 16.531 −3.907 1.00 12.89 ATOM CB THR H 107 71.260 15.655 −2.764 1.00 12.03 ATOM OG1 THR H 107 70.529 14.434 −2.627 1.00 14.85 ATOM CG2 THR H 107 71.265 16.380 −1.449 1.00 14.04 ATOM C THR H 107 69.269 17.071 −3.563 1.00 13.69 ATOM O THR H 107 69.136 18.102 −2.898 1.00 12.77 ATOM N THR H 108 68.251 16.402 −4.094 1.00 14.91 ATOM CA THR H 108 66.861 16.767 −3.896 1.00 14.31 ATOM CB THR H 108 65.998 16.259 −5.054 1.00 16.49 ATOM OG1 THR H 108 66.604 16.644 −6.288 1.00 23.43 ATOM CG2 THR H 108 64.614 16.876 −5.002 1.00 18.43 ATOM C THR H 108 66.287 16.220 −2.598 1.00 13.70 ATOM O THR H 108 66.414 15.027 −2.291 1.00 11.70 ATOM N VAL H 109 65.670 17.119 −1.836 1.00 12.30 ATOM CA VAL H 109 65.026 16.784 −0.582 1.00 14.43 ATOM CB VAL H 109 65.729 17.472 0.619 1.00 14.88 ATOM CG1 VAL H 109 65.026 17.122 1.920 1.00 13.86 ATOM CG2 VAL H 109 67.193 17.060 0.672 1.00 10.78 ATOM C VAL H 109 63.568 17.258 −0.672 1.00 16.33 ATOM O VAL H 109 63.292 18.397 −1.089 1.00 16.26 ATOM N THR H 110 62.645 16.340 −0.382 1.00 16.17 ATOM CA THR H 110 61.216 16.641 −0.371 1.00 14.13 ATOM CB THR H 110 60.426 15.726 −1.325 1.00 13.82 ATOM OG1 THR H 110 60.771 16.028 −2.678 1.00 10.99 ATOM CG2 THR H 110 58.529 15.931 −1.147 1.00 12.81 ATOM C THR H 110 60.707 16.415 1.050 1.00 13.72 ATOM O THR H 110 61.045 15.409 1.680 1.00 14.07 ATOM N VAL H 111 59.395 17.404 1.585 1.00 14.52 ATOM CA VAL H 111 59.414 17.308 2.913 1.00 22.91 ATOM CB VAL H 111 59.539 18.632 3.659 1.00 13.54 ATOM CG1 VAL H 111 59.004 18.481 5.091 1.00 12.26 ATOM CG2 VAL H 111 61.003 19.060 3.675 1.00 12.73 ATOM C VAL H 111 57.946 16.927 2.735 1.00 23.85 ATOM O VAL H 111 57.115 17.748 2.328 1.00 12.86 ATOM N SER H 112 57.635 15.664 3.000 1.00 13.52 ATOM CA SER H 112 56.277 15.186 2.825 1.00 14.65 ATOM CB SER H 112 56.067 14.741 1.369 1.00 13.71 ATOM OG SER H 112 54.733 14.274 1.173 1.00 16.01 ATOM C SER H 112 55.895 14.049 3.757 1.00 25.63 ATOM O SER H 112 56.743 13.287 4.216 1.00 16.01 ATOM N SER H 113 54.594 13.929 3.998 1.00 17.91 ATOM CA SER H 113 54.044 12.883 4.851 1.00 19.30 ATOM CB SER H 113 52.757 13.394 5.523 1.00 20.59 ATOM OG SER H 113 52.993 14.594 6.251 1.00 22.75 ATOM C SER H 113 53.763 11.611 4.016 1.00 18.16 ATOM O SER H 113 53.570 10.527 4.555 1.00 19.67 ATOM N ALA H 114 53.747 11.757 2.698 1.00 17.12 ATOM CA ALA H 114 53.492 10.633 1.808 1.00 16.60 ATOM CB ALA H 114 53.203 11.129 0.405 1.00 15.09 ATOM C ALA H 114 54.709 9.708 1.809 1.00 17.50 ATOM O ALA H 114 55.829 10.144 2.067 1.00 27.91 ATOM N SER H 115 54.489 8.442 1.491 1.00 16.28 ATOM CA SER H 115 55.570 7.478 1.489 1.00 19.52 ATOM CB SER H 115 55.079 6.132 2.064 1.00 19.19 ATOM OG SER H 115 54.606 5.275 1.047 1.00 27.19 ATOM C SER H 115 56.242 7.290 0.127 1.00 18.16 ATOM O SER H 115 55.718 7.698 −0.910 1.00 17.69 ATOM N THR H 116 57.435 6.711 0.158 1.00 18.51 ATOM CA THR H 116 58.225 6.436 −1.034 1.00 17.26 ATOM CB THR H 116 59.628 5.914 −0.630 1.00 15.24 ATOM OG1 THR H 116 60.286 6.915 0.161 1.00 16.91 ATOM CG2 THR H 116 60.471 5.593 −1.848 1.00 10.10 ATOM C THR H 116 57.514 5.381 −1.880 1.00 18.11 ATOM O THR H 116 56.921 4.448 −1.334 1.00 17.85 ATOM N LYS H 117 57.535 5.566 −3.202 1.00 15.14 ATOM CA LYS H 117 56.928 4.625 −4.138 1.00 14.76 ATOM CB LYS H 117 55.487 5.047 −4.448 1.00 11.84 ATOM CG LYS H 117 54.753 4.082 −5.354 1.00 11.64 ATOM CG LYS H 117 53.331 4.533 −5.609 1.00 13.39 ATOM CE LYS H 117 52.618 3.541 −6.493 1.00 14.85 ATOM NZ LYS H 117 52.517 2.187 −5.850 1.00 19.06 ATOM C LYS H 117 57.774 4.596 −5.429 1.00 15.11 ATOM O LYS H 117 58.127 5.650 −5.977 1.00 16.09 ATOM N GLY H 118 58.155 3.400 −5.867 1.00 14.77 ATOM CA GLY H 118 58.963 3.255 −7.067 1.00 13.25 ATOM C GLY H 118 58.079 3.364 −8.279 1.00 13.95 ATOM O GLY H 118 56.894 3.074 −8.202 1.00 16.47 ATOM N PRO H 119 58.625 3.759 −9.426 1.00 15.62 ATOM CG PRO H 119 60.035 4.122 −9.637 1.00 19.10 ATOM CA PRO H 119 57.860 3.915 −10.664 1.00 15.67 ATOM CB PRO H 119 58.772 4.812 −11.495 1.00 15.38 ATOM CG PRO H 119 60.120 4.281 −11.169 1.00 16.10 ATOM C PRO H 119 57.538 2.660 −11.451 1.00 14.47 ATOM O PRO H 119 58.185 1.611 −11.304 1.00 14.94 ATOM N SER H 120 56.558 2.791 −12.328 1.00 13.35 ATOM CA SER H 120 56.178 1.714 −13.232 1.00 15.97 ATOM CB SER H 120 54.668 1.481 −13.221 1.00 18.07 ATOM OG SER H 120 54.260 0.992 −11.952 1.00 22.46 ATOM C SER H 120 56.608 2.310 −14.556 1.00 14.66 ATOM O SER H 120 56.604 3.525 −14.702 1.00 16.58 ATOM N VAL H 121 57.044 1.486 −15.497 1.00 14.09 ATOM CA VAL H 121 57.502 2.004 −16.775 1.00 15.16 ATOM CB VAL H 121 59.038 1.826 −16.919 1.00 13.34 ATOM CD1 VAL H 121 59.524 2.468 −18.215 1.00 14.30 ATOM CG2 VAL H 121 59.755 2.411 −15.710 1.00 11.15 ATOM C VAL H 121 56.753 1.298 −17.902 1.00 16.62 ATOM O VAL H 121 56.621 0.064 −17.905 1.00 18.28 ATOM N PHE H 122 56.211 2.086 −18.821 1.00 15.27 ATOM CA PHE H 122 55.444 1.553 −19.935 1.00 16.26 ATOM CB PHE H 122 53.971 1.986 −19.827 1.00 13.75 ATOM CG PHE H 122 53.328 1.608 −18.525 1.00 17.83 ATOM CD1 PHE H 122 53.066 0.272 −18.225 1.00 16.34 ATOM CD2 PHE H 122 53.022 2.577 −17.578 1.00 17.41 ATOM CE1 PHE H 122 52.520 −0.088 −17.010 1.00 15.75 ATOM CE2 PHE H 122 52.472 2.217 −16.349 1.00 17.96 ATOM CZ PHE H 122 52.224 0.883 −16.071 1.00 16.23 ATOM C PHE H 122 56.028 2.100 −21.211 1.00 16.57 ATOM O PHE H 122 56.629 3.222 −21.244 1.00 18.33 ATOM N PRO H 123 55.989 1.309 −22.281 1.00 15.62 ATOM CD PRO H 123 55.570 −0.103 −22.354 1.00 14.76 ATOM CA PRO H 123 56.530 1.768 −23.555 1.00 14.94 ATOM CB PRO H 123 56.649 0.472 −24.337 1.00 17.14 ATOM CG PRO H 123 55.456 −0.323 −23.836 1.00 16.17 ATOM C PRO H 123 55.648 2.735 −24.319 1.00 16.60 ATOM O PRO H 123 54.411 2.680 −24.245 1.00 17.55 ATOM N LEU H 124 56.286 3.650 −25.031 1.00 13.37 ATOM CA LEU H 124 55.561 4.556 −25.890 1.00 14.24 ATOM CB LEU H 124 55.994 6.013 −25.655 1.00 15.79 ATOM CG LEU H 124 55.665 6.606 −24.265 1.00 17.62 ATOM CD1 LEU H 124 56.269 7.985 −24.102 1.00 13.09 ATOM CD2 LEU H 124 54.153 6.660 −24.041 1.00 18.38 ATOM C LEU H 124 56.077 3.994 −27.221 1.00 16.57 ATOM O LEU H 124 57.307 4.426 −27.742 1.00 15.81 ATOM N ALA H 125 55.420 2.937 −27.697 1.00 16.47 ATOM CA ALA H 125 55.828 2.245 −28.920 1.00 15.66 ATOM CB ALA H 125 54.977 1.002 −29.140 1.00 10.29 ATOM C ALA H 125 55.819 3.109 −30.154 1.00 17.52 ATOM O ALA H 125 54.968 3.984 −30.318 1.00 21.55 ATOM N PRO H 126 56.789 2.892 −31.042 1.00 20.30 ATOM CD PRO H 126 57.897 1.929 −30.946 1.00 20.63 ATOM CA PRO H 126 56.878 3.667 −32.279 1.00 22.95 ATOM CB PRO H 126 58.198 3.188 −32.886 1.00 21.13 ATOM CG PRO H 126 58.302 1.785 −32.395 1.00 22.39 ATOM C PRO H 126 55.700 3.375 −33.193 1.00 27.03 ATOM O PRO H 126 55.427 2.226 −33.504 1.00 27.46 ATOM N SER H 127 54.992 4.430 −33.577 1.00 34.03 ATOM CA SER H 127 53.833 4.346 −34.460 1.00 39.73 ATOM CB SER H 127 53.179 5.724 −34.629 1.00 43.44 ATOM OG SER H 127 52.642 5.910 −35.940 1.00 42.93 ATOM C SER H 127 54.300 3.881 −35.803 1.00 42.00 ATOM O SER H 127 53.500 3.580 −36.684 1.00 43.71 ATOM N SER H 128 55.597 3.962 −36.008 1.00 44.63 ATOM CA SER H 128 56.137 3.532 −37.262 1.00 48.81 ATOM CB SER H 128 57.449 4.268 −37.540 1.00 50.45 ATOM OG SER H 128 57.252 5.678 −37.548 1.00 48.06 ATOM C SER H 128 56.315 2.023 −37.164 1.00 50.25 ATOM O SER H 128 55.845 1.393 −36.207 1.00 49.98 ATOM N LYS H 129 56.944 1.443 −38.175 1.00 49.86 ATOM CA LYS H 129 57.180 0.014 −38.191 1.00 49.05 ATOM CB LYS H 129 55.874 −0.722 −38.414 1.00 49.61 ATOM C LYS H 129 58.151 −0.266 −39.320 1.00 48.36 ATOM O LYS H 129 59.112 −1.022 −39.152 1.00 44.64 ATOM NZ LYS H 129 51.040 −1.190 −37.021 0.00 0.00 ATOM CE LYS H 129 52.290 −0.431 −36.870 0.00 0.00 ATOM CD LYS H 129 53.427 −0.974 −37.734 0.00 0.00 ATOM CG LYS H 129 54.730 −0.196 −37.554 0.00 0.00 ATOM N SER H 130 57.862 0.364 −40.464 1.00 48.61 ATOM CA SER H 130 58.643 0.255 −41.703 1.00 47.96 ATOM CB SER H 130 57.736 0.583 −42.898 1.00 47.61 ATOM C SER H 130 59.875 1.176 −41.704 1.00 48.17 ATOM O SER H 130 60.004 2.065 −40.830 1.00 48.15 ATOM N THR H 131 60.739 0.991 −42.701 0.01 47.53 ATOM CA THR H 131 61.974 1.757 −42.843 0.01 47.59 ATOM CB THR H 131 63.005 0.935 −43.613 0.01 46.60 ATOM C THR H 131 61.827 3.143 −43.476 0.01 47.59 ATOM O THR H 131 62.023 4.157 −42.811 0.01 47.36 ATOM N SER H 132 61.563 3.181 −44.778 0.01 48.07 ATOM CA SER H 132 61.404 4.433 −45.510 0.01 48.10 ATOM CB SER H 132 61.123 4.153 −46.979 0.01 48.72 ATOM C SER H 132 60.313 5.324 −44.927 0.01 47.75 ATOM O SER H 132 59.137 5.192 −45.270 0.01 48.15 ATOM N GLY H 133 60.717 6.221 −44.035 0.01 46.82 ATOM CA GLY H 133 59.778 7.138 −43.419 0.01 45.30 ATOM C GLY H 133 60.485 8.243 −42.661 0.01 43.62 ATOM O GLY H 133 59.855 8.993 −41.914 0.01 44.14 ATOM N GLY H 134 61.792 8.371 −42.878 1.00 42.62 ATOM CA GLY H 134 62.547 9.392 −42.187 1.00 37.35 ATOM C GLY H 134 62.780 9.112 −40.710 1.00 34.73 ATOM O GLY H 134 63.626 8.277 −40.355 1.00 32.41 ATOM N THR H 135 61.982 9.751 −39.859 1.00 33.59 ATOM CA THR H 135 62.140 9.647 −38.406 1.00 32.75 ATOM CB THR H 135 62.648 11.011 −37.859 1.00 34.16 ATOM OG1 THR H 135 63.967 11.256 −38.361 1.00 36.29 ATOM CG2 THR H 135 62.691 11.031 −36.355 1.00 37.02 ATOM C THR H 135 60.920 9.202 −37.598 1.00 29.09 ATOM O THR H 135 59.800 9.638 −37.832 1.00 31.07 ATOM N ALA H 136 61.164 8.374 −36.597 1.00 25.01 ATOM CA ALA H 136 60.105 7.878 −35.744 1.00 23.72 ATOM CB ALA H 136 60.022 6.363 −35.859 1.00 24.23 ATOM C ALA H 136 60.388 8.260 −34.297 1.00 22.99 ATOM O ALA H 136 61.545 8.331 −33.884 1.00 22.43 ATOM N ALA H 137 59.338 8.518 −33.529 1.00 21.07 ATOM CA ALA H 137 59.520 8.836 −32.125 1.00 19.57 ATOM CB ALA H 137 58.811 10.101 −31.763 1.00 18.29 ATOM C ALA H 137 58.991 7.686 −31.293 1.00 20.25 ATOM O ALA H 137 58.015 7.025 −31.664 1.00 20.92 ATOM N LEU H 138 59.678 7.422 −30.194 1.00 19.10 ATOM CA LEU H 138 59.317 6.375 −29.258 1.00 15.77 ATOM CB LEU H 138 60.036 5.075 −29.618 1.00 16.18 ATOM CG LEU H 138 61.569 5.057 −29.693 1.00 14.59 ATOM CD1 LEU H 138 62.140 4.576 −28.386 1.00 16.58 ATOM CD2 LEU H 138 61.983 4.113 −30.775 1.00 15.53 ATOM C LEU H 138 59.760 6.897 −27.899 1.00 15.97 ATOM O LEU H 138 60.466 7.904 −27.818 1.00 16.00 ATOM N GLY H 139 59.338 6.252 −26.827 1.00 15.65 ATOM CA GLY H 139 59.737 6.721 −25.523 1.00 14.54 ATOM C GLY H 139 59.295 5.785 −24.437 1.00 15.97 ATOM O GLY H 139 58.892 4.647 −24.709 1.00 16.46 ATOM N CYS H 140 59.326 6.290 −23.209 1.00 15.70 ATOM CA CYS H 140 58.925 5.539 −22.035 1.00 14.57 ATOM C CYS H 140 58.121 6.419 −21.085 1.00 13.88 ATOM O CYS H 140 58.457 7.592 −20.881 1.00 11.51 ATOM CB CYS H 140 60.153 5.011 −21.302 1.00 16.76 ATOM SO CYS H 140 60.792 3.452 −21.985 1.00 16.67 ATOM N LEU H 141 57.003 5.873 −20.604 1.00 14.15 ATOM CA LEU H 141 56.138 6.532 −19.637 1.00 11.75 ATOM CB LEU H 141 54.664 6.189 −19.886 1.00 12.89 ATOM CG LEU H 141 53.621 6.757 −18.916 1.00 11.36 ATOM CD1 LEU H 141 53.620 8.316 −18.934 1.00 9.80 ATOM CD2 LEU H 141 52.248 6.198 −19.277 1.00 10.76 ATOM C LEU H 141 56.590 5.992 −18.276 1.00 13.36 ATOM O LEU H 141 56.578 4.788 −18.037 1.00 13.78 ATOM N VAL H 142 57.044 6.905 −17.421 1.00 14.52 ATOM CA VAL H 142 57.542 6.601 −16.086 1.00 13.75 ATOM CB VAL H 142 58.923 7.264 −15.872 1.00 12.16 ATOM CG1 VAL H 142 59.516 6.856 −14.542 1.00 9.59 ATOM CG2 VAL H 142 59.866 6.851 −17.005 1.00 10.00 ATOM C VAL H 142 56.527 7.183 −15.125 1.00 15.66 ATOM O VAL H 142 56.541 8.384 −14.850 1.00 15.64 ATOM N LYS H 143 55.616 6.348 −14.630 1.00 17.91 ATOM CA LYS H 143 54.600 6.875 −13.752 1.00 17.78 ATOM CB LYS H 143 53.271 7.025 −14.502 1.00 22.02 ATOM CG LYS H 143 52.450 5.788 −14.689 1.00 23.22 ATOM CD LYS H 143 51.228 6.108 −15.557 1.00 27.56 ATOM CE LYS H 143 50.239 7.105 −14.929 1.00 28.88 ATOM NZ LYS H 143 49.292 6.527 −13.914 1.00 29.43 ATOM C LYS H 143 54.384 6.264 −12.390 1.00 15.32 ATOM O LYS H 143 54.827 5.144 −12.106 1.00 11.57 ATOM N ASP H 144 53.786 7.102 −11.538 1.00 15.37 ATOM CA ASP H 144 53.392 6.800 −10.166 1.00 15.38 ATOM CB ASP H 144 52.338 5.686 −10.153 1.00 18.41 ATOM CG ASP H 144 51.111 6.029 −10.984 1.00 19.01 ATOM OD1 ASP H 144 50.851 7.224 −11.190 1.00 18.51 ATOM OD2 ASP H 144 50.409 5.101 −11.444 1.00 22.72 ATOM C ASP H 144 54.518 6.499 −9.191 1.00 13.76 ATOM O ASP H 144 54.548 5.453 −8.542 1.00 12.14 ATOM N TYR H 145 55.434 7.451 −9.075 1.00 14.87 ATOM CA TYR H 145 56.557 7.312 −8.164 1.00 11.80 ATOM CB TYR H 145 57.880 7.176 −8.936 1.00 12.15 ATOM CG TYR H 145 58.300 8.405 −9.722 1.00 13.86 ATOM CD1 TYR H 145 57.996 8.535 −11.083 1.00 10.29 ATOM CE1 TYR H 145 58.360 9.682 −11.778 1.00 10.58 ATOM CD2 TYR H 145 58.980 9.452 −9.089 1.00 10.94 ATOM CE2 TYR H 145 59.344 10.597 −9.772 1.00 10.46 ATOM CZ TYR H 145 59.036 10.709 −11.104 1.00 10.53 ATOM OH TYR H 145 59.414 11.855 −11.742 1.00 12.24 ATOM C TYR H 145 56.560 8.543 −7.272 1.00 11.16 ATOM O TYR H 145 55.919 9.561 −7.591 1.00 9.37 ATOM N PHE H 146 57.271 8.440 −6.157 1.00 11.54 ATOM CA PHE H 146 57.397 9.518 −5.199 1.00 10.60 ATOM CB PHE H 146 56.155 9.580 −4.292 1.00 12.01 ATOM CG PHE H 146 56.050 10.860 −3.486 1.00 10.87 ATOM CD1 PHE H 146 56.420 10.888 −2.145 1.00 9.67 ATOM CD2 PHE H 146 55.620 12.047 −4.095 1.00 10.37 ATOM CE1 PHE H 146 56.376 12.071 −1.422 1.00 7.13 ATOM CE2 PHE H 146 55.569 13.239 −3.387 1.00 11.35 ATOM CZ PHE H 146 55.950 13.259 −2.045 1.00 10.49 ATOM C PHE H 146 58.603 9.165 −4.351 1.00 11.66 ATOM O PHE H 146 58.849 7.993 −4.102 1.00 13.17 ATOM N PRO H 147 59.475 10.144 −4.061 1.00 15.11 ATOM CD PRO H 147 60.393 10.039 −2.903 1.00 11.77 ATOM CA PRO H 147 59.374 11.538 −4.512 1.00 12.86 ATOM CD PRO H 147 59.920 12.318 −3.301 1.00 11.39 ATOM CG PRO H 147 61.014 11.442 −2.810 1.00 13.59 ATOM C PRO H 147 60.293 11.691 −5.721 1.00 11.82 ATOM O PRO H 147 60.710 10.694 −6.331 1.00 10.54 ATOM N GLU H 148 60.563 12.933 −6.100 1.00 13.23 ATOM CA GLU H 148 61.502 13.210 −7.172 1.00 12.55 ATOM CB GLU H 148 61.467 14.700 −7.516 1.00 13.76 ATOM CG GLU H 148 60.350 15.097 −8.443 1.00 16.65 ATOM CD GLU H 148 60.705 14.890 −9.894 1.00 18.85 ATOM OE1 GLU H 148 60.868 15.905 −10.600 1.00 20.04 ATOM OE2 GLU H 148 60.816 13.720 −10.333 1.00 20.68 ATOM C GLU H 148 62.873 12.884 −6.537 1.00 12.83 ATOM O GLU H 148 63.027 12.967 −5.306 1.00 13.72 ATOM N PRO H 149 63.889 12.558 −7.358 1.00 13.44 ATOM CD PRO H 149 65.297 12.743 −6.955 1.00 9.52 ATOM CA PRO H 149 63.793 12.483 −8.813 1.00 12.75 ATOM CB PRO H 149 64.933 13.390 −9.233 1.00 13.35 ATOM CG PRO H 149 66.009 12.955 −8.279 1.00 11.58 ATOM C PRO H 149 64.003 11.072 −9.379 1.00 11.79 ATOM O PRO H 149 64.357 10.138 −8.672 1.00 13.53 ATOM N VAL H 150 63.802 10.957 −10.677 1.00 11.06 ATOM CA VAL H 150 64.017 9.726 −11.415 1.00 16.43 ATOM CB VAL H 150 62.641 9.208 −12.035 1.00 17.41 ATOM CG1 VAL H 150 62.438 9.689 −13.470 1.00 15.21 ATOM CG2 VAL H 150 62.540 7.717 −11.953 1.00 19.94 ATOM C VAL H 150 65.002 10.163 −12.527 1.00 16.34 ATOM O VAL H 150 65.097 11.351 −12.825 1.00 16.73 ATOM N THR H 151 65.834 9.262 −13.031 1.00 16.34 ATOM CA THR H 151 66.702 9.616 −14.150 1.00 15.33 ATOM CB THR H 151 68.214 9.492 −13.860 1.00 16.67 ATOM OG1 THR H 151 68.521 8.147 −13.507 1.00 19.39 ATOM CG2 THR H 151 68.638 10.415 −12.762 1.00 18.99 ATOM C THR H 151 66.364 8.607 −15.232 1.00 15.33 ATOM O THR H 151 65.975 7.474 −14.927 1.00 15.10 ATOM N VAL H 152 66.463 9.024 −16.489 1.00 15.67 ATOM CA VAL H 152 66.186 8.130 −17.593 1.00 15.90 ATOM CB VAL H 152 64.840 8.463 −18.298 1.00 16.43 ATOM CG1 VAL H 152 64.559 7.429 −19.389 1.00 17.02 ATOM CG2 VAL H 152 63.687 8.514 −17.289 1.00 12.53 ATOM C VAL H 152 67.304 8.188 −18.631 1.00 15.46 ATOM O VAL H 152 67.725 9.273 −19.044 1.00 15.77 ATOM N SER H 153 67.823 7.025 −19.010 1.00 15.40 ATOM CA SER H 153 68.846 6.961 −20.048 1.00 17.96 ATOM CB SER H 153 70.220 6.517 −19.500 1.00 19.47 ATOM CG SER H 153 70.209 5.207 −18.971 1.00 19.50 ATOM C SER H 153 68.321 5.993 −21.100 1.00 17.07 ATOM O SER H 153 67.328 5.298 −20.857 1.00 16.03 ATOM N TRP H 154 68. 51 5.983 −22.271 1.00 16.08 ATOM CA TRP H 154 68.550 5.122 −23.369 1.00 16.39 ATOM CB TRP H 154 68.061 5.975 −24.556 1.00 15.81 ATOM CG TRP H 154 66.678 6.533 −24.338 1.00 16.04 ATOM CD2 TRP H 154 65.446 5.855 −24.584 1.00 15.49 ATOM CE2 TRP H 154 64.406 6.704 −24.147 1.00 15.24 ATOM CE3 TRP H 154 65.117 4.606 −25.127 1.00 13.01 ATOM CG1 TRP H 154 66.343 7.750 −23.788 1.00 16.52 ATOM NE1 TRP H 154 64.980 7.852 −23.666 1.00 14.13 ATOM CZ2 TRP H 154 63.061 6.338 −24.239 1.00 13.45 ATOM CZ3 TRP H 154 63.781 4.250 −25.215 1.00 11.20 ATOM CH2 TRP H 154 62.773 5.110 −24.774 1.00 11.53 ATOM C TRP H 154 69.743 4.288 −23.792 1.00 19.86 ATOM O TRP H 154 70.850 4.819 −23.995 1.00 18.11 ATOM N ASN H 155 69.536 2.978 −23.886 1.00 19.14 ATOM CA ASN H 155 70.595 2.051 −24.284 1.00 18.51 ATOM CB ASN H 155 70.884 2.203 −25.773 1.00 16.21 ATOM CG ASN H 155 69.744 1.697 −26.624 1.00 14.90 ATOM OD1 ASN H 155 68.890 0.968 −26.132 1.00 15.81 ATOM ND2 ASN H 155 69.734 2.045 −27.902 1.00 14.10 ATOM C ASN H 155 71.854 2.231 −23.424 1.00 21.54 ATOM O ASN H 155 72.986 2.289 −23.926 1.00 21.60 ATOM N SER H 156 71.618 2.307 −22.114 1.00 23.82 ATOM CA SER H 156 72.657 2.477 −21.097 1.00 25.32 ATOM CB SER H 156 73.478 1.194 −20.947 1.00 23.36 ATOM OG SER H 156 72.655 0.122 −20.528 1.00 23.97 ATOM C SER H 156 73.569 3.678 −21.339 1.00 26.35 ATOM O SER H 156 74.757 3.628 −21.021 1.00 26.24 ATOM N GLY H 157 73.001 4.756 −21.888 1.00 24.38 ATOM CA GLY H 157 73.763 5.966 −22.160 1.00 21.04 ATOM C GLY H 157 74.256 6.104 −23.590 1.00 23.32 ATOM O GLY H 157 74.639 7.183 −24.016 1.00 23.51 ATOM N ALA H 158 74.194 5.020 −24.352 1.00 23.69 ATOM CA ALA H 158 74.666 5.015 −25.727 1.00 17.48 ATOM CB ALA H 158 74.790 3.588 −26.228 1.00 17.39 ATOM C ALA H 158 73.797 5.822 −26.668 1.00 13.71 ATOM O ALA H 158 74.243 6.195 −27.753 1.00 13.65 ATOM N LEU H 159 72.544 6.058 −26.281 1.00 18.26 ATOM CA LEU H 159 71.636 6.827 −27.127 1.00 19.74 ATOM CB LEU H 159 70.335 6.056 −27.370 1.00 18.94 ATOM CG LEU H 159 69.576 6.197 −28.689 1.00 19.52 ATOM CD1 LEU H 159 68.134 5.790 −28.448 1.00 16.51 ATOM CD2 LEU H 159 69.649 7.583 −29.248 1.00 23.06 ATOM C LEU H 159 71.322 8.107 −26.384 1.00 18.47 ATOM O LEU H 159 70.659 8.083 −25.357 1.00 18.48 ATOM N THR H 160 71.791 9.229 −26.904 1.00 23.36 ATOM CA THR H 160 71.554 10.499 −26.250 1.00 23.65 ATOM CB THR H 160 72.826 10.963 −25.546 1.00 21.22 ATOM OG1 THR H 160 73.915 10.925 −26.475 1.00 22.67 ATOM CG2 THR H 160 73.148 10.037 −24.385 1.00 23.98 ATOM C THR H 160 71.050 11.574 −27.202 1.00 23.49 ATOM O THR H 160 70.370 12.512 −26.785 1.00 19.91 ATOM N SER H 161 71.344 11.442 −28.487 1.00 23.44 ATOM CA SER H 161 70.887 12.454 −29.421 1.00 24.43 ATOM CB SER H 161 71.613 12.343 −30.769 1.00 25.80 ATOM CG SER H 161 71.513 11.035 −31.312 1.00 36.45 ATOM C SER H 161 69.385 12.371 −29.615 1.00 23.52 ATOM O SER H 161 68.837 11.284 −29.794 1.00 26.83 ATOM N GLY H 162 68.718 13.515 −29.511 1.00 22.52 ATOM CA GLY H 162 67.287 13.574 −29.719 1.00 19.26 ATOM C GLY H 162 66.453 13.105 −28.558 1.00 18.67 ATOM O GLY H 162 65.263 12.867 −28.727 1.00 19.57 ATOM N VAL H 163 67.069 12.956 −27.392 1.00 18.18 ATOM CA VAL H 163 66.344 12.514 −26.209 1.00 18.28 ATOM CB VAL H 163 67.252 11.766 −25.184 1.00 16.13 ATOM CG1 VAL H 163 66.465 11.412 −23.930 1.00 15.25 ATOM CG2 VAL H 163 67.799 10.503 −25.794 1.00 16.95 ATOM C VAL H 163 65.763 13.728 −25.521 1.00 18.72 ATOM O VAL H 163 66.399 14.777 −25.452 1.00 21.28 ATOM N HIS H 164 64.541 13.586 −25.031 1.00 17.35 ATOM CA HIS H 164 63.871 14.649 −24.313 1.00 16.94 ATOM CB HIS H 164 62.817 15.341 −25.182 1.00 19.00 ATOM CG HIS H 164 63.372 16.361 −26.128 1.00 18.12 ATOM CG2 HIS H 164 63.975 17.549 −25.898 1.00 16.70 ATOM ND1 HIS H 164 63.256 16.251 −27.497 1.00 18.61 ATOM CE1 HIS H 164 63.753 17.331 −28.068 1.00 14.03 ATOM NE2 HIS H 164 64.194 18.133 −27.119 1.00 18.56 ATOM C HIS H 164 63.175 13.985 −23.152 1.00 17.34 ATOM O HIS H 164 62.250 13.191 −23.347 1.00 16.54 ATOM N THR H 165 63.663 14.252 −21.952 1.00 17.07 ATOM CA THR H 165 63.049 13.703 −20.752 1.00 16.08 ATOM CB THR H 165 64.097 13.062 −19.842 1.00 15.02 ATOM OG1 THR H 165 64.689 11.978 −20.559 1.00 14.53 ATOM CG2 THR H 165 63.475 12.517 −18.570 1.00 13.69 ATOM C THR H 165 62.325 14.853 −20.083 1.00 13.93 ATOM O THR H 165 62.933 15.766 −19.533 1.00 12.69 ATOM N PHE H 166 61.011 14.828 −20.218 1.00 13.31 ATOM CA PHE H 166 60.151 15.860 −19.676 1.00 11.35 ATOM CB PHE H 166 58.715 15.647 −20.176 1.00 11.84 ATOM CG PHE H 166 58.554 15.834 −21.666 1.00 13.49 ATOM CD1 PHE H 166 58.575 14.738 −22.528 1.00 16.51 ATOM CD2 PHE H 166 58.389 17.106 −22.205 1.00 14.83 ATOM CH1 PHE H 166 58.437 14.903 −23.904 1.00 15.29 ATOM CE2 PHE H 166 58.251 17.283 −23.576 1.00 14.45 ATOM CZ PHE H 166 58.275 16.181 −24.427 1.00 15.22 ATOM C PHE H 166 60.172 15.945 −18.154 1.00 12.15 ATOM O PHE H 166 60.378 14.945 −17.466 1.00 9.27 ATOM N PRO H 167 60.059 17.175 −17.619 1.00 13.86 ATOM CD PRO H 167 60.046 18.419 −18.415 1.00 15.57 ATOM CA PRO H 167 60.040 17.482 −16.190 1.00 11.73 ATOM CB PRO H 167 59.691 18.962 −16.170 1.00 12.97 ATOM CG PRO H 167 60.362 19.470 −17.371 1.00 17.36 ATOM C PRO H 167 58.873 16.727 −15.611 1.00 12.24 ATOM O PRO H 167 57.799 16.701 −16.234 1.00 13.95 ATOM N ALA H 168 59.057 16.122 −14.439 1.00 12.11 ATOM CA ALA H 168 57.976 15.386 −13.793 1.00 12.13 ATOM CB ALA H 168 58.475 14.688 −12.552 1.00 8.32 ATOM C ALA H 168 56.858 16.345 −13.423 1.00 13.78 ATOM O ALA H 168 57.081 17.544 −13.234 1.00 15.51 ATOM N VAL H 169 55.645 15.831 −13.371 1.00 12.89 ATOM CA VAL H 169 54.506 16.635 −12.988 1.00 15.57 ATOM CB VAL H 169 53.612 16.990 −14.232 1.00 16.84 ATOM CG1 VAL H 169 52.333 17.668 −13.794 1.00 19.49 ATOM CG2 VAL H 169 54.368 17.932 −15.193 1.00 17.39 ATOM C VAL H 169 53.761 15.763 −11.980 1.00 15.66 ATOM O VAL H 169 53.637 14.553 −12.179 1.00 17.42 ATOM N LEU H 170 53.393 16.347 −10.844 1.00 15.29 ATOM CA LEU H 170 52.668 15.627 −9.804 1.00 15.27 ATOM CB LEU H 170 52.716 16.381 −8.461 1.00 12.42 ATOM CG LEU H 170 52.125 15.662 −7.235 1.00 13.03 ATOM CD1 LEU H 170 53.065 14.595 −6.769 1.00 13.43 ATOM CD2 LEU H 170 51.929 16.616 −6.109 1.00 18.10 ATOM C LEU H 170 51.220 15.507 −10.249 1.00 18.26 ATOM O LEU H 170 50.696 16.503 −10.610 1.00 18.33 ATOM N GLN H 171 50.721 14.276 −10.277 1.00 19.12 ATOM CA GLN H 171 49.349 13.976 −10.672 1.00 18.69 ATOM CB GLN H 171 49.243 12.496 −11.041 1.00 15.23 ATOM CG GLN H 171 50.154 12.095 −12.186 1.00 18.70 ATOM CD GLN H 171 50.341 10.594 −12.300 1.00 21.99 ATOM OE1 GLN H 171 50.953 9.969 −11.436 1.00 22.59 ATOM NE2 GLN H 171 49.852 10.011 −13.385 1.00 21.12 ATOM C GLN H 171 48.437 14.260 −9.479 1.00 21.17 ATOM O GLN H 171 48.901 14.416 −8.335 1.00 18.05 ATOM N SER H 172 47.131 14.270 −9.730 1.00 24.36 ATOM CA SER H 172 46.177 14.508 −8.657 1.00 24.61 ATOM CB SER H 172 44.760 14.628 −9.222 1.00 28.12 ATOM OG SER H 172 44.475 13.541 −10.090 1.00 35.60 ATOM C SER H 172 46.275 13.373 −7.629 1.00 23.66 ATOM O SER H 172 45.942 13.572 −6.464 1.00 26.39 ATOM N SER H 173 46.758 12.201 −8.050 1.00 19.22 ATOM CA SER H 173 46.938 11.055 −7.151 1.00 18.61 ATOM CB SER H 173 47.319 9.825 −7.961 1.00 19.87 ATOM OG SER H 173 48.551 10.027 −8.630 1.00 23.71 ATOM C SER H 173 48.027 11.307 −6.101 1.00 17.92 ATOM O SER H 173 48.162 10.562 −5.125 1.00 18.89 ATOM N GLY H 174 48.800 12.367 −6.309 1.00 17.55 ATOM CA GLY H 174 49.869 12.711 −5.389 1.00 16.52 ATOM C GLY H 174 51.158 12.016 −5.774 1.00 15.28 ATOM O GLY H 174 52.121 12.031 −5.011 1.00 15.34 ATOM N LEU H 175 51.189 11.425 −6.966 1.00 12.52 ATOM CA LEU H 175 52.373 10.715 −7.436 1.00 12.10 ATOM CB LEU H 175 52.034 9.252 −7.725 1.00 11.95 ATOM CG LEU H 175 51.598 8.371 −6.561 1.00 13.01 ATOM CG1 LEU H 175 51.038 7.035 −7.062 1.00 12.11 ATOM CD2 LEU H 175 52.778 8.189 −5.608 1.00 15.83 ATOM C LEU H 175 52.835 11.377 −8.712 1.00 11.41 ATOM O LEU H 175 52.012 11.899 −9.452 1.00 12.88 ATOM N TYR H 176 54.149 11.379 −8.959 1.00 12.75 ATOM CA TYR H 176 54.715 11.984 −10.169 1.00 9.90 ATOM CB TYR H 176 56.186 12.344 −9.977 1.00 6.99 ATOM CG TYR H 176 56.437 13.446 −8.977 1.00 9.80 ATOM CD1 TYR H 176 56.298 14.786 −9.332 1.00 9.18 ATOM CE1 TYR H 176 56.529 15.796 −8.404 1.00 8.22 ATOM CD2 TYR H 176 56.812 13.145 −7.670 1.00 9.26 ATOM CE2 TYR H 176 57.039 14.139 −6.746 1.00 10.18 ATOM CZ TYR H 176 56.900 15.461 −7.115 1.00 8.46 ATOM OH TYR H 176 57.141 16.439 −6.181 1.00 9.44 ATOM C TYR H 176 54.617 11.068 −11.365 1.00 9.94 ATOM O TYR H 176 54.491 9.855 −11.230 1.00 13.21 ATOM N SER H 177 54.755 11.661 −12.536 1.00 10.40 ATOM CA SER H 177 54.729 10.927 −13.787 1.00 13.02 ATOM CB SER H 177 53.276 10.688 −14.232 1.00 12.24 ATOM OG SER H 177 53.214 9.929 −15.425 1.00 15.89 ATOM C SER H 177 55.462 11.760 −14.833 1.00 11.43 ATOM O SER H 177 55.457 12.991 −14.759 1.00 13.35 ATOM N LEU H 178 56.133 11.085 −15.761 1.00 10.36 ATOM CA LEU H 178 56.826 11.750 −16.849 1.00 12.46 ATOM CB LEU H 178 58.150 12.364 −16.371 1.00 11.05 ATOM CG LEU H 178 59.297 11.492 −15.880 1.00 7.67 ATOM CG1 LEU H 178 60.068 10.867 −17.044 1.00 8.40 ATOM CD2 LEU H 178 60.216 12.376 −15.113 1.00 8.48 ATOM C LEU H 178 57.090 10.782 −17.995 1.00 12.58 ATOM O LEU H 178 56.963 9.584 −17.827 1.00 13.76 ATOM N SER H 179 57.403 11.325 −19.167 1.00 14.34 ATOM CA SER H 179 57.763 10.541 −20.351 1.00 14.75 ATOM CB SER H 179 56.769 10.762 −21.504 1.00 14.23 ATOM OG SER H 179 55.540 10.086 −21.291 1.00 15.49 ATOM C SER H 179 59.155 11.009 −20.803 1.00 14.23 ATOM O SER H 179 59.560 12.141 −20.548 1.00 12.08 ATOM N SER H 180 59.888 10.108 −21.437 1.00 14.48 ATOM CA SER H 180 61.219 10.376 −21.985 1.00 13.43 ATOM CB SER H 180 62.301 9.565 −21.280 1.00 12.19 ATOM OG SER H 180 63.564 9.759 −21.901 1.00 14.67 ATOM C SER H 180 61.046 9.835 −23.383 1.00 13.99 ATOM O SER H 180 60.680 8.671 −23.571 1.00 15.36 ATOM N VAL H 181 61.257 10.690 −24.358 1.00 15.02 ATOM CA VAL H 181 61.078 10.307 −25.735 1.00 15.74 ATOM CB VAL H 181 59.957 11.166 −26.398 1.00 15.83 ATOM CG1 VAL H 181 58.639 10.960 −25.647 1.00 12.76 ATOM CG2 VAL H 181 60.357 12.647 −26.430 1.00 15.72 ATOM C VAL H 181 62.377 10.488 −26.475 1.00 17.47 ATOM O VAL H 181 63.265 11.199 −26.000 1.00 15.89 ATOM N VAL H 182 62.496 9.801 −27.607 1.00 17.14 ATOM CA VAL H 182 63.679 9.890 −28.453 1.00 13.84 ATOM CB VAL H 182 64.781 8.846 −28.048 1.00 16.69 ATOM CG1 VAL H 182 64.312 7.417 −28.260 1.00 14.43 ATOM CG2 VAL H 182 66.050 9.117 −28.818 1.00 17.22 ATOM C VAL H 182 63.226 9.693 −29.900 1.00 21.36 ATOM O VAL H 182 62.267 8.963 −30.161 1.00 23.83 ATOM N THR H 183 63.805 10.447 −30.823 1.00 13.93 ATOM CA THR H 183 63.450 10.295 −32.227 1.00 21.38 ATOM CB THR H 183 63.218 11.664 −32.950 1.00 21.63 ATOM OG1 THR H 183 64.273 12.570 −32.639 1.00 24.70 ATOM CG2 THR H 183 61.890 12.294 −32.534 1.00 23.70 ATOM C THR H 183 64.595 9.514 −32.857 1.00 21.52 ATOM O THR H 183 65.764 9.774 −32.565 1.00 23.10 ATOM N VAL H 184 64.259 8.488 −33.628 1.00 23.35 ATOM CA VAL H 184 65.259 7.652 −34.266 1.00 19.98 ATOM CB VAL H 184 65.373 6.269 −33.537 1.00 21.07 ATOM CG1 VAL H 184 65.755 6.479 −32.084 1.00 23.71 ATOM CG2 VAL H 184 64.059 5.439 −33.668 1.00 17.17 ATOM C VAL H 184 64.959 7.437 −35.756 1.00 22.10 ATOM O VAL H 184 63.900 7.836 −36.253 1.00 21.90 ATOM N PRO H 185 65.898 6.821 −36.495 1.00 22.12 ATOM CD PRO H 185 67.247 6.371 −36.096 1.00 23.90 ATOM CA PRO H 185 65.669 6.580 −37.923 1.00 23.15 ATOM CB PRO H 185 66.988 5.933 −38.365 1.00 22.25 ATOM CG PRO H 185 67.988 6.449 −37.377 1.00 21.22 ATOM C PRO H 185 64.522 5.584 −38.097 1.00 23.63 ATOM O PRO H 185 64.509 4.542 −37.439 1.00 24.96 ATOM N SER H 186 63.579 5.864 −38.992 1.00 24.50 ATOM CA SER H 186 62.472 4.932 −39.208 1.00 26.40 ATOM CB SER H 186 61.556 5.427 −40.309 1.00 23.78 ATOM OG SER H 186 60.922 6.625 −39.929 1.00 31.60 ATOM C SER H 186 63.008 3.566 −39.596 1.00 26.90 ATOM O SER H 186 62.520 2.530 −39.132 1.00 28.22 ATOM N SER H 187 64.055 3.578 −40.411 1.00 25.91 ATOM CA SER H 187 64.671 2.352 −40.884 1.00 24.43 ATOM CB SER H 187 65.803 2.698 −41.846 1.00 25.38 ATOM OG SER H 187 66.663 3.674 −41.269 1.00 32.83 ATOM C SER H 187 65.387 1.464 −39.764 1.00 22.75 ATOM O SER H 187 65.330 0.257 −39.942 1.00 23.52 ATOM N SER H 188 65.441 2.048 −38.600 1.00 22.42 ATOM CA SER H 188 65.971 1.274 −37.489 1.00 21.39 ATOM CB SER H 188 66.727 2.186 −36.518 1.00 24.28 ATOM OG SER H 188 65.870 3.153 −35.929 1.00 24.35 ATOM C SER H 188 64.919 0.478 −36.737 1.00 19.89 ATOM O SER H 188 65.252 −0.418 −35.967 1.00 21.67 ATOM N LEU H 189 63.656 0.819 −36.931 1.00 19.37 ATOM CA LEU H 189 62.572 0.120 −36.250 1.00 21.16 ATOM CB LEU H 189 61.215 0.740 −36.620 1.00 22.65 ATOM CG LEU H 189 60.574 1.843 −35.769 1.00 24.15 ATOM CD1 LEU H 189 61.486 2.396 −34.677 1.00 21.90 ATOM CD2 LEU H 189 60.117 2.929 −36.689 1.00 20.64 ATOM C LEU H 189 62.567 −1.358 −36.594 1.00 20.08 ATOM O LEU H 189 62.342 −1.726 −37.741 1.00 21.74 ATOM N GLY H 190 62.405 −2.204 −35.586 1.00 22.92 ATOM CA GLY H 190 62.376 −3.638 −35.815 1.00 23.25 ATOM C GLY H 190 63.359 −4.270 −35.860 1.00 25.44 ATOM O GLY H 190 63.889 −5.489 −35.736 1.00 24.73 ATOM N THR H 191 64.396 −3.451 −36.039 1.00 27.60 ATOM CA THR H 191 66.159 −3.958 −36.098 1.00 28.13 ATOM CB THR H 191 66.858 −3.649 −37.469 1.00 29.33 ATOM OG1 THR H 191 66.835 −2.246 −37.749 1.00 34.09 ATOM CG2 THR H 191 66.345 −4.368 −38.597 1.00 32.02 ATOM C THR H 191 67.001 −3.468 −34.931 1.00 27.84 ATOM O THR H 191 67.686 −4.254 −34.293 1.00 29.90 ATOM N GLN H 192 66.937 −2.183 −34.620 1.00 26.52 ATOM CA GLN H 192 67.721 −1.670 −33.505 1.00 26.83 ATOM CB GLN H 192 68.092 −0.204 −33.751 1.00 27.16 ATOM CG GLN H 192 69.541 0.149 −33.391 1.00 36.31 ATOM CD GLN H 192 69.792 0.041 −31.908 1.00 38.23 ATOM OE1 GLN H 192 70.777 −0.544 −31.457 1.00 36.83 ATOM NE2 GLN H 192 68.870 0.584 −31.132 1.00 44.67 ATOM C GLN H 192 66.946 −1.821 −32.193 1.00 25.50 ATOM O GLN H 192 65.771 −1.483 −32.121 1.00 26.11 ATOM N THR H 193 67.585 −2.373 −31.173 1.00 23.13 ATOM CA THR H 193 66.946 −2.531 −29.876 1.00 23.22 ATOM CB THR H 193 67.600 −3.679 −29.086 1.00 25.71 ATOM OG1 THR H 193 67.396 −4.909 −29.794 1.00 27.62 ATOM CG2 THR H 193 67.012 −3.794 −27.692 1.00 27.67 ATOM C THR H 193 67.023 −1.216 −29.080 1.00 23.94 ATOM O THR H 193 68.081 −0.588 −28.981 1.00 23.16 ATOM N TYR H 194 65.889 −0.783 −28.545 1.00 21.58 ATOM CA TYR H 194 65.823 0.444 −27.774 1.00 18.67 ATOM CB TYR H 194 64.901 1.445 −28.442 1.00 18.25 ATOM CG TYR H 194 65.447 1.934 −29.754 1.00 18.87 ATOM CD1 TYR H 194 66.497 2.842 −29.782 1.00 17.22 ATOM CE1 TYR H 194 66.999 3.310 −30.971 1.00 20.86 ATOM CD2 TYR H 194 64.908 1.497 −30.969 1.00 19.91 ATOM CE2 TYR H 194 65.401 1.963 −32.180 1.00 20.11 ATOM CZ TYR H 194 66.450 2.875 −32.176 1.00 22.81 ATOM OH TYR H 194 66.949 3.387 −33.355 1.00 21.52 ATOM C TYR H 194 65.325 0.114 −26.397 1.00 18.70 ATOM O TYR H 194 64.280 −0.533 −26.231 1.00 18.91 ATOM N ILE H 195 66.100 0.535 −25.407 1.00 15.98 ATOM CA ILE H 195 65.782 0.268 −24.025 1.00 15.14 ATOM CB ILE H 195 66.731 −0.820 −23.489 1.00 14.19 ATOM CG2 ILE H 195 66.476 −1.079 −22.032 1.00 14.73 ATOM CG1 ILE H 195 66.594 −2.082 −24.339 1.00 17.52 ATOM CD1 ILE H 195 67.386 −3.252 −23.844 1.00 21.62 ATOM C ILE H 195 65.932 1.533 −23.183 1.00 16.46 ATOM O ILE H 195 66.932 2.239 −23.308 1.00 14.40 ATOM N CYS H 196 64.910 1.866 −22.392 1.00 15.74 ATOM CA CYS H 196 65.020 3.026 −21.504 1.00 15.04 ATOM C CYS H 196 65.414 2.433 −20.151 1.00 15.47 ATOM O CYS H 196 64.961 1.344 −19.799 1.00 17.09 ATOM CB CYS H 196 63.720 3.839 −21.418 1.00 11.99 ATOM SO CYS H 196 62.289 2.978 −20.709 1.00 15.97 ATOM N ASN H 197 66.369 3.080 −19.479 1.00 14.76 ATOM CA ASN H 197 66.881 2.639 −18.185 1.00 15.71 ATOM CB ASN H 197 68.424 2.530 −18.227 1.00 13.36 ATOM CG ASN H 197 68.955 2.061 −19.583 1.00 14.38 ATOM OD1 ASN H 197 69.482 2.855 −20.369 1.00 12.39 ATOM ND2 ASN H 197 68.618 0.772 −19.864 1.00 14.64 ATOM C ASN H 197 66.436 3.704 −17.173 1.00 17.43 ATOM O ASN H 197 66.676 4.862 −17.212 1.00 17.96 ATOM N VAL H 198 65.532 3.314 −16.294 1.00 15.31 ATOM CA VAL H 198 64.973 4.220 −15.318 1.00 15.22 ATOM CB VAL H 198 63.412 4.109 −15.323 1.00 16.02 ATOM CG1 VAL H 198 62.776 5.110 −14.359 1.00 15.86 ATOM CG2 VAL H 198 62.866 4.306 −16.761 1.00 12.38 ATOM C VAL H 198 65.520 3.951 −13.934 1.00 15.38 ATOM O VAL H 198 65.449 2.831 −13.425 1.00 18.68 ATOM N ASN H 199 66.057 4.985 −13.305 1.00 15.30 ATOM CA ASN H 199 66.604 4.828 −11.970 1.00 15.88 ATOM CB ASN H 199 68.122 5.034 −12.009 1.00 17.62 ATOM CG ASN H 199 68.789 4.716 −10.708 1.00 19.95 ATOM OD1 ASN H 199 69.967 4.990 −10.544 1.00 24.61 ATOM ND2 ASN H 199 68.063 4.113 −9.782 1.00 22.49 ATOM C ASN H 199 65.925 5.821 −11.029 1.00 15.25 ATOM O ASN H 199 65.808 7.003 −11.356 1.00 14.39 ATOM N HIS H 200 65.353 5.293 −9.947 1.00 12.48 ATOM CA HIS H 200 64.670 6.081 −8.921 1.00 15.53 ATOM CB HIS H 200 63.185 5.663 −8.790 1.00 14.60 ATOM CG HIS H 200 62.378 6.502 −7.830 1.00 15.76 ATOM CD2 HIS H 200 62.211 7.843 −7.734 1.00 14.93 ATOM ND1 HIS H 200 61.591 5.954 −6.835 1.00 16.92 ATOM CE1 HIS H 200 60.976 6.919 −6.171 1.00 14 09 ATOM NE2 HIS H 200 61.339 8.074 −6.696 1.00 13.32 ATOM C HIS H 200 65.447 5.843 −7.624 1.00 14.98 ATOM O HIS H 200 65.119 4.978 −6.805 1.00 13.34 ATOM N LYS H 201 66.526 6.595 −7.479 1.00 15.91 ATOM CA LYS H 201 67. 80 6.488 −6.310 1.00 18.09 ATOM CB LYS H 201 68.496 7.515 −6.381 1.00 19.93 ATOM CG LYS H 201 69.484 7.233 −7.489 1.00 28.78 ATOM CD LYS H 201 70.774 8.000 −7.249 1.00 34.66 ATOM CE LYS H 201 71.815 7.701 −8.301 1.00 38.20 ATOM NZ LYS H 201 73.115 8.340 −7.925 1.00 43.65 ATOM G LYS H 201 66.627 6.591 −4.989 1.00 17.71 ATOM O LYS H 201 66.927 5.840 −4.053 1.00 16.20 ATOM N PRO H 202 65.637 7.512 −4.884 1.00 16.23 ATOM CD PRO H 202 65.277 8.587 −5.828 1.00 12.43 ATOM CA PRO H 202 64.862 7.663 −3.644 1.00 14.45 ATOM CB PRO H 202 63.777 8.643 −4.056 1.00 13.02 ATOM CG PRO H 202 64.516 9.552 −4.928 1.00 14.37 ATOM C PRO H 202 64.261 6.357 −3.091 1.00 14.39 ATOM O PRO H 202 64.013 6.259 −1.895 1.00 16.85 ATOM N SER H 203 64.055 5.359 −3.949 1.00 15.31 ATOM CA SER H 203 63.502 4.057 −3.545 1.00 17.23 ATOM CD SER H 203 62.151 3.798 −4.231 1.00 14.94 ATOM CG SER H 203 62.302 3.553 −5.635 1.00 15.74 ATOM C SER H 203 64.444 2.909 −3.920 1.00 18.91 ATOM O SER H 203 64.077 1.735 −3.796 1.00 19.89 ATOM N ASN H 204 65.619 3.247 −4.446 1.00 19.73 ATOM CA ASN H 204 66.589 2.245 −4.867 1.00 21.67 ATOM CD ASN H 204 67.081 1.459 −3.649 1.00 24.42 ATOM CG ASN H 204 68.422 0.782 −3.881 1.00 26.57 ATOM OD1 ASN H 204 69.212 1.197 −4.734 1.00 28.87 ATOM ND2 ASN H 204 68.693 −0.257 −3.103 1.00 27.26 ATOM C ASN H 204 66.004 1.293 −5.927 1.00 23.47 ATOM O ASN H 204 66.334 0.109 −5.956 1.00 23.25 ATOM N THR H 205 65.129 1.818 −6.784 1.00 23.37 ATOM CA THR H 205 64.492 1.037 −7.845 1.00 24.11 ATOM CD THR H 205 62.955 1.294 −7.917 1.00 25.63 ATOM OG1 THR H 205 62.321 0.840 −6.717 1.00 28.17 ATOM CG2 THR H 205 62.332 0.567 −9.101 1.00 26.85 ATOM C THR H 205 65.063 1.389 −9.210 1.00 24.23 ATOM O THR H 205 65.224 2.566 −9.526 1.00 22.91 ATOM N LYS H 206 65.340 0.362 −10.016 1.00 23.89 ATOM CA LYS H 206 65.866 0.510 −11.374 1.00 24.37 ATOM CB LYS H 206 67.286 −0.037 −11.478 1.00 29.60 ATOM CG LYS H 206 68.294 0.567 −10.528 1.00 33.86 ATOM CD LYS H 206 69.653 −0.045 −10.797 1.00 41.22 ATOM CE LYS H 206 70.686 0.392 −9.786 1.00 45.98 ATOM NZ LYS H 206 71.959 −0.336 −10.034 1.00 50.69 ATOM C LYS H 206 64.988 −0.341 −12.266 1.00 23.86 ATOM O LYS H 206 64.677 −1.478 −11.913 1.00 25.27 ATOM N VAL H 207 64.627 0.175 −13.434 1.00 21.70 ATOM CA VAL H 207 63.771 −0.552 −14.363 1.00 18.59 ATOM CB VAL H 207 62.285 −0.056 −14.268 1.00 18.43 ATOM CG1 VAL H 207 61.415 −0.781 −15.279 1.00 17.97 ATOM CG2 VAL H 207 61.727 −0.264 −12.878 1.00 16.57 ATOM C VAL H 207 64.241 −0.337 −15.806 1.00 18.98 ATOM O VAL H 207 64.441 0.797 −16.224 1.00 17.46 ATOM N ASP H 208 64.515 −1.412 −16.536 1.00 18.90 ATOM CA ASP H 208 64.879 −1.263 −17.938 1.00 21.28 ATOM CB ASP H 208 66.054 −2.146 −18.334 1.00 24.33 ATOM CG ASP H 208 67.309 −1.813 −17.583 1.00 27.92 ATOM OD1 ASP H 208 67.899 −2.730 −16.991 1.00 32.30 ATOM OD2 ASP H 208 67.704 −0.637 −17.569 1.00 27.86 ATOM C ASP H 208 63.642 −1.722 −18.671 1.00 20.84 ATOM O ASP H 208 63.037 −2.736 −18.312 1.00 22.22 ATOM N LYS H 209 63.230 −0.960 −19.668 1.00 20.63 ATOM CA LYS H 209 62.047 −1.305 −20.429 1.00 19.95 ATOM CB LYS H 209 60.912 −0.320 −20.125 1.00 20.48 ATOM CG LYS H 209 59.709 −0.423 −21.045 1.00 22.51 ATOM CD LYS H 209 59.031 −1.791 −20.990 1.00 23.59 ATOM CE LYS H 209 58.585 −2.147 −19.585 1.00 24.09 ATOM NZ LYS H 209 57.765 −3.385 −19.580 1.00 23.79 ATOM C LYS H 209 62.371 −1.277 −21.899 1.00 21.05 ATOM O LYS H 209 62.857 −0.263 −22.411 1.00 19.10 ATOM N ARG H 210 62.159 −2.409 −22.565 1.00 22.99 ATOM CA ARG H 210 62.407 −2.490 −23.996 1.00 23.52 ATOM CB ARG H 210 62.569 −3.951 −24.432 1.00 25.36 ATOM CG ARG H 210 63.135 −4.115 −25.838 1.00 34.19 ATOM CD ARG H 210 63.578 −5.558 −26.136 1.00 41.11 ATOM NE ARG H 210 64.549 −6.110 −25.172 1.00 45.70 ATOM CZ ARG H 210 65.558 −6.917 −25.506 1.00 45.18 ATOM NH1 ARG H 210 65.738 −7.255 −26.778 1.00 45.60 ATOM NH2 ARG H 210 66.357 −7.428 −24.571 1.00 44.97 ATOM C ARG H 210 61.225 −1.822 −24.715 1.00 22.56 ATOM O ARG H 210 60.064 −1.975 −24.314 1.00 21.94 ATOM N VAL H 211 61.523 −1.042 −25.745 1.00 20.28 ATOM CA VAL H 211 60.488 −0.355 −26.506 1.00 19.78 ATOM CB VAL H 211 60.659 1.195 −26.412 1.00 16.83 ATOM CG1 VAL H 211 59.537 1.891 −27.110 1.00 11.98 ATOM CG2 VAL H 211 60.714 1.628 −24.960 1.00 14.99 ATOM C VAL H 211 60.627 −0.837 −27.943 1.00 20.10 ATOM O VAL H 211 61.671 −0.677 −28.561 1.00 22.07 ATOM N GLU H 212 59.578 −1.449 −28.474 1.00 22.41 ATOM CA GLU H 212 59.615 −1.993 −29.831 1.00 22.33 ATOM CB GLU H 212 59.888 −3.486 −29.741 1.00 24.22 ATOM CG GLU H 212 58.992 −4.175 −28.714 1.00 30.31 ATOM CD GLU H 212 59.156 −5.688 −28.681 1.00 36.52 ATOM OE1 GLU H 212 58.119 −6.380 −28.685 1.00 42.79 ATOM OE2 GLU H 212 60.302 −6.195 −28.638 1.00 38.30 ATOM C GLU H 212 58.278 −1.780 −30.509 1.00 21.74 ATOM O GLU H 212 57.274 −1.487 −29.844 1.00 23.29 ATOM N PRO H 213 58.239 −1.885 −31.844 1.00 20.03 ATOM CG PRO H 213 59.332 −2.079 −32.808 1.00 19.08 ATOM CA PRO H 213 56.966 −1.695 −32.536 1.00 18.93 ATOM CB PRO H 213 57.345 −1.935 −34.001 1.00 18.96 ATOM CG PRO H 213 58.748 −1.473 −34.068 1.00 17.26 ATOM C PRO H 213 55.994 −2.757 −32.005 1.00 18.93 ATOM O PRO H 213 56.412 −3.857 −31.628 1.00 18.24 ATOM N LYS H 214 54.717 −2.409 −31.924 1.00 19.00 ATOM CA LYS H 214 53.706 −3.332 −31.410 1.00 19.14 ATOM CB LYS H 214 52.483 −2.552 −30.924 1.00 16.91 ATOM CG LYS H 214 51.526 −3.410 −30.161 1.00 17.14 ATOM CD LYS H 214 50.262 −2.680 −29.811 1.00 20.10 ATOM CE LYS H 214 49.434 −3.588 −28.931 1.00 24.84 ATOM NZ LYS H 214 48.149 −2.977 −28.549 1.00 28.31 ATOM C LYS H 214 53.222 −4.400 −32.394 1.00 19.27 ATOM O LYS H 214 53.060 −4.132 −33.577 1.00 20.70 ATOM N SER H 215 52.998 −5.614 −31.902 1.00 21.20 ATOM CA SER H 215 52.459 −6.677 −32.744 1.00 21.88 ATOM CB SER H 215 52.848 −8.059 −32.209 1.00 21.65 ATOM OG SER H 215 52.273 −9.089 −33.001 1.00 19.53 ATOM C SER H 215 50.931 −6.494 −32.683 1.00 21.88 ATOM O SER H 215 50.308 −6.622 −31.615 1.00 20.22 ATOM N CYS H 216 50.340 −6.142 −33.813 1.00 21.67 ATOM CA CYS H 216 48.902 −5.919 −33.871 1.00 23.98 ATOM C CYS H 216 48.066 −7.189 −33.695 1.00 27.00 ATOM O CYS H 216 48.470 −8.289 −34.111 1.00 26.45 ATOM CB CYS H 216 48.538 −5.216 −35.174 1.00 18.31 ATOM SG CYS H 216 49.561 −3.741 −35.453 1.00 18.30 ATOM N ASP H 217 46.945 −7.040 −32.990 1.00 31.27 ATOM CA ASP H 217 46.009 −8.136 −32.750 1.00 33.27 ATOM CB ASP H 217 45.320 −7.991 −31.392 1.00 33.17 ATOM CG ASP H 217 44.278 −9.088 −31.123 1.00 36.31 ATOM OD1 ASP H 217 43.634 −9.600 −32.069 1.00 32.97 ATOM OD2 ASP H 217 44.085 −9.424 −29.935 1.00 37.95 ATOM C ASP H 217 44.977 −8.004 −33.849 1.00 36.08 ATOM O ASP H 217 44.272 −6.989 −33.945 1.00 37.14 ATOM N LYS H 218 44.896 −9.035 −34.679 1.00 36.90 ATOM CA LYS H 218 43.951 −9.047 −35.772 1.00 37.91 ATOM CB LYS H 218 44.203 −7.863 −36.721 1.00 41.24 ATOM CG LYS H 218 45.634 −7.710 −37.172 1.00 41.93 ATOM CD LYS H 218 45.801 −6.602 −38.194 1.00 45.62 ATOM CE LYS H 218 45.758 −5.216 −37.587 1.00 45.59 ATOM NZ LYS H 218 45.929 −4.191 −38.654 1.00 46.72 ATOM C LYS H 218 44.039 −10.359 −36.519 1.00 37.04 ATOM O LYS H 218 44.749 −11.268 −36.108 1.00 33.26 ATOM N THR H 219 43.284 −10.447 −37.604 1.00 38.01 ATOM CA THR H 219 43.248 −11.628 −38.450 1.00 39.39 ATOM CB THR H 219 41.948 −11.656 −39.246 1.00 42.48 ATOM OG1 THR H 219 41.822 −10.426 −39.989 1.00 47.38 ATOM CG2 THR H 219 40.770 −11.783 −38.286 1.00 39.71 ATOM C THR H 219 44.432 −11.539 −39.390 1.00 38.37 ATOM O THR H 219 44.447 −10.745 −40.343 1.00 36.99 ATOM N HIS H 220 45.435 −12.349 −39.089 1.00 36.18 ATOM CA HIS H 220 46.672 −12.372 −39.862 1.00 34.59 ATOM CB HIS H 220 47.858 −12.471 −38.889 1.00 33.40 ATOM CG HIS H 220 47.890 −11.347 −37.893 1.00 32.87 ATOM CD2 HIS H 220 47.558 −11.302 −36.580 1.00 30.42 ATOM ND1 HIS H 220 48.Z80 −10.067 −38.231 1.00 31.96 ATOM CE1 HIS H 220 48.196 −9.282 −37.170 1.00 27.03 ATOM NE2 HIS H 220 47.759 −10.006 −36.156 1.00 29.87 ATOM C HIS H 220 46.656 −13.500 −40.894 1.00 32.03 ATOM O HIS H 220 46.005 −13.277 −41.939 1.00 33.00 ATOM OXT HIS H 220 47.241 −14.578 −40.662 1.00 26.67 

1. A method of identifying a Synagis binding compound, comprising the step of using a three-dimensional structural representation of Synagis, Synagis Fab, or a fragment thereof comprising a Synagis antigen binding site, to computationally screen a candidate compound for an ability to bind the Synagis antigen binding site.
 2. The method of claim 1 further including the steps of: synthesizing the candidate compound; and screening the candidate compound for Synagis binding activity.
 3. A method of identifying a Synagis binding compound, comprising the steps of (a) using a three-dimensional structural representation of Synagis, Synagis Fab, or a fragment thereof comprising a Synagis antigen binding site, to computationally screen a candidate compound for an ability to bind the Synagis antigen binding site, (b) synthesizing the candidate compound; and (c) screening the candidate compound for Synagis binding activity, wherein the structural information comprises the atomic structure coordinates of residues comprising a Synagis CDR.
 4. The method of claim 3 in which the Synagis CDR is L1, L2, L3, H1, H2 or H3.
 5. The method of claim 4 in which the structural information comprises the antigen binding site of Synagis.
 6. The method of claim 5 in which the structural information comprises the Fv fragment of Synagis.
 7. The method of claim 6 in which the structural information comprises the Fab fragment of Synagis.
 8. A method of identifying a Synagis binding compound comprising the step of using a three-dimensional structural representation of Synagis, Synagis Fab, or a fragment thereof comprising a Synagis antigen binding site, to computationally design a synthesizable candidate compound that binds Synagis.
 9. The method of claim 8 in which the computational design comprises the steps of: identifying chemical entities or fragments capable of associating with the Synagis binding site; and assembling the chemical entities or fragments into a single molecule to provide the structure of the candidate compound.
 10. The method of claim 9 further including the steps of: synthesizing the candidate compound; and screening the candidate compound for Synagis binding activity.
 11. A method of identifying a Synagis binding compound comprising the step of using a three-dimensional structural representation of Synagis, Synagis Fab, or a fragment thereof comprising a Synagis antigen binding site, to computationally design a synthesizable candidate compound that binds Synagis, wherein the structural information comprises the atomic structure coordinates of residues comprising a Synagis CDR.
 12. The method of claim 11 in which the Synagis CDR is L1, L2, L3, H1, H2 or H3.
 13. The method of claim 11 in which the structural information comprises the antigen binding site of Synagis.
 14. The method of claim 11 in which the structural information comprises the Fv fragment of Synagis.
 15. The method of claim 12 in which the structural information comprises the Fab fragment of Synagis.
 16. The method of claim 11 in which the computational design comprises the steps of: identifying chemical entities or fragments capable of associating with the Synagis binding site; and assembling the chemical entities or fragments into a single molecule to provide the structure of the candidate compound.
 17. The method of claim 16 further including the steps of: synthesizing the candidate compound; and screening the candidate compound for Synagis binding activity. 